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The transcriptional coactivator PPARgamma coactivator 1alpha (PGC-1α) 
is a regulator of mitochondrial biogenesis and function and is decreased in 
the striatum of patients with Huntington’s Disease (HD). HD is an 
autosomal dominant neurological disorder caused by a polyglutamine 
repeat in the huntingtin protein which leads to degeneration of striatal and 
cortical tissues. PGC-1α undergoes targeted downregulation by mutant 
huntingtin protein (mtHtt) and PGC-1α knockout mice have striatal lesions 
similar to HD transgenic mice. Exogenous PGC-1α partially reverses the 
toxic effects of mutant huntingtin in cultured stria al neurons while in vivo 
administration of PGC-1α to the striatum in a mouse model of HD reduces 
neuronal volume loss. Synaptic N-methyl-D-aspartate receptor (NMDAR)-
activity can drive the expression of PGC-1α which is neuroprotective 
against oxidative and excitotoxic stress in vitro whereas extrasynaptic 
NMDAR expression is increased in HD. Excessive NMDAR activity, 
specifically through extrasynaptic rather than synaptic NMDARs, leads to 
excitotoxic death in neurons and its regulation hasbeen targeted in the 
search for therapeutic interventions for multiple neurological disorders.  
The data presented in this thesis show that the repression of PGC-1α by 
mtHtt may be significant in the dysregulation of NMDARs in HD. Both 
PGC-1α knockdown and mutant huntingtin are found to increase 
extrasynaptic NMDAR activity and excitotoxicity in a non-additive way, 
suggesting common regulatory mechanisms. Furthermor exogenous PGC-
1α expression is sufficient to reverse this increase in extrasynaptic 
NMDAR currents and excitotoxicity by mtHtt. This thesis adds 
mechanistic insight into previous understanding of the synergistic roles of 
mtHtt, NMDAR activity and PGC-1α in HD.  
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Finally, we show that chronic knockout of PGC-1α in the PGC-1α(-/-) 
mouse causes distinct alterations in glutamatergic signaling that do not 
mimic the observation of acute knockdown of PGC-1α. We propose that 
the loss of PGC-1α in a number of neurological disorders contributes to 
concurrent increases in aberrant glutamate signaling nd excitotoxicity in 








This work was carried out in the School of Biomedical Sciences at the 
University of Edinburgh. I have composed the work and nalysis presented 
in this thesis. The work complied in this thesis ha not been submitted for 





July 2012  





Table of Contents 
 
Abstract ................................................................................................... i 
Table of Contents ................................................................................ iii 
List of figures ............................................................................................. xi 
Acknowledgements ............................................................................... xvi 
Chapter 1: .................................................................................................... 1 
Introduction ........................................................................................................................... 1 
1.1 Neurodegeneration ................................................................................ 2 
1.2 The excitotoxic theory of neurodegenerative disase .................................. 7 
1.2.2 NMDAR assembly, trafficking and distribution ....................................... 1 
1.2.2 NMDAR assembly, trafficking and distribution ..................................... 11
1.2.3 Excitotoxic cell death .................................................................... 13 
1.2.4 What distinguishes synaptic and extrasynaptic NMDAR activity? ......... 16 
1.3 Pro-survival and pro-death signalling from NMDARs .............................. 18
1.3.1 Synaptic NMDAR activity promotes cell survival ................................. 19 
1.3.2 Synaptic NMDAR activity is anti-apoptotic ........................................... 20
iv 
 
1.3.2a The intrinsic apoptosis cascade .............. .. .......................................... 20 
1.3.2b Repression of pro-apoptotic genes ............ .. ....................................... 23 
1.3.2c Induction of pro-survival genes ...................................................... 24 
1.3.3 Synaptic NMDAR activity reduces oxidative stre s ............................... 25 
1.4 Extrasynaptic NMDARs promote cell death ....................................... 28
1.4.1 Extrasynaptic NMDAR activity and disease ...... ................................ 28
1.4.2 Extrasynaptic NMDARs are pro-death................................................... 29
1.4.2a Loss of mitochondrial membrane potential ....... ................................ 29
1.4.3b Expression of proapoptotic genes ......................................................... 32 
1.4.2c Inactivation of CREB ..................................................................... 32 
1.4.2d Repression of Ras-ERK cascade .................................................. 33 
1.4.2e Calpain activation ...................................................................... 33 
1.5 Huntington’s Disease ....................................................................... 35 
1.5.1 Increased excitotoxicity in HD .......................................................... 36 
1.5.2  NMDARs and mutant huntingtin inclusions ...... ............................... 37
1.5.3 NMDARs in Huntington’s disease .............. ..................................... 38 
1.6 PGC-1α ............................................................................................... 41 
1.6.1 PGC-1α: structure and function ............................................................. 44 
1.6.2 PGC-1α in the brain .......................................................................... 46 
v 
 
1.6.3 Regulation of PGC-1α in neurons .......................................................... 47 
1.7 PGC-1α and Huntington’s disease ............................................................ 49 
1.7.1 Mitochondrial defects in HD ............................................................. 49 
1.7.2 Repression of PGC-1α by mutant huntingtin ..................................... 50 
1.7.3 PGC-1α and other neurodegenerative diseases .............................. 53 
PGC-1α: Parkinson’s Disease ......................................................................... 53 
PGC-1α: Amyotrophic lateral sclerosis .......................................................... 53
PGC-1α: Ischemia .......................................................................................... 54 
PGC-1α: Alzheimer’s disease ................................................................... 54 
1.8 Experimental Aim ............................................................................ 55 
Chapter 2: .................................................................................................. 57 
Methods ............................................................................................................................... 57 
2.1 Primary rat and mouse culture ........................................................... 58 
2.1.1 Animals used for this study .............................................................. 58 
2.1.2 Primary cell culture ...................................................................... 59 
2.2 Plasmid preparation ............................ ............................................. 61 
2.3 Transfection of plasmids ................................................................... 61 
2.4 Nucleofection of plasmids ........................................................................ 62 
vi 
 
2.5 RNA isolation, reverse transcriptase-polymerase chain reaction, and 
quantitative polymerase chain reaction. ................................................... 62 
2.6 Electrophysiological recording and analysis ............................................. 64 
2.6.1 External recording solution: artificial cerebospinal fluid (aCSF). ......... 65 
2.6.2 Recording electrodes ......................... . ............................................ 65 
2.6.3 Internal Recording solution ................. ............................................. 65 
2.6.4 Whole-cell agonist-evoked currents ....................................................... 66 
2.6.5 Recording extrasynaptic NMDAR currents ....... ................................. 66
2.6.6 Miniature excitatory postsynaptic currents ...... ..................................... 67 
2.7 Induction of excitotoxicity and following the fate of transfected 
neurons ................................................................................................ 68 
2.8. Simulation of synaptic activity in cell culture .......................................... 69 
2.9. Luciferase reporter assays ............................................................... 70 
2.10 Microarray analysis ............................................................................. 70 
2.11 Statistics ............................................................................................ 71 
Chapter 3: .................................................................................................. 72 
Neuroprotection from PGC-1α-mediated repression of extrasynaptic NMDARs ................ 72 
3.1 Chapter summary .................................................................................. 73 
3.2 Results ........................................................................................... 74 
3.2.1 PGC-1α regulates excitotoxicity in rat cortical cultures ......................... 74 
vii 
 
3.2.2 PGC-1α expression regulates whole-cell NMDAR currents ................... 78 
3.2.3 PGC-1α overexpression does not alter the GluN2B subunit 
composition of NMDARs ............................................................................... 79 
3.2.4 Excitotoxicity and extrasynaptic NMDAR activiy ................................ 84 
3.2.5 PGC-1α does not affect miniature synaptic activity ......................... 88 
3.2.6 PGC-1α preferentially represses extrasynaptic NMDAR activity ........... 92 
3.2.7 Exogenous PGC-1α expression leads to decreased GluN1 mRNA and 
GluN1 promoter activity. ............................................................................. 97 
3.3 Discussion .................................... ................................................. 99 
3.3.1 Summary of experimental results .................................................... 99 
3.3.2 Potential routes to altered NMDAR-activity ..... ................................. 101 
3.3.3 Transcriptional regulation of NMDAR subunit expression .................. 101 
3.3.4 Receptor stability at synaptic and extrasynaptic sites ........................... 103 
3.3.5 Mitochondrial function and NMDARs ............ ................................. 106 
Chapter 4: ................................................................................................ 107 
PGC-1α repression underlies the effect of mtHtt on extrasynaptic NMDAR currents ...... 107 
4.1 Chapter summary .................................................................................. 108 
4.2 Results ......................................................................................... 109 
4.2.1 MtHtt increases excitotoxicity in primary cortical neurons .................. 109 
4.2.2 MtHtt increases whole-cell NMDAR currents in cortical neurons ........ 111 
viii 
 
4.2.3 No change in mEPSCs in cells expressing mtHtt (148Q) ..................... 113 
4.2.4 ‘Quantal block’ of synaptic NMDARs ................................................. 114 
4.2.5 MtHtt enhances extrasynaptic NMDAR currents ....... ......................... 117 
4.2.6 Does mtHtt alter NMDAR activity via the repression of PGC-1α?....... 120 
4.2.7 MtHtt (148Q) and PGC-1α knockdown cause a non-additive increase 
in excitotoxicity ................................................................................... 122 
4.2.8 MtHtt (148Q) and PGC-1α knockdown cause a non-additive increase 
in NMDAR current density ........................... .. ........................................... 122 
4.2.9 MtHtt-increase in extrasynaptic NMDAR-currents is occluded by 
knockdown of PGC-1α ............................................................................ 123 
4.2.10 PGC-1α rescues mtHtt (148Q)-mediated increase in excitotoxicity .... 127 
4.2.11 PGC-1α rescues mtHtt (148Q)-induced increase in NMDAR current 
density ................................................................................................ 127 
4.2.12 PGC-1α overexpression rescues mtHtt (148Q) increase in 
extrasynaptic currents ......................................................................... 128 
4.2.13 Striatal neurons ........................................................................ 132 
4.2.14 A non-additive increase in excitotoxicity by mtHtt expression and 
PGC-1α knockdown in striatal cultures ........................................................ 133 
4.2.15 PGC-1α rescues mtHtt-increase in excitotoxicity in striatal cells ....... 133 
ix 
 
4.2.16 In striatal cultures, mtHtt and PGC-1α knockdown increase 
NMDAR currents non-additively........................ ........................................ 135 
4.2.17 PGC-1α overexpression rescues mtHtt-induced increase in currents .. 137 
4.3 Discussion .................................... ............................................... 138 
4.3.1 Consequences for neurological disease ................................................ 138 
4.3.2 Current therapeutic targets: Extrasynaptic NMDAR activity ................ 141 
5.3 Future potential: Targeting PGC-1α ................................................... 142 
Chapter 5: ................................................................................................ 143 
PGC-1α knockout mice have alterations in AMPA but not NMDA- type 
glutamate receptors .................................................................................. 143 
5.1 Introduction .................................................................................. 144 
5.2 Results ......................................................................................... 146 
5.2.1 PGC-1α(-/-) mice display no change in whole-cell NMDAR currents .... 146 
5.2.2 PGC-1α(-/-) mice have reduced AMPAR current density ........... ..... 149 
5.2.3 PGC-1α(-/-) mice have reduced AMPAR GluA1-4 mRNA expression ... 152 
5.2.4 Cortical neurons from PGC-1α(-/-) mice have reduced mEPSC 
frequency and amplitude ........................................................................ 154 
5.2.5 Decreased complexin I: a candidate for altered AMPAR exocytosis .... 157 
5.3 Discussion .................................... ............................................... 160 
x 
 
5.5.1 Disregulation of AMPARs in PGC-1α(-/-) neurons.............................. 160 
5.3.2 Discrepancies between acute and chronic PGC-1α knockdown on 
NMDARs. ............................................................................................... 162 
Chapter 6: ................................................................................................ 165 






List of figures 
 
Figure 1.1 The projected increase in neurodegeneration highlights the 
significance of NDG research 
 
3 
Table 1.1 Examples of Neurodegenerative diseases and some of the 
common pathologies in cellular processes 
 
4 
Figure 1.2 Ionotropic glutamate receptors 
 
8 
Figure 1.3 Cartoon illustration of the structure of NMDARs 
 
10 
Figure 1.4 Synaptic NMDA receptors activation is pro-survival, 
extrasynaptic NMDA receptors activation is pro-death 
 
15 
Figure 1.5 Intrinsic and extrinsic apoptosis 
 
21 
Figure 1.6 Synaptic NMDAR activity induces neuroprotective cascades 
 
27 




Figure 1.8  Function of PGC-1α   
 
43 
Figure 1.9 Interplay between PGC-1α, mtHtt and NMDARs in 





Figure 3.1 PGC-1α is neuroprotective against excitotoxic insult 
 
76 








Figure 3.4 Knockdown of endogenous PGC-1α increases agonist-evoked 
NMDAR currents 
 
Figure 3.5 PGC-1α overexpression does not alter the subunit 





Image 3.1 Pharmacological isolation of extrasynaptic NMDARs 
 
86 




Figure 3.7 siRNA knockdown of PGC-1α does not alter mEPSC frequency 
of amplitude in cortical neuronal culture 
 
90 
Figure 3.8 MK-801-blockade of synaptic NMDARs saturates by 10 min 
incubation in siRNA-expressing cells 
 
91 
Figure 3.9 Extrasynaptic NMDAR current density is increased in cortical 
neurons expressing PGC-1α siRNA and decreased in neurons 





Figure 3.10 The effect of PGC-1α siRNA and PGC-1α overexpression is 
greater on extrasynaptic NMDAR-currents compared to the total whole-
cell agonist-evoked currents 
 
Figure 3.11 PGC-1α overexpression preferentially represses 












Figure 4.1 Mutant Huntingtin mtHtt(148Q) increases vulnerability to 
excitotoxicity in vitro 
 
110 




Figure 4.3 mtHtt(148Q) expression does not alter mEPSC frequency of 
amplitude in cortical neuronal culture  
 
115 




Figure 4.5 Extrasynaptic NMDAR current density is increased in cortical 
neurons expressing mtHtt(148Q) 
 
118 
Figure 4.6 The effect of mtHtt-expression is greater on extrasynaptic 










Figure 4.8 MtHtt(148Q) expression and siRNA knockdown of PGC-1α 
have a non-additive effect on excitotoxicity 
 
124 
Figure 4.9 Co-expression of MtHtt(148Q) and PGC-1α-siRNA results in a 
non-additive increase in agonist-evoked NMDAR currents 
 
125 
Figure 4.10 Increase of extrasynaptic NMDAR current density by 












Figure 4.13 PGC-1α overexpression rescues mtHtt(148Q)-induced 
increase in extrasynaptic current density 
 
131 
Figure 4.14 NMDA-induced death in mtHtt-expressing cells in striatal 
cultures in the context of PGC-1α knockdown or overexpression 
 
134 
Figure 4.15 In striatal cultures, mtHtt and PGC-1α knockdown increase 136 
xv 
 
NMDAR currents non-additively, whilst PGC-1α overexpression rescues 
mtHtt-induced increase in currents 
 






Figure 5.2 Cortical neurons from PGC-1α
(-/-) 
mice had reduced agonist-









Figure 5.4 Cultured cortical neurons from PGC-1α
(-/-) 
mice have reduced 
mEPSC frequency and amplitude 
 
155 










  neurons have reduced complexin I mRNA expression 159 
 









I would like to thank the BBSRC for funding me throughout the course of 
this study. I am also extremely grateful to my supervisors Giles and David 
for their wonderful support and guidance over the last four years. Working 
in the Hardingham lab has provided a really fantastic opportunity to 
interact with some very talented scientists and I have continuously relied 
on their support both scientifically and emotionally throughout this 
process. I would especially like to thank Karen, Francesc and Tim for 
teaching me so much about scientific thinking and self-discipline and Marc 
for introducing me to this project and his technical support.  
I am also highly indebted to Paul, Bashayer, Sofia, J ng, Sean, Steph, 
Emma, Aoife and Lasani for all their help and guidance in the lab and for 
putting up with over 200 episodes of answemethis. 
I feel overwhelmingly lucky to have had such awesome friends around me 
during this PhD, who were there for the good times and not-so-good times- 
I will miss you all very much! I am especially grateful to Cian- I can’t 
believe how lucky I am to have you in my life; thanks for your relentless 
optimism and patience throughout. 
Finally, I would like to thank my family John, Lou, Kaff, Bobby and Tom 
for the craic. Most importantly, Mum, thank you for making us believe we 















The prevalence of neurodegenerative disease (NDG) is rapidly escalating 
(Cowan and Kandel, 2001). Since advancing age is major f ctor in these 
diseases, as the aging population is expected to grow (Fig 1.1), 
neurodegenerative disease will continue to be a major public health issue. 
In the absence of effective treatments, NDGs will put an increasing burden 
on future economics. Uncovering the underlying molecular and cellular 
mechanisms responsible for the patho-progression of eurodegenerative 
disorders is key in the development of medical interventions.  
Neurodegeneration refers to the progressive loss of neuronal function and 
viability associated with neurodegenerative diseases including, but not 
limited to, Alzheimer’s disease (AD), Huntington disease (HD), 
Parkinson’s disease (PD), and Amyotrophic lateral sclerosis (ALS). 
Despite the distinct profiles of neuronal loss associated with each disease 
(Table 1.1), advances in the last few decades have identified disruptions in 
subcellular processes common to all or some of these diseases (Table 1.1) 
including protein aggregation, mitochondrial dysfunction, defects in 
axonal transport, excitotoxicity and aberrant initiat on of programmed cell 
death (Ikonomidou and Turski, 2002; Vila and Przedborski, 2003; Lashuel 






















Fig 1.1 The projected increase in neurodegeneration highlights the 
significance of NDG research
of the United Kingdom population mid 2010
Statistics; cited March 2012) (B) Projected world prevalence of dementia 








 (A) Estimated and projected age structure 
- mid 2035 (UK Government 











Table 1.1 In this table I have collected e
pathologies in cellular processes
diseases 
xamples of some of the common 






1.1.1 Studying molecular cascades in NDGs 
Identifying common phenotypes between NDGs highlights cellular 
cascades that may account for preferential vulnerability of neuronal tissue 
in these diseases, albeit offering no explanation for the regional-specificity 
of neuronal loss. However, with the end goal being the establishment of 
disease interventions, it is essential that we are abl to distinguish between 
the causes and symptoms of pathology. This requires th  analysis of 
relationships between these disease-associated components and assessment 
of their relative contribution to cellular health and function which may not 
be immediately evident for a number of reasons.  
Firstly, disease-specific phenotypes may indeed be pathological but 
alternatively they could be protective compensatory mechanisms. One 
such example is the formation of mutant huntingtin inclusions in HD, long 
considered a hallmark of the disease (Davie et al., 1997), has in recent 
years been recognised as a compensatory protective mechanism and in 
such, restricting this process exacerbates cells death (Okamoto et al., 
2009).  
Secondly, although the apparent timecourse of cellular changes may 
correlate with the onset of the disease, this is not pr of that such changes 
are pathological. For example Palop et al. (2006), argue that although 
neuronal death is what ultimately determines the onset of clinical 
phenotype in Alzheimer’s diseases, the timecourse of neuropathological 
symptoms correlates more closely with alterations in ynaptic function that 
occur when the remaining tissue is no longer able to compensate for lost 
synaptic inputs. Within this model, despite matching the timecourse of 
disease progression, disease-specific alterations in synaptic profiles may be 
considered as mechanisms that temporarily protect physiological function.  
Finally, the pitfalls in antagonising known pathological cascades 
without fully understanding the physiological roles of the targeted protein 
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was highlighted by the failure of N-methyl-D-aspartate receptors 
(NMDAR)-antagonists in preclinical trials for the treatment of stroke 
(Ikonomidou and turski, 2002).  Although it was known that NMDAR-
activity contributed to pathology of stroke, it has since been shown that 
specific populations of NMDARs can couple to either pro-death or pro-
survival cascades (Hardingham and Bading, 2010) and further 
understanding of the full molecular cascades are requi d in order to 
identify a safe and effective target for medical interventions. Together 
these models propose that studying the molecular basis of NDG is essential 
for both expanding our knowledge of the diseases as well as identifying 
potential therapeutic targets.  
This thesis addresses the role of NMDAR signalling a d excitotoxic cell 
death in  neurodegenerative disease; the potential therapeutic benefits of 
enhancing an endogenous neuroprotective cascade, regulated by the 
transcriptional coactivator PGC-1α, that may be diminished in NDGs, is 
emphasised with specific interest in neuronal viability and function in HD. 
The work presented in this thesis is now published (Puddifoot et al., 2012; 
PGC-1α Negatively Regulates Extrasynaptic NMDAR Activity and 






1.2 The excitotoxic theory of neurodegenerative disease 
 
The ability of glutamatergic activity to induce neuronal cell death has been 
known for over 50 years (Lucas & Newhouse 1957; Curtis et al. 1959). On 
observation that injections of monosodium glutamate could induce 
neuronal necrosis in several regions of the brain, Olney termed this 
phenomena ‘excitotoxicity’ (Olney 1969). Glutamate is the main 
excitatory neurotransmitter in the mammalian brain nd can activate a 
number of glutamate receptors both metabotropic and ionotropic. 
Ionotropic glutamate receptors (summarised in Fig 2.) contain a pore 
which opens upon receptor activation allowing the selective passage of 
ions into the cell across the plasma membrane. Studies by Choi (1988; 
1987a; 1987b) and Tymianski et al. (1993) showed that excitotoxicity has 
an explicit requirement for Ca2+ influx into the neuron and the source of 
Ca2+ is specific to Ca2+ entry through the N-methyl-D-aspartate (NMDA) 
subclass of ionotropic glutamate receptors. For the decade that followed, 
many groups gathered evidence for the role of excessiv  NMDAR Ca2+ 
influx in neurodegenerative disease and stroke (Rothman &  Olney 1986; 
Choi 1988; Lipton & Rosenberg 1994; Arundine & Tymianski 2004; Fan 






















Figure 1.2 Ionotropic g
of ionotropic glutamate receptors. All are heteromeric, composed of four 
subunits from the subsets outlined above. The receptors differ in their 
permeability to select ions; of interest is the high permeability of 
NMDARs to Ca2+ relative to other glutamate receptors.








NMDARs are a subfamily of glutamatergic receptors expr ssed almost 
ubiquitously throughout the CNS during pre and post natal development 
and thereafter. NMDARs are named after the selectiv agonist N-Methyl-
D-Aspartate which distinguishes them from the two other ionotropic 
glutamate receptors: the α-amino-3-hydroxy-5-methyl-4-isoazolepropionic 
acid (AMPA) receptor and the 2-carboxy-3-carboxymethyl-4-
isopropenylpyrrolidine (kainate) receptor.  Two major attributes of 
NMDARs that differentiates them from the other ionotropic glutamate 
receptors include (i) the necessary relief of a voltage-dependent inhibition 
by extracellular magnesium for ion permeation through the channel pore 
(Kutsuwada et al., 1992) and (ii) the receptor’s high permeability to 
calcium ions upon activation. Combined these properties have implicated 
the NMDAR in a number of inter- and intra-cellular p ocesses. Indeed, 
calcium influx into neurons has been shown to trigger diverse molecular 
cascades which lead to cellular and synaptic growth and development as 
well as neuroprotection and conversely pro-death signalling (Bliss & 








Figure 1.3 Cartoon i
NMDARs are found embedded in the post
neurons throughout the CNS. The NMDAR is composed of four 
subunits; the majority of receptors contain two glycine (Gly)
GluN1 and two glutamate (Glu)
At resting membrane potential (~ 
NMDAR is blocked by the presence of Mg
subunit expressed (
define the majority of the functional properties of the receptor.(B) 
Each subunit is composed of four f
terminal domain (ATD), the ligand binding domain (LB), the 
membrane spanning domain which includes the re
4), and an intracellular C
previously published in Puddifoot et al., (2009)
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llustration of the structure of NMDARs 
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-binding GluN2 subunits as shown. 
-70 mV) the ionic pore of the 
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1.2.2 NMDAR assembly, trafficking and distribution 
There are seven possible NMDAR subunits: GluN1, GluN2A-D and 
GluN3A-B (Monyer et al., 1992; Das et al., 1998). Although some 
receptors do exist as triheteromers formed as GluN1/GluN2/GluN3 
assemblies, the majority of NMDARs exist as an assembly of two GluN1 
and two GluN2 subunits (Dingledine et al. 1999; Stephenson et al. 2008; 
Fig 1.3). It is the GluN2 subtype contained within a y given recombinant 
that is thought to define the majority of the biophysical and 
pharmacological properties of the receptor; this includes the glutamate 
efficacy, calcium conductance level and potency of bl ck by magnesium 
(Monyer et al., 1994; Cull-Candy et al., 2001). 
The inclusion of specific NMDAR subunits within receptors is both 
temporally and spatially regulated throughout development (Monyer et al., 
1994). GluN1 expression is high in most brain areas throughout 
development (Monyer et al., 1994), whereas the expression profile of 
GluN2 subunits varies during maturation (Cull-Candy & Leszkiewicz 
2004). GluN2 subunit expression is dominated by GluN2B at early 
developmental stages and although GluN2B expression levels remain high 
through adulthood, as the cells mature the relative levels of GluN2A 
subunits expression increases becoming the most abund nt subunit (Cull-
Candy et al. 2001).  
Once assembled in the endoplasmic reticulum, cell surface expression  of 
the receptors requires the coordinated interactions f the NMDARs, 
membrane-associated guanylate kinases (MAGUKs) and kinesin KIF17–
LIN10 motor complex to carry out the cytoplasmic and membrane 
interactions required for NMDAR trafficking (Gladding and Raymond, 
2011). Receptors destined for the synapse are supported by a large protein 
complex termed the post-synaptic density (PSD). ThePSD contains a 
network of scaffolding, adaptor and effector proteins which regulate 
12 
 
receptor trafficking, membrane stability as well asthe activation of 
downstream signalling cascades (Sheng &  Lee 2000). 
NMDARs are also expressed at peri-synaptic sites (within 200–300 nm of 
the PSD) or extra-synaptic sites (throughout the dendritic membrane and 
soma), together termed extrasynaptic from herein (Gladding and Raymond, 
2011). Studies in hippocampal cultures show a developmental change in 
the proportion of receptors at extrasynaptic sites from 75% at DIV5-7 
(Tovar & Westbrook 1999) to 20-50% >DIV9 (Rosenmund et al., 1995). It 
has been shown that once at the cell surface, the location of receptor is not 
rigid, that is NMDARs can undergo lateral diffusion within the cell 
membrane (Tovar & Westbrook 2002; Groc et al. 2009). However this is 
contested by Harris and Petit (2007) who show that in acute slices, 
NMDAR expression is stable and once expressed at the cell surface there 
is no NMDAR mobility.  
13 
 
1.2.3 Excitotoxic cell death 
 
Excessive calcium entry after prolonged NMDAR activity was found to 
induce both necrotic and apoptotic cell death depending of the stimulus 
intensity/duration (Bonfoco et al., 1995). Necrotic and apoptotic cell death 
are both morphologically and mechanistically distinct. Necrotic cell death 
is classically thought to result from ionic deregulation and rapid ATP 
depletion which leads to swelling of both the cell and cellular organelles 
with eventual breakdown of the plasma membrane and release of cellular 
content including proinflammatory molecules. In necroti  cell death, 
excessive Ca2+ influx is exacerbated by aberrant calpain cleavage of the 
Na+/Ca2+ exchanger (NCX) which under normal conditions is re ponsible 
for Ca2+ extrusion (Bano et al., 2005). 
In contrast apoptotic cell death, often termed ‘programmed cell death’, is 
characterised by cellular and nuclear shrinkage, chromatin condensation 
and genomic fragmentation without plasma membrane br akdown. 
Apoptosis requires the activation of cysteine proteases (caspases), it is 
ATP-dependent and can be activated either by ligation of the death 
receptor or by release of proapoptotic factors from the mitochondria (Zou 
et al., 1997; Ashkenazi and Dixit, 1998). 
Although it was previously believed that there exists a threshold of activity 
above which NMDAR activity becomes excitotoxic (Lipton and 
Nakanishi, 1999; Hardingham and Bading, 2003), the current 
understanding has been shifted by the finding that NMDAR toxicity is 
conferred not simply by excessive amounts of activity, but rather by the 
activation of NMDARs located at extrasynaptic sites (Hardingham et al. 
2002). For example, Hardingham et al. (2002) show that similar calcium 
loads through synaptic versus extrasynaptic NMDARs differentially 
14 
 
couple to CREB-dependent transcription; whereas synaptic activity 
induces CREB expression and activity and promotes cll survival, 
extrasynaptic NMDAR activation causes a dominant CREB shut-off and 
triggers cell death. Therefore, NMDAR activity provides an interesting 
paradox in which the activation of this protein complex can initiate the 
expression of either neuroprotective or neurodestructive transcriptional 
profile depending on the location of the receptor (Hardingham & Bading 















Fig 1.4 Synaptic NMDARs activation is pro-survival, extrasynaptic 
NMDARs activation is pro-death NMDARs transmit information from 
outside the cell to inside the cell. When NMDARs are ctivated at synaptic 
sites they couple to pro-survival pathways. When NMDARs at 
extrasynaptic sites are activated they couple to pr-death signaling 
cascades. In this figure the dendrite is depicted without spines representing 




1.2.4 What distinguishes synaptic and extrasynaptic NMDAR 
activity? 
Despite a great deal of progression in identifying pro-survival and pro-
death pathways coupled to synaptic and extrasynaptic c vity (discussed 
in detail below), the basis for the differences in synaptic versus 
extrasynaptic NMDAR signalling is unknown. However, three 
independent theories have been proposed to explain these observations. 
The first is the potential differences in the subunit composition of the 
NMDAR complex at synaptic versus extrasynaptic sites l ads to 
differential activation of signalling cascades. As well as determining the 
ligand efficacy, channel conductance and magnesium block of the 
NMDAR, the GluN2 subunits of NMDARs contain distinct ytoplasmic 
tails that can interact with intracellular proteins (Sheng et al., 1994; Zhong 
et al., 1994; Cull-Candy et al., 2001). Early in development the GluN2B 
subunit is most abundant and after the first post natal week, there is a 
switch at which point GluN2A expression is enriched (Stiegerwald et al., 
2000). It has been suggested that extrasynaptic receptors retain a higher 
proportion of GluN2B subunits (Groc et al., 2006). However, Petralia et al. 
(2010) and Harris and Pettit (2007) report an even distribution of GluN2A 
and GluN2B receptors at synaptic and extrasynaptic si es. In addition, 
although Liu et al., (2007) found differential coupling of GluN2A and 
GluN2B to pro-survival and pro-death cascades respectively, the 
selectivity of the GluN2A agonist used has been disputed (Frizelle et al., 
2006). Furthermore, GluN2B and GluN2A receptors have both displayed 
the ability to promote cell survival or cell death (von Engelhardt et al., 
2007; Martel et al., 2009). Such investigations have been confounded by 
the absence of a selective GluN2A antagonist. However, an elegant study 
recently published by Martel et al., (2012) used chimeric NMDAR 
subunits with the C terminal domains (CTDs) of GluN2A and GluN2B 
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switched to demonstrate that the CTD of GluN2B promotes excitotoxicity 
better than that of GluN2A and this was independent of the identity of the 
other domains of the subunit. 
A second theory is that there are differences in the components of the 
NMDAR signalling complexes at synaptic and extrasynaptic sites (Collins 
and Grant, 2007).  However, a number of key members of the post-
synaptic density membrane associated guanylate kinases (MAGUKs) are 
found at both synaptic and extrasynaptic sites. In particular the post-
synaptic density protein 95 (PSD95) and disks large homologue 3 
(SAP102) were found associated with extrasynaptic NMDARs in 
hippocampal cultures (Petralia et al., 2010).  
The third model proposes that differences in the dynamics of calcium 
transients through extrasynaptic versus synaptic NMDARs affects the 
downstream signalling complexes. In contrast to synaptic NMDARs which 
are activated transiently after synaptic glutamate rel ase, the timecourse of 
extrasynaptic NMDAR activation is chronic, resulting from increased 
background calcium concentrations.  Despite evidence that the equivalent 
changes in calcium concentration from synaptic activity versus 
extrasynaptic NMDAR activity (Hardingham et al., 200 ), this model 
suggest that it is the prolonged increase in calcium concentrations that may 





1.3 Pro-survival and pro-death signalling from 
NMDARs 
 
Studies in rodents both in vivo and in vitro have greatly contributed to our 
understanding of the distinct pathways activated/repressed by synaptic and 
extrasynaptic NMDAR activity. In cortical neuronal cultures, synchronous 
bursts of NMDAR activity can be stimulated by using the GABAR 
antagonist bicuculline to disinhibit circuit activiy alongside the K+ channel 
blocker 4-AP which depolarises cells increasing the probability that they 
will fire action potentials. Extrasynaptic NMDARs are pharmacologically 
isolated by first blocking synaptic NMDARs with the open channel 
blocker MK-801 and subsequently applying the agonist NMDA to the 
culture. in vivo, pathways downstream of synaptic NMDAR activity have 
been confirmed by analysis of cortical tissue from mice injected with MK-
801.  
Strikingly such analysis has shown that not only do NMDARs couple to 
distinct pathways depending on whether they are located at the synapse or 
at extrasynaptic sites, but in some cases, extrasynaptic NMDAR signalling 
opposes synaptic NMDAR signalling in a dominant manner (Hardingham 




1.3.1 Synaptic NMDAR activity promotes cell survival 
 
Abolishing synaptic NMDAR activity is highly detrimental to neuronal 
health (Ikonomidou et al., 2001). Antagonism of NMDAR activity in vivo 
has been shown to decrease the number of healthy cells and induce large-
scale apoptosis (Gould et al., 1994; Ikonomidou et al., 1999; Pohl et al., 
1999; Adams et al., 2002; Papadia et al., 2008) and amplifies neuronal loss 
in both acute traumatic brain injury and ongoing neurodegeneration 
(Ikonomidou et al., 2000). A multitude of studies have shown a powerful 
coupling of synaptic NMDAR activity to pro-survival signalling through 
both the induction/repression of gene expression and posttranslational 
modifications of existing proteins. 
For over two decades molecular signalling cascades downstream of 
neuronal activity have been studied as an example of how genetic profiles 
can be regulated by physiological stimuli (Morgan et al., 1987).  Indeed, 
synaptic NMDAR activity has been shown to bestow neuroprotective 
properties on the postsynaptic cell that enhance neuro al survival in the 
face of noxious stimuli (Papadia et al., 2008; Leveille et al., 2008; Lau et 
al., 2009). In addition, the acquired neuroprotection can outlast the 
timecourse of the activity itself (Papadia et al., 2005). This 
physiologically-driven neuroprotection was shown to have both 
transcriptional-dependent and independent factors and provides a robust 
protection by altering a number of fate-determining cascades. This 
includes; the repression of apoptotic genes and upreg lation of anti-
apoptotic genes, increase in pro-survival genes such as those involved in 
mitochondrial biogenesis and  function, and the enhancement of 




1.3.2 Synaptic NMDAR activity is anti-apoptotic 
 
The phenomena known as ‘apoptosis’ was defined by Kerr et al., (1972) 
describing common morphological features observed during controlled cell 
death. Apoptosis, often referred to as ‘programmed c ll death’ is thought 
to be a means of regulating cell populations during development and in the 
event of cellular stress such as DNA damage (Kerr et al., 1972; Renehan et 
al., 2001). Changes in cell morphology include pyknosis, chromatin 
condensation, nuclear fragmentation, plasma membrane blebbing, finally 
resulting in engulfment by resident phagocytes (Kerr et al., 1972). Despite 
common morphological traits, Kroemer et al., (2009) argue that 
heterogeneity of biochemical mechanisms which can induce programmed 
cell death indicate distinct subtypes of apoptosis. For example, there exist 
two known sub categories into which apoptotic events fall: intrinsic or 
extrinsic apoptosis. Extrinsic apoptosis is initiated by ligand activation of 
dedicated transmembrane death receptors from the tumour necrosis factor 
superfamily (Ashkenazi and Dixit, 1998) which can activate caspase -8 
and caspase-9 (Riedl and Salvesen, 2007; Fig 1.5). 
 
1.3.2a The intrinsic apoptosis cascade 
In the intrinsic apoptotic pathway, Cytochrome C released from the 
mitochondria binds APAF1, initiating the formation of the apoptosome 
(Riedl and Salvesen, 2007). In turn, the apoptosome activates the initiator 
enzyme Caspase-9 which leads to the cleavage of and subsequently the 
irreversible activation of caspase-3 and caspase-7 (Riedl et al., 2001). 
Caspase-3 and Caspase-7 are responsible for executing the morphological 












Figure 1.5 Intrinsic and extrinsic apoptosis: 
apoptosis, through mitocho
activation of the death receptor. 
associated X protein; BH3 interacting domain death agonist;  PUMA, pro
apoptotic Bcl2 homology domain 3 (BH3)




Two distinct routes to 
ndrial (orange) cytochrome C release or 
BAK, Bcl2-antagonist/killer; BAX, Bcl2
-only member gene BCL








In addition, apoptosis is regulated by the Bcl-2 family of proteins, which 
can fall into three categories: pro-apoptotic multimeric domain members, 
pro-apoptotic BH3 only domain members or anti-apoptotic members.  
Examples of multidomain members include Bcl2-associated X protein 
(BAX) or BAK which form oligometric structures that permeabilise the 
outer mitochondrial membrane, allowing release of cyto hrome-C. This 
requires the binding of BH3 domains. The anti-apoptotic members Bcl-2 
and Bcl-XL antagonise the formation of BAX/BAK mediated pores, 
through binding to BH3 domains. However, the pro-apptotic BH3 only 
Bcl-2 members such as BAD, BID, BIM and PUMA can inhibit this 
interaction by binding to antiapoptotic Bcl-2 proteins. This leads to the 
disinhibition of BAX and BAK (Youle and Strasser, 2008) and increased 













1.3.2b Repression of pro-apoptotic genes  
 
One mechanism of neuroprotection from ongoing synaptic NMDAR 
activity is the repression of endogenous apoptotic genes (Papadia et al., 
2005; Lau and Bading, 2009; Léveillé et al., 2010; Soriano et al., 2011). 
The phosphoinositol-3-kinase (PI3K)/Akt pathway is a potent repressor of 
apoptotic genes and is activated by synaptic NMDAR activity (Papadia et 
al., 2005). Synaptic NMDA Ca2+ transients activate the calcium–binding 
protein calmodulin. Calmodulin activates phosphoinos tol-3-kinase 
causing the synthesis of phosphatidylinositol trisphosphate which recruits 
Akt to the plasma membrane where is it phosphorylated by 
phosphoinositide dependent protein kinase (Brazil et a ., 2004).  
Akt phosphorylates and represses the pro-apoptotic genes; glycogen 
synthase kinase-3 (GSK-3), the BH3-only Bcl2 family member BAD, the 
BH3-only member gene Puma and the stress-activated protein kinase 
(SAPK) subtype c-Jun N-terminal kinase (JNK) (Hardingham & Bading 
2010).  
Synaptically activated Akt also represses the proapoptotic transcription 
factors forkhead box protein O (FOXO) and P53. FOXO1 and FOXO3 are 
the major FOXOs in neurons. FOXOs mediate the transcription of the pro-
death genes including Bcl2-interacting mediator of cell death (Bim), Puma, 
Fas ligand (Fas1) and thioredoxin-interacting protein (Txnip) (Hardingham 
and Bading 2010). Akt phospohorylates FOXOs causing their nuclear 
exportation, and since Foxo1 is itself a FOXO target ne, this leads to 
prolonged repression of the FOXO1 pathway (Dick andBa ing, 2010; Al-
Mubarak et al., 2010).  The synaptically repressed transcription factor P53 
promotes the expression of the pro-death genes Bcl2-associated X protein 
(BAX) and apoptotic protease activating factor 1 (APAF1) (Lau and 
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Bading 2009). This potent activation of the PI3 Kinase/Akt pathway is 
specific to synaptic NMDARs (Soriano et al., 2006; Papadia et al., 2008). 
 
1.3.2c Induction of pro-survival genes 
 
Synaptic NMDAR Ca2+ influx, reinforced by the subsequent release of 
Ca2+ from internal stores, leads to an increase in both s mal- and nuclear- 
calcium concentrations. One major pathway to neuroprotection from 
nuclear- Ca2+ is via the activation of nuclear Ca2+/calmodulin-dependent 
protein (CaM) kinase IV and subsequent phosphorylation of the 
transcription factor cyclic-AMP response element biding protein (CREB) 
(G E Hardingham et al. 2001; Papadia et al. 2005; Lee et al. 2005). Outside 
the nucleus, these calcium transients also increase ERK1/2 
phosphorylation of the CREB binding protein (CBP) and 
dephosphorylation of transducer of regulated CREB activity (TORC) 
leading to the nuclear translocation of these two transcriptional 
coactivators necessary for the activation of CREB (Screaton et al., 2004). 
Whereas continuous synaptic NMDAR activity can protect neurons 
independent of CREB activity, long lasting protection from NMDAR Ca2+ 
is blocked by the CREB isoform ICER (Papadia et al., 2005).  
 
Importantly, although neuronal protection can last long after the 
stimulation has ceased, the associated CREB-phosphorylati n is transient.  
CREB-activity is now widely accepted to promote neuronal survival; 
targets of activity-driven CREB include the pro-survival growth factor 
brain-derived neurotrophic factor (BDNF) and the immediate early gene; 
c-fos (Dragunow, 2004; Lee et al., 2005; Papadia et l., 2005; Greer and 
Greenberg, 2008) and understanding the full  spectrum of gene changes 
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downstream of synaptic activity has been an ongoing goal of our lab and 
others. A recent study by (Zhang et al., 2009) identifi d a number of pro-
survival genes regulated by nuclear Ca2+ signalling; this cohort of genes 
was termed Activity-regulated Inhibitor of Death (AID) genes. The AID 
genes were highlighted from a large number of genes alterations 
downstream of nuclear calcium signalling, due to their previous 
implications in apoptosis (Zhang et al., 2009). The AID genes include 
activating transcription factor 3 (Atf3), B-cell translocation gene 2 (Btg2), 
B-cell lymphoma 6 (Bcl6), growth arrest and DNA-damage-inducible 45 
beta (Gadd45b), Gadd45g, inhibin beta A (Inhba), interferon activated 
gene 202B (Ifi202B), neuronal PAS domain protein 4(Npas4), nerve 
growth factor-induced gene Band serine protease inhibitor B2 (Serpinb). 
AID genes promote neuronal viability both in vivo and in vitro and the 
reduction of  NMDA-induced break—down of mitochondrial membrane 
potential  by Npas4, Bcl6, Inhibin b-A, Ifi202b, and Nr4a, suggest a 
common protective mechanism that builds defences against mitochondrial 
stress. In addition, we have recently shown that synaptic NMDAR activity 
induces the expression of the CREB-target gene peroxisome proliferator 
activated receptor gamma coactivator 1 alpha (PGC-1α); PGC-1α a 
transcriptional coactivator known to enhance the transcription of genes 
involved in mitochondrial biogenesis and function  (Soriano et al., 2011). 
 
 
1.3.3 Synaptic NMDAR activity reduces oxidative stress 
 
Oxidative stress occurs when the production of reactive oxygen species 
outweighs the cell’s ability to neutralise them viathe intrinsic antioxidant 
pathways. The accumulation of oxidative damage into nucleic acids, lipids, 
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proteins or carbohydrates is thought to contribute to the patho-progression 
of many neurodegenerative diseases (Mariani et al., 2005). Synaptic 
NMDAR activity promotes the expression of antioxidant genes and 
protects against oxidative stress both in vivo and in vitro (Papadia et al., 
2008). Again, this neuroprotective mechanism is distinct to synaptic 
NMDARs, in vitro bath application of NMDA which activates both 
synaptic and extrasynaptic NMDARs does not protect against antioxidant 
insults (Papadia et al., 2008). A key antioxidative pathway is the thiol-
reducing thiorexodin-peroxiredoxin system. The thioredoxin system 
consists of thioredoxin reductase, thioredoxin and peroxiredoxins which 
detoxify peroxides by transferring reducing equivalents from NADH to 
peroxide. Synaptic activity enhances thioredoxin by repressing the FOXO 
target gene the thioredoxin inhibitor Txnip (Papadia et al., 2008). In 
conditions of increases oxidative stress the antioxdidant peroxiredoxin can 
become hyperoxidized, synaptic activity enhances the reduction of 
hyperoxidized peroxiredoxins by increasing the exprssion of sulfiredoxin 







Figure 1.6 Synaptic NMDAR activity induces neuroprotective 
cascades Image from Hardingham and Bading (2010); Synaptic activity 
can prevent both apoptotic and non-apoptotic cell dath by reducing 
endogenous pro-apoptotic cascades, enhancing antioxidant defences and 
promoting mitochondrial health.  
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1.4 Extrasynaptic NMDARs promote cell death 
 
1.4.1 Extrasynaptic NMDAR activity and disease 
 
The activation of extrasynaptic NMDARs has been mechanistically linked 
to both acute and chronic neuronal injury in ischemic stroke and HD. 
Extrasynaptic NMDAR activation requires the presence of glutamate 
outside of the synaptic cleft. This occurs in cerebral ischemia, where 
glutamate uptake by glia cells is impaired. Under th se conditions the glial 
glutamate transporters no longer buffer extracellular glutamate, but rather 
release glutamate themselves. This leads to a buildup of glutamate causing 
chronic depolarisation of the cell. The proximity of glia to extrasynaptic 
sites suggests that this glutamate release may activate extrasynaptic 
receptors (Petralia et al., 2010). Indeed mimicking this process in vivo with 
the glutamate transport inhibitor v L-trans-pyrrolidine-2,4-dicarboxylate 
(PDC), which causes glutamate transporters to pump glutamate out of the 
cell, causes excitotoxicity due to extrasynaptic NMDAR activation (Gouix 
et al., 2009). In addition, ischemia has recently been shown to increase the 
activity of extrasynaptic receptors via death-associated protein kinase 
DAPK 1 phosphorylation of the GluN2B NMDAR subunit which causes 
increased channel conductance (Tu et al., 2010). 
A recent study by Milnerwood et al. (2010) identified a specific 
enhancement of both the expression and activity of extrasynaptic 
NMDARs in HD. This activity enhances the patho-progression of the 
disease (Okamoto et al. 2009) and as such is part of a p sitive feedback 
loop. Extrasynaptic NMDAR activity in HD is a major topic of this study 




 1.4.2 Extrasynaptic NMDARs are pro-death  
 
Site-specificity of NMDARs upstream of pro-death cas des is supported 
by the finding that extrasynaptic NMDARs alone is sufficient to induce 
equivalent levels of excitotoxic cell death as those seen after prolonged 
activation of all (synaptic and extrasynaptic) NMDARs together (Stanika 
2009). Activation of extrasynaptic NMDARs leads to the activation or 
repression of a number of cellular cascades that ultimately leave the cell 
vulnerable to oxidative stress and apoptotic cell dath (Hardingham and 
Bading, 2010). These include; mitochondrial calcium uptake and 
subsequent mitochondrial membrane depolarisation,  the repression of 
anti-apoptotic genes downstream of synaptic NMDARs, the promotion of 
pro-apoptotic genes transcription, and  aberrant calpain cleavage. (Fig 1.7)  
 
1.4.2a Loss of mitochondrial membrane potential  
Mitochondrial function is closely linked to excitotoxic events (Nicholls 
and Budd, 2000). Inhibiting mitochondrial calcium uptake strongly 
attenuates glutamate induced cell death (Stout el al., 1998). In fact, since 
calcium entering the cell via NMDARs is absorbed faster by mitochondria 
compared to calcium entry through voltage-dependent calcium channels or 
kainate receptors (Peng and Greenamyre, 1998), mitochondrial absorption 
dynamics is thought to play a role in the source spcificity of NMDAR-
toxicity.  Calcium enters the mitochondria through the calcium uniporter 
which relies on the mitochondrial membrane potential. 
The collapse of the mitochondrial membrane potential and the subsequent 
shift in the mitochondrial membrane permeability called the mitochondrial 
permeability transition (MPT) is a significant event that occurs early in 
excitotoxicity. A number of catastrophic events follow including the 
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depletion of cellular ATP, ionic imbalance, production of reactive oxygen 
species, and the release of cytochrome C which is known to induce the 
apoptotic cascade. Importantly, activation of extrasynaptic NMDARs, but 
not synaptic NMDARs, causes a rapid breakdown of the mitochondrial 






















Figure. 1.7 Extrasynaptic NMDAR activity enhances pro-death 
signalling cascades Image from Hardingham and Bading (2010); 
Extrasynaptic NMDARs are activated during acute traum ; during 
ischemic insult, glutamate outside the synaptic cleft activates extrasynaptic 
NMDARs and extrasynaptic NMDAR conductance is enhanced by DAPK-
phosphorylation of the NMDAR GluN2B subunit. Extrasynaptic 
NMDARs contribute to pathology of  HD (HD); in HD the presence of 
mutant huntingtin protein enhances extrasynaptic NMDAR expression and 
activity. Extrasynaptic NMDAR activity causes a dominant ‘shut-off’ of 
neuroprotective cascades including ERK1/2 and CREB regulated 
transcription, blocking PI3K via FOXO translocation, Calpain mediated 






1.4.3b Expression of proapoptotic genes 
Synaptic NMDAR activity promotes the nuclear export of he proapoptotic 
transcription factors FOXOs, whereas, extrasynaptic NMDARs have the 
opposite effect, causing the translocation and of FOXOs into the nucleus 
(Dick and Bading, 2010). As discussed above FOXOs regulates the 
transcription of pro-apoptotic genes and are known to contribute to 
oxidative and excitotoxic stress (Lehtinen et al., 2006; Lau and Bading, 
2010). 
 
1.4.2c Inactivation of CREB 
 
As discussed above, CREB-dependent transcription is responsible for the 
long-lasting neuroprotection afforded by synaptic NMDAR activity 
(Papadia et al., 2005). In contrast to this, the bath application of NMDA is 
a very poor activator of CREB (Bading et al., 1993). An explanation for 
this was first shown in 2002; Hardingham et al., (200 ) found that whereas 
synaptic NMDAR activity induces the phosphorylation f the CREB 
residue Ser-133, extrasynaptic NMDAR activity causes d phosphorylation 
of the same site, resulting in a dominant CREB-inact v tion signal. This 
CREB dephosphorylation has since been shown to be regulated by the 
juxtasynaptic attractor of caldendrin on dendritic boutons proteins 
(JACOB). JACOB is a binding partner of the calcium binding protein 
caldendrin (Dieterich et al., 2008). Caldendrin binds JACOB in a calcium-
dependent manner, preventing its nuclear import (Dieterich et al., 2008). 
Whereas synaptic NMDAR activity enhances caldendrin-retention of 
JACOB outside the nucleus, extrasynaptic NMDARs promotes nuclear 
import of (JACOB) which lead to CREB-dephosphorylation (Hardingham 
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et al., 2002). These CREB-shut off pathways are dominant over synaptic 
NMDAR-CREB activation. 
 
1.4.2d Repression of Ras-ERK cascade 
 
Extrasynaptic NMDARs also antagonise the Ras-ERK signalling pathway 
(Ivanov et al., 2006; Léveillé et al., 2008a). The extracellular-signal-
regulated kinases 1/2 (ERK1/2) pathway enhances neuronal survival by 
promoting CREB dependent gene expression (Mayr and Montminy 2001). 
In resemblance to the bidirectional control of CREB-activation, the 
regulation of the ERK1/2 pathway by NMDAR activity is also strongly 
dependent on the population of receptors activated. In contrast to synaptic 
NMDAR activity which leads to ERK activation, extrasynaptic activity 
couples to ERK dephosphorylation and inactivation (Ivanov et al., 2005). 
In addition, extrasynaptic NMDAR activity represses the small GTPase 
Ras (Kim et al., 2005); Ras is upstream of ERK and is required for 
activation of the neuroprotective Ras-ERK pathway (Avruch et al., 2001).  
 
1.4.2e Calpain activation 
 
In 2009 Xu et al., (2009) demonstrated that extrasyn ptic but not synaptic 
NMDAR activation can induce the calcium-activated cysteine proteases 
calpains, causing aberrant protein cleavage that contributes to 
excitotoxicity. Prior studies by Bano et al., (2005; 2007) have shown that 
calpain cleavage of the Na+/Ca2+ exchanger 3 (NCX3) contributes to 
excitotoxic and oxidative stress. NCX3 ordinarily regulates calcium 
expulsion and thus its inactivation is thought to contribute to delayed 
calcium deregulation associated with excitotoxicity (Bano et al., 2005).   
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Activation of calpains by extrasynaptic NMDARs also eads to cleavage of 
STEP (Xu et al., 2009). STEP is a negative regulator of P38MAPK and 
activating STEP cleavage via extrasynaptic NMDARS induces 
disinhibition of P38MAPK which is neurotoxic in cerebellar granule cells 




1.5 Huntington’s Disease 
  
Huntington disease (HD) is the most prevalent inherited neurodegenerative 
disease with an incidence of around 1 in 10,000 indiv duals. Characteristic 
symptoms include movement disorder, psychiatric and cognitive 
impairment followed by premature death normally within 10-15 years of 
disease diagnosis.  
The neurodegeneration of HD leads to widespread loss/dy function in the 
cortex in early stages of the disease (Rosas et al., 2002), followed by 
significant cell loss in the caudate and putamen (Subramaniam and Snyder, 
2011) which is thought to account for the motor, psychiatric and cognitive 
features of disease. Speculation that initial stages of HD  are driven by 
cortical dysfunction  with consequential malfunction in cortico–striatal 
pathways has been raised (Imarisio  et al., 2008). 
HD is inherited in an autosomal dominant manner and is caused by a CAG 
trinucleotide repeat in the HTT gene on chromosome 4, 17 codons 
downstream of the initiator ATG codon in exon 1. This mutation causes a 
polyglutamine expansion in the N terminal of the protein huntingtin (The 
HD Collaborative Research Group, 1993). It is currently believed that this 
polyglutamine insert causes a toxic gain of function on the mutant protein,  
which after sequential cleavage gives N-terminal frgments which contain 
the expanded polyglutamine region (Imarisio  et al., 2008). A hallmark of 
the disease is the accumulation of insoluble mutant Huntington protein into 
cellular aggregates; this has recently been shown to be a protective 
mechanism which protects the cell from the toxicity of the protein 
(Arrasate et al., 2004). The presence of mutant huningtin protein is known 
to disrupt a number of cellular processes including mitochondrial function, 
proteosome activity, synaptic and extrasynaptic NMDAR function and 
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excitotoxicity; as well as perturbing transcriptional pathways (Zeron et al., 
2002a; Donaldson et al., 2003; Jenkins et al., 2005; Cui et al., 2006). 
However, the full interplay between these mechanisms and their 
contribution to disease pathology is not fully understood. 
 
1.5.1 Increased excitotoxicity in HD 
 
Initial evidence for a potential role of NMDAR activi y in the 
neurodegeneration of HD came from studies demonstrating the ability to 
imitate the pathology of HD in vivo using NMDAR agonists. Injection of 
NMDAR agonists into the rodent striatum was seen to selectively destroy 
the medium spiny neurons sparing interneurons, thus mimicking the 
pattern of neuronal loss observed in HD (R J Ferrante et al. 1987; Beal et 
al. 1986). In addition, Hantraye et al. (1990) were able to replicate both the 
behavioural changes and neuropathology of HD in non-human primates by 
intrastriatal injection of the NMDAR agonist quinolinic acid. Subsequent 
investigations in YAC transgenic mice expressing the full length 
huntingtin with a polyQ expansion of 72 (YAC72) confirmed that 
excessive neuronal loss in response to quinolic acid was also observed in
vivo in this HD mouse model (Zeron et al. 2002). Cultured MSN from 
YAC72 HD mouse model exhibited enhanced apoptotic cell death in 
response to NMDA stimulation (Zeron et al., 2002). In addition, cultured 
cortical neurons acutely expressing either full length or truncated exon 1 
mtHtt, containing the polyglutamine repeat, also display increased 
excitotoxicity in response to glutamate stimulation (Okamoto et al. 2009). 
This toxicity was reversed by NMDA antagonists APV, Ifenprodil and 
interestingly low dose memantine, which selectively blocks extrasynaptic 
NMDARs ( Okamoto et al. 2009). 
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In 2009, Okamoto et al. showed that while synaptic NMDAR activity 
reduces the toxicity of mutant huntingtin, extrasynaptic NMDAR activity 
has the opposite effect, increasing the patho-progression of the disease. 
This study provided mechanistic insight in to the opp sing roles of 
NMDARs located at synaptic versus extrasynaptic sites, which have 
opposite effects on the formation of insoluble marcoin lusions. 
 
 
1.5.2  NMDARs and mutant huntingtin inclusions 
 
Aggregation of the mutant huntingtin protein into insoluble 
macroinclusions is a hallmark of the disease (Davies et al. 1997) ans is 
accompanied by striatal and cortical atrophy. The concurrence of aggregate 
formation and neuropathology of the disease lead to the prediction that 
inclusion formation was neurotoxic and disrupted cellular processes by 
sequestering proteins such as transcription factors (McCampbell, 2000) 
and components of the ubiquitin–proteasome system (UPS) (Donaldson et 
al., 2003). In contrast, multiple factors now suggest that rather than being 
toxic, the formation of these large insoluble inclusions are an example of 
one protective mechanism neurons use to counter the mutant protein. Like 
other neurodegenerative diseases, HD typically has a late onset, with 
symptoms presenting between 30-40 years of age. However, the mutant 
gene is present throughout life suggesting early mechanisms are in place to 
deal with mutant huntingtin. The argument that inclusion formation is an 
example of this is strongly supported by evidence that inclusion formation 
in certain cell types and brain regions does not correlate with their 
temporal vulnerability. For example, Gutekunst et al. (1999) found that 
mutant huntingtin aggregates were much more common in the cerebral 
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cortex than the striatum at a time when striatal loss was high and cortical 
atrophy was low. In addition Kuemmerle et al. (1999) reported 
disproportionate aggregation in striatal interneurons which are spared in 
HD compared to the more vulnerable medium spiny neurons.  
Consistent with this theory, a recent study by Okamoto et al. (2009) has 
shown that synaptic and extrasynaptic NMDARs have opposing influence 
on the toxicity of mutant huntingtin by altering mutant huntingtin inclusion 
formation. Synaptic NMDAR activity was found to prom te neuronal 
viability by enhancing the formation of non-toxic inclusions of the mutant 
huntingtin protein. Synaptic NMDAR activity increases the expression of 
the chaperonin T complex 1 ring complex (TRiC) subunit TCP1. TCP1 is a 
key mediator of inclusion formation and TCP1 knockdown significantly 
decreases protein aggregation, concurrently increasing neurotoxicity 
(Okamoto et al., 2009). In striking contrast, extrasynaptic NMDAR 
activity was found to activate a small GTPase called Rhes which causes 
sumoylation of mutant huntingtin, preventing inclusion formation and 
increasing toxicity (Okamoto et al. 2009; Subramaniam et al. 2011). 
 
1.5.3 NMDARs in Huntington’s disease 
 
A large body of work from Lynn Raymond’s lab has documented a 
striking increase in whole-cell NMDAR currents, synaptic NMDARs 
currents, NMDA-induced Ca2+ influx and increased NMDAR membrane 
insertion in MSN from the YAC72 HD mouse which expresses a mutant 
huntingtin that contains a 72 polyglutamine expansio  (Zeron et al., 2002; 
Li, et al., 2004; Zeron et al. 2004; Fan et al. 2007). This agrees with early 
work showing mtHtt to selectively increase currents when coexpressed 
with recombinant GluN1/GluN2B NMDARs in non-neuronal cells but not 
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when coexpressed with GluN1/GluN2A. Interestingly, relative expression 
GluN2B NMDAR subunit compared to other GluN2 subunits is enriched 
in striatal MSNs  (Christie et al. 2000; Li et al. 2004).  
Until recently, contrasting evidence existed for the role of NMDAR 
activity in the YAC 128 HD mouse which expresses a mutant huntingtin 
that contains a 128 polyglutamine expansion. Although both groups agreed 
that there is increased NMDAR vulnerability in the YAC 128 mouse, 
while Zhang et al. (2008) found an increase in GluN2B NMDAR current 
density in the YAC128 mouse, Fernandes et al. (2007) failed to observe a 
change in the NMDAR current density in this model. 
These conflicting results were resolved by a recent study demonstrating 
that mutant huntingtin, in the YAC128 mouse model of HD, selectively 
enhances the expression and function of NMDARs at extrasynaptic sites 
(Milnerwood et al., 2010). Changes in NMDAR expression in the YAC128 
mouse were likely masked in the previous study by the combined study of 
synaptic and extrasynaptic whole cell currents (Fernandes el al., 2007). 
Milnerwood et al., (2010) found a specific enhancement of GluN2B-
containing extrasynaptic NMDAR activity in the YAC128 mouse that 
persists into adulthood. This was accompanied by reduc d CREB-
phosphorylation consistent with a dominant extrasynptic NMDAR signal 
(Milnerwood et al. 2010; Hardingham et al. 2002). The imbalance of 
CREB-signalling towards the CREB-shut off pathway further exacerbates 
neuronal health by disrupting pro-survival signalling. Of particular interest 
to this study is the ability of both extrasynaptic NMDAR activity and 
mutant huntingtin to disrupt PGC-1α coactivation of pro-survival pathways 
discussed below. In addition, the NMDAR antagonist memantine which is 
known to selectively block extrasynaptic NMDARs at low concentrations 
is neuroprotective in a mouse model of HD (Okamoto et al., 2009). In vivo 
administration of low doses memantine in YAC128 HD mice increased 
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aggregate formation, reduced striatal volume loss and improved motor 
function (Okamoto et al., 2009). 
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1.6 PGC-1α  
 
 
The regulation and adaptation of biological processes in response to 
environmental cues requires coordinated changes in ge e expression. 
Classically, this gene-regulation was thought to bepredominantly 
regulated by DNA-binding transcription factors. More recently the 
biological control through the regulation of highly versatile transcriptional 
coactivators and corepressors has been appreciated (Lonard & O’Malley 
2007; Spiegelman & Heinrich 2004). Transcriptional 
coactivators/corepressors alter transcriptional output without directly 
binding to DNA. Rather, they are proteins that bind activators or repressor 
proteins i.e transcription factors/repressors which contain a DNA-binding 
motif, and are subsequently able to mediate their navigation through the 
chromatin structure and facilitate interactions with transcriptional 
machinery. 
 The inducible family of proteins: the peroxisome proliferator activated 
receptor gamma coactivator 1 (PGC-1) family, coactiv te the transcription 
of genes involved in mitochondrial biogenesis and oxidative metabolism 
and antioxidant defences (Lin et al., 2005). The PGC-1 family consists of 
three proteins PGC-1α, PGC-1β and PGC-related coactivator (PRC). 
Whereas PRC appears to be ubiquitously expressed, PGC-1α  and PGC-1β 
are expressed in highly metabolic tissues including brown adipose, brain, 
heart and kidney tissue (Handschin, 2009). Of the thr e proteins, PGC-1α 
has been most widely studied and is of particular interest to us due to its 
emerging role in neuronal health.  Downregulation of PGC-1α has been 
causally linked to the pathoprogression of HD and Parkinson’s disease 
(Cui et al., 2006; Qin et al., 2009;) and exogenous expression of PGC-1α 
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has proved neuroprotective in models of these disorers as well as 
Alzhiemer’s dieseaes, amyotrophic lateral scelrosis, i chemia and 
excitotoxicity (Chen et al., 2010; Cui et al., 2006; Luo et al., 2009; Qin et 
al., 2009; Shin et al., 2011a; Zhao et al., 2011). In this study, we 
investigate a novel mechanism of neuroprotection downstream of PGC-1α 
activity and describe how the loss of PGC-1α can increase the vulnerability 
















Figure 1.8 Function of PGC
remodelling and histone modification. PGC
factor targets (for example the RXR/PPARs complex), recruits histone 
acetylation transferase complexes including CBP/p300 and SRC, causing 
histone acetylation and chromatin remodellin
these proteins makes the chromatin more permissive for transcription
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1.6.1 PGC-1α: structure and function 
 
Upon binding to its target, PGC-1α selectively activates the transcription 
of a subset of genes downstream of the target transc iption factor (Schmidt 
& Mandrup 2011). PGC-1α increases transcriptional output by the 
recruitment of chromatin remodelling and histone modifying enzymes (Fig 
1.8). At its N-terminus, PGC-1α has a strong transcriptional activation 
domain which recruits histone acetylation transferas  complexes including 
3’-5’-cyclic adenosine monophosphate (cAMP) response element-binding 
protein p300 (CBP/p300) and steroid receptor coactiv tor-1 (SRC). 
Histone acetylation by these proteins makes the chromatin more 
permissive for transcription. At its C-terminus, PGC-1α recruits the thyroid 
receptor-associated protein/vitamin D receptor interacting protein/mediator 
complex (TRAP/DRIP). TRAP/DRIP assists interactions with the 
transcriptional machinery (Liu &  Lin 2011). 
The ability of PGC-1α to coactivate an array of both nuclear receptor and 
non-nuclear receptor transcription factors enables the regulation of a 
number of distinct tissues-specific processes. For example, in brown 
adipose tissue (BAT), PGC-1α promotes adaptive thermogenesis after cold 
exposure by coactivating the nuclear receptors PPARγ and the thyroid 
hormone receptor TRβ on the promoter of uncoupling protein-1 (UCP-1). 
PGC-1α  coactivation of  hepatic nuclear factor-4alpha (HNF-4alpha) is 
necessary for fasting-induced gluconeogenesis in the liver (Yoon et al., 
2001). In skeletal muscle, PGC-1α -coactivation of myocyte enhancer 
factor 2 proteins drive slow fibre gene expression (Li et al. 2002).  
Despite its functional versatility, loss of PGC-1α is generally associated 
with detrimental consequences in tissue function or viability (Handschin, 
2009). Substantial evidence suggests that PGC-1α  has a common role as a 
master regulator of mitochondrial biogenesis, fatty cid oxidation, electron 
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transport, and oxidative phosphorylation in an array of tissues including 
the heart, liver, skeletal muscle and the brain (Handschin, 2009). 
Exogenous expression of PGC-1α induces mitochondrial biogenesis by the 
coactivation of NRF-1, NRF-2, and the orphan nuclear r ceptor estrogen-








1.6.2 PGC-1α in the brain 
 
PGC-1α expression peaks in the rat brain between post-natal d y 3-15 in 
the cortex, striatum, and hippocampus (Cowell et al., 2007). Neurological 
impairment is evident in the two current PGC-1α knockout (KO) mice. 
One PGC-1α KO displays movement disturbances including myoclonus, 
exaggerated startle response, dystonic postering, frequent limb clasping 
and has brain lesions in the striatum and in cortical layers V/VI, the 
nucleus accumbens, substantia nigra, hippocampus and m mmalliary body 
(Lin et al. 2004). The other PGC-1α KO displays increased anxiety 
accompanied by microvacuolation in the pyramidal neurons of the cerebral 
cortex (Leone et al., 2005). PGC-1α null mice are also more sensitive to 
the neurodegenerative effects of the oxidative stres ors MPTP and kainic 
acid affecting the substantia nigra and hippocampus, respectively (Leone et 
al., 2005). 
Neurons are highly susceptible to oxidative stress by reactive oxygen 
species as in the absence of high levels of synaptic activity, neurons 
produce very little of the reactive-oxygen-species detoxifying enzymes 
(Mariani et al., 2005; Papadia et al., 2008). In addition, neurons are 
especially sensitive to defects in mitochondrial function for two reasons: 
(I) by converting the mitochondrial membrane potential to ATP via the 
ATP-synthase, mitochondria are the major source of cellular ATP. 
Neurons are subject to extreme fluctuations in ion c centrations due to 
action potential propagation and synaptic activity. The activity of ATP-
driven membrane bound ionic pumps are required to maintain ionic 
homeostasis, if cellular ATP is depleted, the neurons can become 
depolarised and vulnerable to disruptions in calcium homeostasis. (II) 
Since the mitochondria are themselves required to buffer fluctuations in 
cytosolic Ca2+ through a calcium uniporter, Ca2+ overload may lead to 
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mitochondrial permeabilization through the activation of the permeability 
transition pore, causing further release of calcium and loss of 
mitochondrial membrane potential. In the brain PGC-1α promotes 
neuronal viability and increases oxidative capacity b  promoting 
mitochondrial biogenesis (Wareski et al., 2009) and upregulating the 
reactive oxygen species (ROS)-detoxifying enzymes GPx1 and SOD2 (St-
Pierre et al., 2006).  
 
Altered metabolic function and mitochondrial health is a common feature 
of neurodegenerative disorders including HD, Alzhiemer’s disease, 
Parksinson’s disease, Amyotrophic lateral sclerosis, I chemia and 
excitotoxicty (Henchcliffe and Beal, 2008; Knott et al., 2008; Sheng et al., 
2011). Accordingly, models of the aforementioned neurological disorders 
have all displayed marked neuroprotection in respone to exogenous PGC-
1α expression (Cui et al., 2006; Luo et al., 2009; Okamoto et al., 2009; Qin 
et al., 2009; Chen et al., 2010; Mudò et al., 2011; Soriano et al., 2011; 
Zhao et al., 2011; Shin et al., 2011b). 
 
 
1.6.3 Regulation of PGC-1α in neurons 
Classically, synaptically-driven gene regulation is thought to occur by the 
activation of Ca2+ -responsive transcription factors (West et al., 2001). 
However, we have recently shown that the transcriptional co-activator 
PGC-1α is upregulated by synaptic NMDAR activity in vitro and is 
underexpressed after antagonism of synaptic NMDARs in vivo (Soriano et 
al., 2011). Synaptic activity can drive the upregulation of the major 
transcription factor CREB. CREB binds to and activates the PGC-1α 
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promoter increasing mRNA expression. Upregulation of PGC-1α outlasts 
the time window of activity-induced CREB-elevation in accord with the 
long-lasting neuroprotection afforded by synaptic activity (Papadia et al., 
2005; Soriano et al., 2011). 
PGC-1α can be both positively and negatively regulated by post-
translational modifications. These include sumoylation and 
phosphorylation which regulate overall PGC-1α activity in response to 
environmental cues (reviewed by Liu & Lin 2011).  In addition, PGC-1α 
pathway specificity can be governed by stimulus-induced phosphorylation 
preventing the interaction of PGC-1α with specific transcription factors 
(Lustig et al., 2011). In neurons, post-translational modifications of PGC-
1α are linked to the calcium activated kinases ERK and P38 MAPK (Luo 
et al. 2009). Studies in myoblasts and more recently i  neurons have 
shown that PGC-1α contains a negative regulatory domain and can recruit 
p160 myb binding protein (p160MBP) which reduces its transactivation 
ability (Puigserver et al. 2001; Wareski et al. 2009) . However, P160MBP 
–PGC-1α interaction is blocked by the phosphorylation of PGC-1α by p38 
MAPK. Indeed, in a recent study we have shown that synaptic activity can 
increase the transactivation potential of PGC-1α and this relies of p38 
MAPK phosphorylation of PGC-1α (Soriano et al., 2011). 
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1.7 PGC-1α and Huntington’s disease 
 
 
1.7.1 Mitochondrial defects in HD 
 
Defects in energy metabolism and mitochondrial functio  are thought to be 
involved in the progressive pathology of HD. Not only do HD patients 
suffer weight loss despite sufficient calorific intake (Myers et al. 1991), 
early Positron Emission Topography (PET) and Nuclear Magnetic 
Resonance Spectroscopy (NMR) studies showed HD patients to have 
altered energy homeostasis in the striatum, occipital cortex and frontal 
cortex (Kuwert et al. 1990; 1993;  Jenkins et al. 2005; 1998; Harms et al. 
1997). Support for changes in mitochondrial function came from 
observations that administration of the complex II inhibitor 3-NP mimics 
HD striatal and cortical lesions as well as disease-associated behaviours in 
rats, primates and humans (Beal et al. 1993; Chyi & C. Chang 1999; 
Ludolph et al. 1991). Much evidence has since emerged for defects in 
respiratory chain function and expression of complexes I-IV in HD (Turner 
and Schapira, 2010). In addition, evidence for  an oxidative stress 
component in HD comes from an increase of in vivo and in vitro free 
radical damage to DNA, lipids and proteins in HD (Butterworth, 1998; 
Browne et al., 1999; Greco et al., 2000).  
The transcriptional coactivator PGC-1α regulates several genes involved in 
mitochondrial biogenesis, respiration and detoxification of reactive 
species, therefore the discovery that mutant Huntingtin negatively 
regulates PGC-1α expression and function revealed one mechanism by 
which mitochondrial function is disrupted in the disease (Cui et al., 2006; 




1.7.2 Repression of PGC-1α by mutant huntingtin 
 
Striking similarities in the behavioural and neuropathological phenotype of 
the PGC-1α KO mouse and HD first suggested a possible role for PGC-1α 
in neurodegenerative disease (Lin et al. 2004). ThePGC-1α knockout 
mouse displays a number of movement disturbances includi g stimulus 
induced myoclonus, exaggerated startle response, dystonic postering, 
frequent limb clasping and has brain lesions predominantly in the striatum, 
but also in cortical layers V/VI, the nucleus accumbens, substantia nigra, 
hippocampus and mammalliary body (Lin et al. 2004). 
In 2006 two independent groups identified a relationship between 
disrupted PGC-1α activity and disease aetiology in HD (Cui et al., 2006; 
Weydt et al., 2006). A common loss of PGC-1α and PGC-1α-target genes 
encoding mitochondrial complexes was identified in all three of (i) human 
HD post mortem striatal tissue, (ii) striatal neurons of two HD mouse 
models, the HD KI mouse and HD N171-82Q mouse, and (iii) the HD 
striatal cell line STHdhQ111 (Cui et al., 2006; Weydt et al., 2006). PGC-1α 
rescued mitochondrial respiration in  STHdhQ111 cells  (Cui et al., 2006; 
Weydt et al., 2006) as well as toxicity in HD75 primary striatal cells (Cui 
et al., 2006) and lentiviral delivery of PGC-1α reduced striatal volume loss 
in the R6/2 HD mouse (Cui et al., 2006). 
Finally, mtHtt is proposed to directly interact with he PGC-1α promoter 
and repress CREB-dependent transcription of PGC-1α mRNA (Cui et al., 
2006). Cui et al. (2006) showed that mutant huntingtin occupies the PGC-
1α promoter and disrupts promoter activity; furthermoe reduced 
transcription of PGC-1α could be reversed overexpressing the transcription 
factor CREB alongside Transcription initiation factor TFIID subunit 4 
(TAF4) a component of the RNA polymerase machinery. Together this 
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evidence suggests that the loss of PGC-1α in HD may results from direct 
disruption of PGC-1α expression by mtHtt.  
Given the aforementioned role of PGC-1α in promoting neuronal health 
this describes one mechanism by which the cells becom  more vulnerable 
in HD and presents a potential therapeutic target. In addition, the interplay 
between PGC-1α, synaptic activity and mutant huntingtin expression 

















Figure 1.9 Interplay between PGC-1α, mtHtt and NMDARs in HD  
Image from Hardingham and Bading (2010). Destructive cascade: 
Although mutant huntingtin protein (mtHTT) can form insoluble 
aggregates which prevents its toxicity, mtHTT is toxic in its soluble form 
(c). MtHTT can repress the CREB-dependent transcription of PGC-1α (b) 
and can increase extrasynaptic NMDAR activity (a), exacerbating 
apoptotic cell death. In return, extrasynaptic NMDARs couple to the small 
GTPase Rhes (h) which reduces inclusion formation and increases the 
toxicity of mtHtt protein. Protective cascade: Synaptic NMDAR activity 
increases expression of the chaperonin T complex 1 ring complex (TRiC) 
which protects against mtHtt-apoptosis by inducing i clusion formation 
(d). Synaptic NMDARs also upregulate PGC-1α activity by promoting 
CREB-dependent transcription of PGC-1α gene (e) and by p38 
phosporylation of PGC-1α protein (f). PGC-1α protects against mtHtt-
induces cell death (g). 
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1.7.3 PGC-1α and other neurodegenerative diseases 
PGC-1α: Parkinson’s Disease 
 
Parkinson’s disease (PD) is a progressive neurodegenerative disease with 
the preferential loss of dopaminergic neurons of the substantia nigra. 
mRNA analysis shows a decrease in PGC-1α and the PGC-1α -target 
NRF-1 in PD striatal samples (Shin et al., 2001). This study found PGC-1α 
to be repressed by the Parkin-interacting substrate (PARIS) which is 
aberrantly overexpressed in one mouse model of autosomal recessive PD, 
the Parkin knock out mouse. Consistent with a role of  PGC-1α  in PD 
neuropathology, both transgenic expression of PGC-1α and 
pharmacological activation of PGC-1α caused an increase in the 
mitochondrial antioxidant expression and protect against cell degeneration 
in the MPTP model of PD (Mudo et al., 2011). 
 
PGC-1α: Amyotrophic lateral sclerosis  
 
Amytrophic lateral sclerosis (ALS) is a neurogenerative disease of the 
spinal cord and motor cortex attacking both the upper and motor neurons, 
leading to paralysis and death. ALS is thought to be mostly sporadic, 
however about 10% of cases are inherited, of which 20% are associated 
with mutations in the gene SOD1 (Zhao et al., 2011). Zhao et al., (2011) 
demonstrated that in crossing the PGC-1α transgenic mouse expressing 
human PGC-1α with the SOD1-G93A mouse model of ALS, they were 
able to rescue mitochondrial defects, motor  neuron l ss, motor 
performance and increase the life span in the double transgenic compared 





in vivo and in vitro models of ischemia have implicated PGC-1α as part of 
an inducible neuroprotective cascade against the neuropathology which 
results from cardiovascular disorders. Transient global ischemia (TGI) is 
associated with delayed neuronal loss in the CA1 subfield of the 
hippocampus and increased abundance of toxic reactiv  oxygen species 
(Piantadosi et al., 1996). PGC-1α expression is upregulated in the rat 
model of TGI along with the ROS-detoxifying enzymes UCP2 and SOD2 
(Chen et al., 2009). This is thought to be a protectiv  mechanism against 
neuronal damage, and indeed, disrupting PGC-1α in this model prevents 
UCP2 and SOD2 production, increases oxidative stress and exacerbates 
neuronal loss (Chen et al., 2009). In agreement, cultured cortical neurons 
stimulated with the in vitro model of ischemia, oxygen-glucose-
deprivation (OGD), have elevated PGC-1α expression, whereas virally-




PGC-1α: Alzheimer’s disease 
 
Alzhiemer’s diease (AD) is an age-related progressive disorder 
characterised by the formation of two classical lesion  (i) senile plaques 
composed of amyloid-β peptides and (ii) neurofibrillary tangles (Selkoe, 
2001). A recent study by Qin et al. (2009) reports the decline of PGC-1α 
mRNA and protein concurrent with increased dementia rating, Aβ-plaque 
formation and Aβ peptide in AD human tissue. In addition, exogenous 
PGC-1α expression was able to reverse hyperglycemia induced 
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amyloidogeneis. This study revealed a potential role f PGC-1α as a 
protective agent against AD pathology. 
 
1.8 Experimental Summary 
 
PGC-1α is widely studied for its role in mitochondrial biogenesis and 
function. However, given the concomitant loss of PGC-1α and the increase 
in excitotoxicity and altered glutamatergic activity n a number of NDGs 
(table 1.1), we propose that PGC-1α expression and NMDAR 
excitotoxicity may be causally linked.  In this thesis we aim to investigate 
the role of PGC-1α in excitotoxic cell death. We report the surprising 
finding that loss of PGC-1α increases neuronal vulnerability by altering 
NMDAR currents.   
In chapter three we investigate the role of PGC-1α in excitotoxic cell 
death and NMDAR current amplitude. We present the surprising finding 
that siRNA knockdown of PGC-1α in mouse cortical cell cultures leads to 
increased extrasynaptic NMDAR currents and increased excitotoxic cell 
death. Finally overexpression of PGC-1α reduces extrasynaptic NMDAR 
currents and protects against NMDA insult.  
 
In chapter four we explore the relationship between mutant huntingtin 
expression and PGC-1α on NMDAR currents and excitotoxicity. By 
expressing exon 1 of mutant huntingtin, containing a 148 CAG repeat, in 
cortical and striatal neuronal culture, we confirm that mutant huntingtin 
represses PGC-1α expression (Cui et al., 2006). We show that mutant 
huntingtin increases extrasynaptic NMDAR currents and excitotoxicity 
and this is non-additive to the effect of PGC-1α knockdown in these 
neurons. We also demonstrate that overexpression of PGC-1α can reverse 
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the increase in extrasynaptic NMDAR currents and cell vulnerability in 
both cortical and striatal cultures. 
 
In chapter five we use cortical tissue from a PGC-1α knock out (KO) mice 
to investigate the influence of chronic loss of PGC-1α throughout 
embryonic development on AMPA and NMDA –type glutamate receptors. 
We show that cultured PGC-1α KO neurons do not have altered whole-cell 
NMDAR currents or vulnerability to NMDA. However, KO neurons 
display reduced whole cell AMPAR currents, AMPAR mEPSC frequency 
























2.1 Primary rat and mouse culture 
2.1.1 Animals used for this study 
For acute study of the effect of plasmids transfection, E21 Sprague Dawley 
rats were used. 
PGC-1α KO and WT pups were obtained from Alberto Camacho Morales 
(Cambridge). PGC-1α transgenic mice had been generated by Astrazeneca 
Transgenic and Comparative Genomics, Sweden and details of the creation 
of the knockout have been published in D’Errico et al., (2011). Briefly, a 
targeting construct containing a floxed neomycin phosphotransferase in 
place of exons 3-5 of PGC-1α was created from a C57 mouse BAC 
template and was electroporated into AZX1, a C57BL/6JOlaHsd-derived 
ES cell line. One of the clones that underwent desired recombination was 
expanded and injected into Balb/cOlaHsd blastocysts to generate chimeric 
mice. Chimeric males were bred to C57BL/6JOlaHsd femal s. 
Heterozygous PGC1α ∆ex3–5 floxed Neo mice were bred to a constitutive 
Cre-deleter strain of mice to generate the heterozyg us PGC1α ∆ex3–5+/− 
mice lacking the Neo resistance cassette and leaving a single LoxP site at 
the deletion junction of intron 2 and 5. These mice were genotyped by 
using a forward primer (F2) in intron 2 and a reverse primer (R2) in intron 
5. Heterozygous PGC1α+/− littermate mice were then intercrossed to 
generate homozygous PGC1α−/− mice. The absence or presence of PGC-
1a RNA in wildtype, heterozygous or knockout mice was confirmed by 
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real time PCR analysis of RNA extracted from liver tissue( D’Errico et al., 
2011). For routine genotyping, DNA was extracted from cerebellar tissue 
using the phenolchloroform-isoamyl alcohol method. Genotype was 
determined by the presence of either a KO- or WT-specific DNA fragment 
using traditional PCR analyses. PGC-1α null mice have previously been 
shown to express defects in adaptive energy homeostasis and CNS 
hyperactivity. (Lin et al., 2004). 
 
2.1.2 Primary cell culture 
Cortical neurons from E21 Sprague Dawley rats and mice were cultured 
using the same technique with a couple of exceptions stated below. 
Neurons were cultured as described Bading et al., (2001) except that the 
growth medium was comprised of Neurobasal A medium + B27 
(invitrogen), 1% rat serum and 1 mM glutamine. Mothers were killed by 
cervical dislocation and pups removed in sterile conditions. Rat embryos 
were culled by intraperitoneal injection of sodium pentobarbital (dose). 
Mouse pups were culled by decapitation. 
The brain was removed and placed in dissociation medium (DM) (81.8 
mM Na2SO4, 30 mM K2SO4, 5.84 mM MgCl2, 252 µM CaCl2, 1 mM 
HEPES, 0. 1% Phenol Red, 20 mM Glucose,  1mM Kyurenic. 
Cortical/striatal tissue was incubated in DM with 10 units/ml of papain 
(Worthington Biochemical Corporation) for forty minutes at 37°C. The 
brain was cut along the midline separated left and right hemispheres. In 
order to isolate the cerebral cortex, we removed the olfactory bulb, 
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cerebellum, medulla, pons, midbrain, thalamus, hypothalamus and basal 
ganglia, followed by extraction of the hippocampus (in rats only) all 
remaining  structures were classified as cortical for this study. Cortices 
were then washed with DM and subsequently by growth medium 
containing NeuroBasal-A Medium, B-27 Supplement, Anti-Anti 
Supplement (anti-bacterial/anti-mycotic) (Invitrogen), 1mM glutamine and 
1% Rat Serum (Harlan SeraLab). Mouse cortices were incubated in growth 
medium for 5-6 hours at RT to enable transit from a laboratory in 
Cambridge to Edinburgh. Corticies were triturated in 37°C growth medium 
using a 2 ml disposable plastic pipette.  
The resulting cell suspension was then diluted using Opti-MEM 
(Invitrogen) supplemented with Glucose (20 mM), to obtain a 
concentration of one cortical hemisphere per 14 ml cell suspension. This 
solution was then plated on precoated sterile coverslip, with 0.5 ml of cell 
suspension used per well of a 24- well plate. Culture plates were incubated 
at 37 °C in a humified 5% CO2 atmosphere for two and  half hours, after 
which the cell suspension was removed and replaced with 1 ml of growth 
medium. At DiV 4, 1 ml of growth media supplemented with 9.6 µM 
cytosine-D-arabinofuranoside hydrochloride (AraC) (Sigma) was added to 
prevent proliferation of glial cells. 
Experiments were carried out at 8-10 days in vitro. At this stage, cortical 
neurons have developed a network of processes, express functional N-
methyl D-aspartate (NMDA)-type and AMPA/Kainate-type glutamate 
receptors and have formed synaptic contacts. For a lot of this study we are 
interested in the effect of plasmids/gene deletion on pyramidal neurons. 
For cell death and electrophysiological studies, pyramidal neurons were 
selected by morphology based on the presence of a large apical dendrite 




2.2 Plasmid preparation 
pcDNA-PGC-1α was a gift from P. Puigserver (Dana Farber Cancer 
Institute). PGC-1α  was subcloned in the pEF/V5-His A vector by excising 
the cDNA from the pcDNA vector with EcoRI and AgeI digestion and 
blunting it to clone it in the EvorV site of pEF/V5-His A vector. Myc-
wtHtt-N63-18Q (wtHtt(18Q)) and Myc-mtHtt-N63-148Q (mtHtt-(148Q)) 
were a gift from Stuart Lipton [Sanford-Burnham Medical Research 
Institute (Okamoto et al., 2009).  For cell death and electrophysiologyical 
recordings pEGFP-N1 driven by the CMV promoter was coexpressed with 
the plasmid of interest to label transfected neurons (see below). For 
nucleofection, GFP was subcloned from the pEGFP-N1 into the pEF/V5-
His A vector, this enabled high efficiency expression representative of 
other plasmids driven by EF-promoter. For plasmid generation, the GFP 
fragment was excised from pEGFP-N1 using Not1/EcoR1 and inserted 
into Not1/EcoR1 sites of pEF/V5-His A vector (Invitrogen) 
 
2.3 Transfection of plasmids 
Before transfection, neurons were transferred into trophic transfection 
medium ("TMits") supplemented with insulin-transferin-sertinin TMits 
was comprised of 10% MEM(Invitrogen) and 90% salt-glucose-glycine 
(SGG) medium (Bading et al., 1993) SGG:114 mM NaCl, 0.219% 
NaHCO3, 5.292 mM KCl, 1mM MgCl2, 2 mM CaCl2, 10 mM Hepes, 1 
mM glycine, 30 mM glucose, 0.5 mM sodium pruvate, 0.1% Phenol Red; 
osomlarity 325 mosm/l. Lipofectamine 2000 (Invitrogen) was used for all 
transfections as recommended concentration in TMits. Cells were placed in 
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transfection media for a minimum of four hours, befor  being tranfered 
into fresh TMits. 
 
2.4 Nucleofection of plasmids 
Nucleofection was carried out using Lonza Nucleofector. Cortical neurons 
were cultured in Neurobasal A medium + B27 (invitrogen), 1% rat serum 
and 1 mM glutamine (as above). Procedure followed user manual; 5ug 
DNA was used per 5 million cells. Effeciency of nucleofection was 
assessed by tracking expression of EF-GFP in control eurons. After 72 h, 
RNA was isolated from neurons for qPCR analysis.  
 
2.5 RNA isolation, reverse transcriptase-polymerase chain 
reaction, and quantitative polymerase chain reaction. 
RNA was isolated using the Qiagen RNeasy isolation reagents including 
the optional DNAse treatment, following passage of the cells through a 
QiaShredder column. cDNA was synthesized from 1-3 µg RNA using the 
Stratascript QPCR cDNA Synthesis kit (Stratagene). Briefly, the required 
amount of RNA (up to 3 µg) was diluted in RNase-free water (up to 7 µl 
final volume) and mixed on ice with 1x cDNA Synthesis master mix 
(10µl), random primers: oligo-dT primers 3:1 (total 2 µl- 200 ng) and 
either 1 µl RT/RNase block enzyme mixture (for RT reactions) or 1 µl 
water (for No RT control reactions). Reaction mixtures were mixed and 
spun down and incubated for 2 min. at 25°C, 40 min. at 42 °C and 5 min. 
at 95°C. cDNA was stored at -20°C.  
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Dilutions of this cDNA were subsequently used for real-time PCR (cDNA 
equivalent to 6 ng of initial RNA per 15 µl qPCR reaction) qPCR was 
performed in an Mx3000P QPCR System (Stratagene) using Brilliant 
SYBR Green QPCR Master Mix (Stratagene) according to the 
manufacturer’s instructions. Briefly, the required amount of template was 
mixed on ice with 1x Brilliant SYBR Green Master Mix, the required 
concentration of forward and reverse primers, 30 nMROX passive 
reference dye and water to the required reaction volume. Technical 
replicates as well as no template and no RT negative controls were 
included and at least 3 biological replicates were studied in each case. The 
sequence of the primers used are as follows:  
PGC-1α –F: 5’-GAATGCAGCGCTCTTAGC-3’,  
PGC-1-R: 5’-GCT TTT GCT GTT GAC AAA TG-3’  
GluN1 –F: 5’-CTGCGACCCCAAGATTGTCAA-3’  
GluN1-R: 5’-TATTGGCCTGGTTTACTGCCT -3’  
RPl13a-F 5’-GAGGTCGGGTGGAAGTACCA-3’  
Rpl13A-R 5’-TGCATCTTGGCCTTTTCCTT-3’  
complexin I,  F 5′-CCACTGCAGGACATGTTCAA-3′  
complexin I R 5′-TAAGATTGGTAGGGAGGGGG-3′  
GluA1-F 5’- CAACAATCACAGGAACATGCG-3’ 
GluA1 -R 5’-GAGAACTGGGAACAGAAACGGT-3’ 
GluA2 -F 5’- GGAGCAAATGTCTCTGGATTTC-3’, 
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GluA2 -R 5’-ATCACTTGGACAGCATCATACG-3’ 
GLUA3-F -5’ –TTCGGAAGTCCAAGGGAGAGT-3’  
GluA -R;  5’CACGGCTTTCTCTGCTCAATG-3’   
GluA4-F 5’-GGCTCGTGTCCGCAAGTC-3’  
 GluA4-R 5’-TTCGCTGCTCAATGTATTCATTC 3’.  
The cycling program was 10 min. at 95 °C; 40 cycles of 30 sec. at 95 °C, 
40 sec. at 60°C with detection of fluorescence and 30 sec. at 72 °C; 1 cycle 
(for dissociation curve) of 1 min. at 95 °C and 30 sec. at 55 °C with a ramp 
up to 30 sec. at 95 °C (ramp rate: 0.2°C/sec) with continuous detection of 
fluorescence on the 55-95 °C ramp. The data were analysed using the 
MxPro QPCR analysis software (Stratagene). Expression of the gene of 
interest was normalized to rpl13a, a commonly used control. 
 
2.6 Electrophysiological recording and analysis 
Recordings of agonist-evoked whole-cell currents were made 48-72 h after 
transfection. All recording were performed within a Faraday cage 
(Technical manufacturing Corporation (TMC)) mounted on a pressurised 
air table (TMC Micro-g Vibration isolation system), to prevent noise 
interference. Coverslips containing cortical neurons were transferred into a 
recording chamber containing artificial cerebrospinal fluid (aCSF) 
described below. Cells were visualised using a 40x water immersion lens 
(Carl Zeiss Germany). In all cases data was acquired using an  Axopatch-
1C amplifier (Molecular Devices, Union City, CA) with cells in whole-cell 




2.6.1 External recording solution: artificial cerebrospinal fluid 
(aCSF). 
 External recording solution was made of artificial cerebrospinal fluid 
(aCSF) containing (in mM): 152 NaCl, 2.8 KCl, 10 HEP S, 2 CaCl2, 10 
glucose, 20 µM strychnine, 50 glycine and 300nM tetrodotoxin (TTX), pH 
7.3 (320-330 mOsm). The external solution was applied at a constant flow 
rate of 4mls per minute at room temperature (22-25⁰C) 
 
2.6.2 Recording electrodes 
Patch pipettes were made from thick-walled borosilicate glass with  
dimensions 1.5mm O.D. x 0.86 I.D containing a filament (Harvard 
Apparatus, Kent, UK). Glass was mounted onto a Flaming Brown 
Micorpipette Puller (Model 97; Sutter instruments Co. USA) and pulled 
into a patch electrode to have a final resistance between 5-10 MΩ. 
Electrodes were mounted on a headstage (Axon instrument company, MP-
285) to enable fine manipulation. 
 
2.6.3 Internal Recording solution 
Pipettes were filled with an internal solution contai ing (in mM): 155 K-
gluconate, 2 MgCl2, 10 Na-HEPES, 10 Na-PiCreatine, 2 Mg2-ATP and 0.3 




2.6.4 Whole-cell agonist-evoked currents 
 To record whole cell agonist evoked currents coverslips containing 
cortical neurons were transferred into a recording chamber containing 
artificial cerebrospinal fluid (aCSF). Cells were voltage clamped at -60mV 
and the agonist in question was applied for an average of 30 seconds and 
steady-state current recordings were made. Agonists concentrations were; 
100 µM NMDA, 50 µM AMPA or 100 µM GABA. Agonist application 
and current recording was repeated twice for each cell for all agonist 
responses. Data were filtered at 1 kHz and digitized at 5 kHz for 
subsequent off-line analysis.  
 
2.6.5 Recording extrasynaptic NMDAR currents 
Recording of extrasynaptic NMDAR currents were performed 48-72h post 
transfection. Neurons were placed in Mg2+--free aCSF composed of (in 
mM): 152 NaCl, 2.8 KCl, 10 HEPES, 2 CaCl2, 10 glucose, 20 µM 
strychnine and 50 glycine, pH 7.3 (320-330 mOsm) supplemented with 
PTX (50 µM), TTX (300 nM) and MK-801 (10 µM) at room temperature. 
After a 10 minute incubation period, neurons were washed with MK-801-
free aCSF and placed in a recording chamber. Patch pipettes and internal 
solutions were the same as described above. NMDA (100µM) was applied 
for an average of 30 seconds and steady-state current recordings were 
made. Agonist application and current recording was repeated twice for 
each cell. Data were filtered at 1 kHz and digitized at 5 kHz for subsequent 
off-line analysis. Extrasynaptic NMDAR-current density was calculated as 
the steady-state current amplitude normalised to the cell capacitance. For 
each MK-801 stimulation 3 cells were recorded per coverslip and the mean 
current density per stimulation was calculated as n=1. 
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2.6.6 Miniature excitatory postsynaptic currents 
For miniature excitatory postsynaptic currents (mEPSCs) recordings, 
coverslips containing cortical neurons were transferred into a recording 
chamber containing artificial cerebrospinal fluid (aCSF) containing (in 
mM) 150 NaCl, 2.8 KCl, 10 HEPES, 2 CaCl2, 10 glucose, 20 µM 
strychnine, 50 glycine and 1.3 Mg2+, pH 7.3 (320-330 mOsm) and 
supplemented with 20 µM strychnine, 300 nM tetrodotxin (TTX) and 50 
µM picrotoxin (PTX). Patch pipettes and internal soluti ns were the same 
as described above. MEPSCs were recorded (Baxter and Wyllie, 2006) 
using an Axopatch-1C amplifier (Molecular Devices, Union City, CA). 
Events were recorded for 5-10 minutes (minimum of 300 events) from 
neurons clamped at −70 mV. Recordings were rejected if the cell holding 
current was higher than −100 pA. For data analysis, mEPSCs were filtered 
at 2 kHz and digitized at 10 kHz using WinEDR v6.1 software (John 
Dempster, University of Strathclyde, UK) and analyzed using 
MiniAnalysis software (Synaptosoft, Fort Lee, NJ). mEPSCs were 
manually selected with a minimum amplitude threshold f 10 pA 




2.7 Induction of excitotoxicity and following the fate of 
transfected neurons 
Following the fate of transfected neurons after induction of excitotoxicity 
was performed as described (Soriano et al., 2011). 24 hours after 
transfection neurons were transferred to a non-trophic growth medium 
("TMo") containing 10% MEM(Invitrogen), 90% salt-glucose-glycine 
(SGG) medium (Bading et al., 1993) SGG:114 mM NaCl, 0.219% 
NaHCO3, 5.292 mM KCl, 1mM MgCl2, 2 mM CaCl2, 10 mM Hepes, 1 
mM glycine, 30 mM glucose, 0.5 mM sodium pruvate, 0.1% Phenol Red; 
osomlarity 325 mosm/l. After 24 hours in trophically-deprived medium, 
pictures of GFP-expressing neurons were taken using a Leica AF6000 LX 
imaging system, with a DFC350 FX digital camera. Neurons were exposed 
to 10µM-20µM NMDA in trophically deprived media for 1 h, after which 
10 µM MK-801 (Tocris) was added to the neurons to bl ck ongoing 
NMDAR activity. Using the automated cell-finder function within the 
Leica AF6000 LX software, images of the same neurons were taken 24 
hours after insult.  
Acute studies: Cell death was determined by counting he number of 
surviving GFP-expressing cells pre- and post-insult. Cell death was 
indentified by the absence of healthy GFP-expressing neurons. Analysis of 
cell death was performed blind to the plasmid transfection/geneotype in 
each case. In >90% of cases evidence of death was observed as fluorescent 
cell debris and fragmented nuclei, confirming death due to excitotoxicity 
rather then quenching of eGFP- fluorescent signal. This is also underlined 
by the fact that death measured by this technique is blocked by caspase 
inhibitors (Papadia et al., 2008). For each condition the fate of ~100-150 
neurons was monitored over 3-6 independent experiments.  
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PGC-1α KO studies:  (Performed by Karen Bell, unpublished) Neurons 
were transferred to a non-trophic growth medium ("TMo") containing 10% 
MEM(Invitrogen), 90% salt-glucose-glycine (SGG) medium (Bading et 
al., 1993) SGG:114 mM NaCl, 0.219% NaHCO3, 5.292 mM KCl, 1mM 
MgCl2, 2 mM CaCl2, 10 mM Hepes, 1 mM glycine, 30 mM glucose, 0.5 
mM sodium pruvate, 0.1% Phenol Red; osomlarity 325 mosm/l. After 24 
hours, neurons were exposed to 10µM-20µM NMDA in trophically 
deprived media for 1 h, after which 10 µM MK-801 (Tocris) was added to 
the neurons to block ongoing NMDAR activity.  24 hours after insult 
neurons were fixed and subjected to 4′,6-diamidino-2-phenylindole (DAPI) 
staining, and cell death was quantified by the counting (blind) of the 
number of apoptotic nuclei as a percentage of the total. Neurons that die in 
response to exposure to excitotoxic levels of NMDAR agonists exhibit 
swollen cell bodies and pyknotic nuclei with small irregular chromatin 
clumps, a characteristic of necrotic cell death as opposed to apoptotic-like 
death (Fujikawa et al., 2000).  
 
2.8 Stimulation of synaptic activity in cell culture 
Bursts of action potential firing were induced by treatment of neurons with 
50 µM bicuculline, and burst frequency was enhanced by addition of 250 




2.9 Luciferase reporter assays 
PGC-1α-luc was a gift from A. Fukamizu [University of Tsuk ba (Daitoku 
et al., 2003)]. pTK-RL was from Promega. GluN1-Luc was a gift from G. 
Bai (University of Maryland (Liu et al., 2003)).  
Firefly luciferase-based reporter gene constructs [GluN1-Luc, PGC-1α-
Luc] were transfected along with renilla expression vector (pTK-RL) and 
plasmid of interest (globin, 18Q, 148Q, efPGC-1α) at a ratio of 0.2:0.1:0.2. 
Neurons were stimulated where appropriate 24 h after transfection. 
Luciferase assays were performed using the dual glo assay kit (Promega) 
with Firefly luciferase-based reporter gene activity. In the case of NR-1-
Luc reporter activity was normalised to the renilla control (pTK-RL 
plasmid).  
2.10 Microarray analysis 
 RNA 6000 Nanochips in the Agilent 2100 Bioanalyzer were used to 
assess the quality of RNA. Following this, Affymetrix One-cycle cDNA 
Synthesis Kit and GeneChip Sample Cleanup Module were used to 
synthesize and purify double stranded cDNA Double-stranded. The 
double-stranded DNA was used as template for the in vitro transcription 
using GeneChip IVT Labelling Kit (Affymetrix) yielding biotin-labelled 
cRNA. Purified biotinylated target cRNA was then fragmented into short 
sequences. The hybridisation cocktail consisted of 15 µg fragmented 
biotin-labelled cRNA spiked with eukaryotic hybridisation control. Eighty 
microliters of the hybridisation cocktail was first hybridized to the test-
chips to check the cRNA integrity and assess the system veracity. After 
that, the Mouse Genome 430A plus 2.0 microarrays (Affymetrix) were 
directly loaded with 130 µl of hybridisation cocktail solution and then 
placed in Genechip Hybridisation Oven 640 (Affymetrix) rotating at 
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60 rpm at 45 °C for 16 h. After hybridisation, the arrays were washed on 
Genechip Fluidics Station 450 (Affymetrix) and scanned using Genechip 
Scanner 3000 (Affymetrix) according to the manufacturer's procedure. 
Expression was calculated using the robust multiarray average algorithm 
implemented in the Bioconductor (http://www.bioconductor.org) 
extensions to the R statistical programming environme t24. Robust 
multiarray average generates a background-corrected an  quantile-
normalized measure of expression on the log 2 scale of measurement. 
 
2.11 Statistics 
For all experiments a minimum of 3 independent cultures were used and 
the n number of cells analysed is stated throughout. For experiments that 
rely on spontaneous synaptic properties of the neuronal culture (mEPSCs, 
experiments, quantal block protocol) and for cell death experiments, the 
statistical n is equal to the number of independent cul ures from single 
pups. In other cases, where we analyse the effect of he plasmid 
transfection on properties intrinsic to each cell (i.e., whole cell current), 
statistical n is equal to the number of cells analysed across a minimum of 3 
independent cultures. In each figure the statistical n is underlined for 
clarity. For the majority of cases a one-way ANOVA or t-test is used. For 
cases in which we analyse the interaction of two independent variables (i.e. 
coexpression of PGC-1α or globin with mtHtt of wtHtt)  two-way ANOVA 
is used followed by post hoc Dunnet’s or as stated. Analysis of cell death 
was performed blind to the plasmid transfection/geneotype in each case. 














3.1 Chapter summary 
In this chapter we investigate the neuroprotective mechanisms downstream 
of PGC-1α signalling. We confirm that exogenous PGC-1α is 
neuroprotective in our in vitro model of excitotoxicity in cultured rat 
cortical neurons. We also find that knockdown the endogenous PGC-1α 
increases the vulnerability of neurons to excitotoxic cell death.  These 
results are consistent with neurodegeneration previously reported in PGC-
1α knockout mice as well as the neuroprotective capacity of PGC-1α  in 
HD models. Having validated that PGC-1α is neuroprotective our in vitro 
model, we present the novel finding that PGC-1α expression mediates 
NMDAR current density in these neurons. Finally we show that whereas 
siRNA knockdown of PGC-1α leads to increased extrasynaptic NMDAR 
currents, overexpressing PGC-1α specifically represses extrasynaptic 
NMDAR currents. This repression of extrasynaptic NMDAR currents 
downstream of PGC-1α is surprising given its known role as a 
transcriptional regulator of mitochondrial biogenesis and function; 
however this result is consistent with the neuroprotective capacity of PGC-







3.2.1 PGC-1α regulates excitotoxicity in rat cortical cultures 
 
In order to investigate the role of PGC-1α in excitotoxic cell death we 
cultured cortical neurons from embryonic day 21 Sprague-Dawley rats. We 
then used an in vitro overexpression model to assess whether enhancing 
PGC-1α levels alters the vulnerability of neurons to subsequent toxic 
insults. Neurons were transfected at DIV8 with PGC-1α or control 
(Globin) plasmids along with an eGFP-marker to label th  neurons that 
were successfully transfected.  In order to track the fate of transfected 
cells, 48h post transfection, GFP-expressing cells were imaged. By 
marking the positions of the images taken using LEICA AF6000 LX 
software, we were able to reimage the same cells for comparison after 
NMDA-insult enabling us to track the fate of individual cells. 
We have previously shown stimulation with NMDA 20 µM (for 1 hour) 
triggers excitotoxicity in trophically-deprived neurons (Soriano et al., 
2006). We induced excitotoxicity in the neuronal cultures by 1 hour 
stimulation with NMDA (20 µM), after which the stimulation was stopped 
by applying the NMDAR antagonist MK-801 (10 µM). 24h post 
stimulation images of the same cells were retaken to track cell fate. 
Excitotoxic cell death was quantified by counting the loss of GFP-positive 
cells as a percentage of the total GFP-positive cells before treatment. We 
found that overexpressing PGC-1α protects neurons against NMDA-
induced cell death (Fig 3.1 p<0.05). 
We next investigated whether the loss of endogenous PGC-1α had an 
effect on excitotoxic cell death, by using two independent on-target 
siRNAs against PGC-1α. To validate the siRNAs we overexpressed Flag-
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tagged PGC-1α and confirmed the effectiveness of the siRNA in 
preventing PGC-1α expression (Fig. 3.2C). Knockdown of endogenous 
PGC-1α exacerbated neuronal death in response to a modest (10 µM) dose 
of NMDA (Fig. 3.2A,B) agreeing with studies by other groups (Luo et al., 
2009; Chen et al., 2010).  
This result is in agreement with the ability of PGC-1α to build antioxdative 
defenses and induce mitochondrial biogenesis, which should protect 
against the oxidative compenent of excitoxic cell death. However in 
Soriano et al. (2011) we found that, while exogenous PGC-1α protection 
against oxidative stress was occluded by co-transfection with the 
corepressor SMRT (Soriano et al., 2011), protection against exitotoxicity 
was uneffected by SMRT co-expression, suggesting these processes of 




















Figure 3.1 PGC-1α is neuroprotective against excitotoxic insult
(A) Images of neurons expressing GFP plus either a control (globin) 
plasmid or PGC-1α before and 24h after stimulation with 
Cells transfected (DIV7) were imaged 48h post transfection and 
excitotoxicity was induced by NMDA (20 µM) stimulation for 1h. 24h 
post stimulation images of the same cells were retaken to track cell fate. 
(B) Cell death was quantified by coun
a percentage of the total GFP
Overexpression of PGC
induced cell death (150




NMDA (20 µM). 
ting the loss of GFP-positive cells as 
-positive cells before treatment. 
-1α strongly protects neurons against NMDA

























Figure 3.2 Loss of endogenous PGC
excitotoxicity (A) Images of cortical neurons (DIV7) transfected with GFP 
plus either non-targeting control siRNA or one of two PGC
siRNA(i) or siRNA(ii)
fate was assessed by the loss of GFP
percentage of GFP-positive cells before treatment.  Knockdown of PGC
1α increased excitotoxicity in response to 10
from n=3 cultures were analysed per group).  *p<0.05, **p<0.01 (C) 
validate the siRNAs we coexpressed siRNAs (i) and (ii) with Flag
PGC-1α and confirmed that both siRNAs repressed subsequent anti
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3.2.2 PGC-1α expression regulates whole-cell NMDAR currents 
 
It has long been accepted that aberrant calcium signall ng due to excess 
NMDAR activity can initiate the excitotoxic pathway (Olney, 1969; Choi, 
1987; Tymianski et al., 1993) having a causal role in neuropathological 
disorders (Rothman and Olney, 1986; Choi et al., 1988; Lipton and 
Rosenberg, 1994; Arundine and Tymianski, 2004). Excitotoxic death in 
response to bath application of NMDA in neuronal cel ulture is dose 
dependent (Soriano et al., 2006) and is proportional to the number of 
receptors activated and the corresponding Ca2+ current. We therefore 
investigated whether increased NMDA vulnerability in the absence of 
PGC-1α and conversely the neuroprotection afforded by exog n us PGC-
1α may be due to direct/indirect regulation of cellular calcium influx 
through the NMDAR. We used whole-cell patch-clamp to examine the 
influence of exogenous PGC-1α overexpression or siRNA knockdown of 
PGC-1α on NMDAR current density in cultured cortical neurones. 
Neurons were transfected at DIV8 with either PGC-1α, PGC-1α siRNA(i) 
or PGC-1α siRNA(ii) plus eGFP to mark transfected neurons. 48h post 
transfection, coverslips were transferred to Mg2+-free aCSF and GFP-
positive cells were voltage clamped at -60mV. Bath application of NMDA 
(100 µM) triggers an influx of positive ions into the cell as represented by 
the downward deflection in the current traces in Fig 3.3. The size of the 
deflection in the current traces is equal to the amplitude of the evoked 
current response. The total membrane capacitance is directly proportional 
to the membrane surface area (Eq 1.). Therefore, to acc unt for differences 
in the size of neurons, the current amplitude is normalised to the 
membrane capacitance of the cell giving us the current density.  
 





Surprisingly, modifying the expression of PGC-1α led to changes in the 
NMDAR current density in these neurons.  PGC-1α overexpression caused 
a 32% decrease in total whole-cell NMDAR currents (NMDA 100 µM, 
Fig.3.3) and correspondingly PGC-1α siRNAs caused a significant 
increase (siRNA(i) 38% siRNA(ii) 80%) in whole cell NMDAR responses 
(NMDA 100µM, Fig.3.4). This result presents the unexpected fin ing that 
the transcriptional coactivator PGC-1α is able to regulate NMDAR current 
density in cortical neurons. Furthermore this suggests that neuroprotection 
from PGC-1α may be due to the repression of NMDAR currents and
subsequently reduced activation of excitotoxic cascades. This is consistent 
with the concurrent loss of PGC-1α and increased excitotoxicity in a 
number of neurodegenerative diseases as described in chapter 1.  
NMDAR signalling to cell death is known to be regulated by the calcium 
influx through the extrasynaptic pool of NMDARs (Hardingham and 
Bading 2005). In addition, our lab has recently shown that the C-terminus 
of the GluN2B and GluN2A have differing affinities for the activation of 
cell-death cascades (Martel et al., 2012). We investigated whether PGC-1α 
expression protects against excitotoxicity by selectiv ly altering the 
subunit composition of the NMDARs and secondly whether PGC-1α 
predominantly represses extrasynaptic activity. 
 
3.2.3 PGC-1α overexpression does not alter the GluN2B subunit 
composition of NMDARs 
One potential method of altering current density is by changing the 
efficacy of the NMDARs expressed in the neurons. The majority of the 
biophysical properties of the NMDARs are determined by the GluN2 
subunit composition including the affinity of magnesium block of the 
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channel, single-channel conductance, and glutamate affinity (Monyer et al. 
1994; Sucher et al. 1996; Meguro et al. 1993; Wyllie et al. 1996). In 
addition the C-terminal domain of the GluN2A and GluN2B subunits 
differentially couple to cell death (Martel et al., 2012). At the age of which 
these experiments are carried out (DIV 10-11), the GluN2B subunit is 
dominantly expressed in control neurons (Liu et al., 2004 and Fig 3.5). We 
investigated whether the increase in excitotoxicity and NMDAR currents 
in cells overexpressing PGC-1α could be due to altered ratio of GluN2 
subunits expressed. We used the GluN2B selective antago ist Ifenprodil to 
test the proportion of the total NMDAR current that is mediated by 
GluN2B subunits. Ifenprodil had equal effect on agonist-evoked NMDAR 
currents in control and PGC-1α expressing neurons at DIV 10 and DIV 16 
(Fig 3.5). This suggests that a switch in the dominant GluN2 subunits is 




Figure 3.3 PGC-1α overexpression reduces agonist
currents Agonist evoked whole
neurons transfected with GFP plus (A) globin (control) or (B) PGC
Neurons were placed in Mg
clamped at -60 mV using whole
currents were evoked by applying NMDA (100 µM) until the cell r
a steady-state. (C) NMDAR
state current amplitude normalised to the cell capaitance. Overexpression 
of PGC-1α caused a decrease in NMDAR current density. *t test p<0.05 
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Figure 3.4 Knockdown of endogenous PGC
evoked NMDAR currents 
from cortical neurons expressing GFP plus (A) control non
siRNA, (B) PGC-1α siRNA(i) or (C) PG
placed in Mg2+-free external recording solution and held at 
whole cell patch-clamp technique. NMDA (100 µM) was bath
cells inducing an inward current. (D) NMDAR current density was 
quantified from the wh
to cell capacitance. Neurons expressing either one of PGC
PGC-1α siRNA(ii) displayed greater than 30% increase in NMDAR 
current density compared to the control. One way ANOVA with post ho
Dunnett’s test *p<0.05, **p<0.01 (
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Fig 3.5 PGC-1α overexpression does not alter the subunit composition 
of NMDARs (A) The sensitivity of whole
by the GluN2B antago
PGC-1α expressing cells at (A) DIV10 and (B) DIV16 (





-cell NMDAR currents to block 
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3.2.4 Excitotoxicity and extrasynaptic NMDAR activity 
 
In the Central nervous system NMDARs reside both at synaptic sites 
where they partake in excitatory neurotransmission as well as at peri-
synaptic and extra-synaptic sites throughout the dendritic membrane 
(grouped as ‘extrasynaptic’ from herein). In contrast to synaptic NMDAR 
activity, which is known to be essential for neuronal survival (Ikonomidou 
et al., 1999) extrasynaptic NMDAR activity is detrimental to neuronal 
health (Hardingham et al., 2002; Léveillé et al., 2008a; Gouix et al., 2009). 
Because excess activation ofextrasynaptic NMDARs is an important 
mediator of excitotoxicity, we next investigated the influence of PGC-1α 
overexpression and knock-down on extrasynaptic NMDAR currents.  
 
Pharmacological isolation of extrasynaptic NMDARs 
 
To measure extrasynaptic NMDAR currents we pharmacologically 
isolated extrasynaptic receptors by first blocking synaptic NMDARs 
(Image 3.1). 48h post transfection, neurons were placed in Mg2+--free 
recording solution supplemented with PTX (50 µM), TTX (300 nM) and 
MK-801 (10 µM). Under these conditions miniature excitatory synaptic 
potentials (mEPSPs) are generated by spontaneous presynaptic release of 
single quanta of glutamate which activates synaptic NMDARs. These 
receptors are then immediately and irreversibly blocked by the open-
channel blocker MK-801. Extrasynaptic NMDARs, which remained closed 
during this ‘quantal block’ protocol, remain susceptible to activation by 
NMDA. Subsequent NMDA-evoked currents are recorded un er voltage-
clamp, which are now only mediated by extrasynaptic NMDARs. This 
protocol was previously used to study extrasynaptic signalling Papadia et 
al., (2008).  
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To ensure full blockade of synaptic NMDARs within the 10 minutes of 
MK-801/TTX/zero Mg2+ treatment, we conducted a timecourse 
experiment. Neurons were incubated for 0-30 minutes a  room temperature 
after which NMDAR-currents were evoked. This revealed that by 10 
minutes incubation in ACSF containing MK-801 blockade of synaptic 
NMDARs plateaus, and longer treatments have no further effect (Fig. 3.6). 
  
 
Image 3.1 Pharmacological isolation of extrasynaptic NMDARs 
Irreversible blockade of synaptic NMDARs by MK
spontaneous mEPSPs enable us to isolate the extrasynaptic p



























min incubation 48h post transfection, neurons were placed in Mg
recording solution supplemented with PTX (50 µM)
MK-801 (10 µM). Neurons were incubated for 0
temperature. After incubation, neurons were washed with MK
recording solution. Neurons were held under voltage
using whole-cell patch
recorded.  Extrasynaptic NMDAR
steady-state current amplitude normalised to the cell capaitance. (A) 
Example NMDA-responses from neurons expressing GFP plus after 0
minutes incubation with MK
currents is saturated by 10 minutes stimulation implying maximal blockade 




blockade of synaptic NMDARs saturates by 10 
, TTX (300 nM) and 
-30 minutes at room 
-
-clamp (-
-clamp and NMDA (100 µM) -evoked currents were 
-current density was calculated as the 










3.2.5 PGC-1α does not affect miniature synaptic activity 
 
The isolation of extrasynaptic NMDARs using the MK-801/TTX/zero 
Mg2+-protocol relies on mEPSCs activity to open synaptic NMDARs 
which are subsequently blocked by MK-801. To ensure PGC-1α 
expression does not alter mEPSC properties we tested the frequency and 
amplitude of mEPSCs in neurons expressing PGC-1α siRNA. This was an 
important control specifically for the PGC-1α siRNA knockdown because 
in Fig 3.9 we show that increased currents remain post MK-801 block in 
siRNA-expressing cells. Had the mEPSCs been altered in siRNA-
expressing cells, this could have been due to insufficient blockade of 
synaptic NMDARs. 
Neurons were transfected (DIV7) with GFP plus contrl siRNA, PGC-1α 
siRNA(i) or PGC-1α siRNA(ii). 48h post transfection, neurons were 
placed in recording solution supplemented with PTX (50 µM), TTX (300 
nM) and Mg2+ (1.3mM). mEPSCs were recorded in voltage clamp (-70 
mV) for 5-10mins using whole-cell patch clamp.  PGC-1α knockdown did 
not affect the frequency or amplitude of mEPSCs (Fig 3.7, p=0.76, 0.60 
respectively, 1-way ANOVA (n=5-6)).  We next confirmed that 10 
minutes of MK-801/TTX/zero Mg2+ treatment was sufficient for saturation 
of the blockade of NMDA-induced currents to in siRNA-expressing cells 
(Fig 3.8), reassuring us that the remaining currents were mediated by 
extrasynaptic NMDARs (Fig 3.8). The experiments in Fig 3.7 and 3.8 
indicate that the changes observed in subsequent experiments were due to 
alteration in the extrasynaptic pool of receptors, rather than the mEPSC 
properties of the neurons. In fig 3.8 current density after quantal block was 
normalised to the mean current in transfected (expressing the same 
construct) untreated (no quantal block) cells. This controls for difference in 
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the baseline current. This experiment also reveals th t the proportion of the 
whole cell current that is blocked by the quantal block protocol differs 
between control and siRNA expressing cells. In PGC-1α siRNA cells Mk-
801 blocks 63.4% of the mean current pre-quantal block compared to 78% 
in control cells. The effect of PGC-1α siRNA on the balance between 
synaptic and extrasynaptic NMDARs is the focus of the next set of 
experiments. 
  
Figure 3.7 siRNA knockdown of PGC
frequency or amplitude in cortical neuronal culture 
mEPSC traces from cortical neurons transfected (DIV7) with GFP plus 
control siRNA, PGC
transfection, neurons were placed in recording solution supplemented with 
PTX (50 µM), TTX (300 nM) and Mg
in voltage clamp (-70 mV) for 5
The amplitude distribution was similar for all three transfection groups. 
(C) Likewise, no change was observed in the inter
distribution between gr
change was observed in either the (D) mean mEPSC amplitude or (E) 
mean frequency between groups (





-1α does not alter mEPSC 
(A) Ex
-1α siRNA(i) or PGC-1α siRNA(ii). 48h post 
2+ (1.3mM). mEPSCs were recorded 
-10mins using whole-cell patch clamp. (B) 
-event interval 
oups (300 events per cell from n= 6, 5, 5 cells





















min incubation in siRNA
cell currents is saturated by 10 minutes MK
indicating maximal blockade of synaptic NMDARs. NMDAR current 
density was analysed following  t=0,5,10
Current response was normalis
control for differences in baseline current between wtHtt and mtHtt. (total 
17 cells expressing control siRNA; total 18 cells expr ssing PGC




blockade of synaptic NMDARs saturates by 10 
-expressing cells MK-801-reduction of whole
-801-Mg2+/TTX incubation 
2 ,30 incubation with MK









3.2.6 PGC-1α preferentially represses extrasynaptic NMDAR 
activity 
 
To record extrasynaptic NMDAR currents, 48h post transfection, neurons 
were placed in Mg2+--free recording solution supplemented with PTX (50 
µM), TTX (300 nM) and MK-801 (10 µM) for 10 minutes at room 
temperature. After a 10 minute incubation, neurons were washed with MK-
801-free recording solution. Neurons were held under voltage-clamp (-60 
mV) using whole-cell patch-clamp and NMDA (100 µM) -evoked currents 
were recorded. Extrasynaptic NMDAR-current density was calculated as 
the steady-state current amplitude normalised to the cell capacitance. PGC-
1α knockdown resulted in a striking increase in extrasynaptic NMDAR 
currents. Conversely, overexpression of PGC-1α greatly reduced 
extrasynaptic NMDAR currents (Fig 3.9) 
Both the positive and negative manipulation of PGC-1α expression lead to 
a far greater change in extrasynaptic compared to synaptic NMDAR (Fig. 
3.10). In agreement with studies on hippocampal neurons at >DIV9 
(Rosenmund et al., 1995) assessment of NMDAR currents pre and post 
synaptic NMDAR blockade revealed that extrasynaptic NMDAR currents 
represent 32.4% of whole cell currents (Fig 3.11A, n=11). Thus we predict 
that alterations in whole-cell currents resulting from PGC-1α 
knockdown/overexpression are largely attributable to the changes in 
extrasynaptic NMDAR currents.  
In order to directly confirm that PGC-1α adjusts the balance between 
synaptic and extrasynaptic NMDAR activity, we performed paired 
recordings of NMDA-evoked currents pre and post quantal block protocol 
in the same cell. From which we can extract the sizof the synaptic and 
extrasynaptic pools of NMDARs in control cells versus cells expressing 
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PGC-1α. First, the total-whole cell current response to NMDA (100 µM) is 
recorded, followed by 10 minutes MK-801 quantal block protocol and 
finally the subsequent response to NMDA (100 µM), which is now 
mediated only by the extrasynaptic pool or receptors is recorded. 
Subtracting the NMDA response post quantal block from the response pre 
quantal block gives us the amplitude of the synaptic NMDAR current. 
PGC-1α does not alter the synaptic NMDAR current density (Fig 3.11B); 
however, PGC-1α overexpression caused a significant decrease in the 
current density of extrasynaptic NMDARs (Fig 3.11C). 
Together this data shows that the concurrent neuroprotection and changes 
in NMDAR current density downstream of PGC-1α reflect alterations in 
the balance between synaptic and extrasynaptic NMDARs  and that higher 




Figure 3.9 Extrasynaptic NMDAR current density is increased in 
cortical neurons expressing PGC
overexpressing PGC
Mg2+--free recording solution supplemented with PTX (50 µM), TTX (300 
nM) and MK-801 (10 µM) for 10 minutes at room temperature
minute incubation, neurons were washed with MK
solution. Neurons were held under voltage
cell patch-clamp and NMDA (100 µM) 
Extrasynaptic NMDAR
current amplitude normalised to the cell capacitance. (A) Example traces 
of extrasynaptic NMDAR
PGC-1α siRNAs (B) Overexpression of PGC
extrasynaptic NMDAR current density (
* t-test p<0.05). (C) Conversely, extrasynaptic NMDAR cur
increased by the siRNA knockdown of PGC
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Figure 3.10 The effect of PGC
is greater on extrasynaptic NMDAR
whole-cell agonist-evoked currents 
greater reduction in whole cell NMDAR current density than total cell 
NMDAR current density (mean increase: 
28.04 ± 6.225 total,  N=4,4 *
(ii) caused a greater increase in extrasynaptic NMDAR currents compared 
to the total cell NMDAR current density
increase: 139.0% ± 22.03 extra
respectively **t-test p<0.01.  PGC
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Fig 3.11 PGC-1α overexpression preferentially represses extrasynaptic 
NMDARS but not synaptic NMDARS To directly assess the distinct 
effects of PGC-1α overexpression on synaptic versus extrasynaptic pools 
of NMDAR receptors we performed paired recordings of total followed by 
extrasynaptic currents in the same cell. First the total-whole cell current 
response to NMDA (100 µM) is recorded, followed by 10 minutes MK-
801 quantal block protocol and finally the subsequent response to NMDA 
(100 µM), which is now mediated only by the extrasynaptic pool or 
receptors. (A) At DIV10-11, the extrasynaptic NMDARs represent 32.4% 
of the total pool of NMDARs (n=11 from 3 independent cultures) (B) 
PGC-1α does not alter the synaptic NMDAR current density, measured by 
subtracting the current response after quantal block from that before 
quantal block, and normalising to cell capacitance. (C) PGC-1α 
overexpression caused a significant decrease in the current density of 
extrasynaptic NMDARs activated by NMDA (100 µM) post quantal block 






 3.2.7 Exogenous PGC-1α expression leads to decreased GluN1 
mRNA and GluN1 promoter activity. 
 
In view of the fact that the known processes downstream of PGC-1α lead 
to the positive regulation of transcriptional activity, these results raise the 
surprising finding that PGC-1α activity can repress the activity of the 
NMDAR. Since NMDAR activity can be regulated at many stages from 
transcription, to trafficking, to post translational modifications of active 
receptors, we next asked whether PGC-1α  regulation of NMDARs 
involved changes in transcription of the ubiquitous NMDAR subunit 
GluN1. Nucleofection of PGC-1α in cortical cultures lead to a 21±6% 
decrease in GluN1 mRNA expression (Fig 2.10) with a parallel 102±2% 
increase in the PGC-1α target cytochrome C compared to control (GFP-
expressing) cells.  
We then tested whether exogenous PGC-1α expression interferes with the 
GluN1-promoter activity. To do this, we coexpressed PGC-1α and a 5.4kb 
GluN1-promoter (a gift from Guang Bai; (Bai et al., 2003)). PGC-1α 
overexpression reduced the activity of a luciferase reporter of the GluN1- 
promoter (Fig. 2.10, 43±9%, p=0.009). Together this data shows that 



























































































Figure 3.12 Exogenous PGC-1α increases GluN1 mRNA expression 
and promoter activity (A,B) Dissociated cortical rat neurons were 
nucleofected with either PGC-1α or GFP plasmids. Exogenous PGC-1α 
expression (A) decreased the mRNA expression of GluN1 (n= 5 
nucleofections from 5 independent cultures, paired t-test p< 0.05) and (B) 
increased the mRNA expression of cytochrome C (n= 5 cultures, paired t-
test, p<0.01 ). (C) GluN1-promoter activity was assayed by luciferase 
activity in cells expressing the GluN1-promoter-luciferase report r with 
either Globin (control) or PGC-1α. PGC-1α significantly decreased GluN1 






3.3.1 Summary of experimental results 
This study shows the potent neuroprotective capacity of PGC-1α expressed 
in cortical neurons by the regulation of NMDAR activity specifically at 
extrasynaptic sites. We have previously shown PGC-1α expression is part 
of an endogenous activity-dependent pro-survival signalling cascade and in 
reducing PGC-1α expression, neurons become more vulnerable to both 
oxidative and excitotoxic stress (Soriano et al., 2011). The known role of 
PGC-1α in upregulating the transcription of genes involved in 
mitochondrial biogenesis and function as well as ROS-detoxifying 
enzymes is thought to explain one mechanism in which it exerts its 
protection against these two insults (St-Pierre et al., 2006). Indeed, 
excitotoxic cell death also shares many phenotypic components with 
oxidative-stress including the loss of mitochondrial membrane potential 
and increased ROS-production (Nicholls et al. 2012; Hardingham & 
Bading 2010). However, the selective disruption of the anti-oxidative 
potential of PGC-1α by coexpression of the corepressor SMRT, which 
does not affect PGC-1α signalling to anti-excitotoxic neuroprotection 
(Soriano et al., 2011) suggested a second independent mechanism might 
exist.  
Here we presents the novel finding that upregulation and conversely 
depression of PGC-1α expression in cortical neurons causes a bidirectional 
control of extrasynaptic NMDAR currents and vulnerability to NMDA-
induced death. This suggests that the neuroprotection afforded by PGC-1α 
signalling is partially due to the repression of the neurotoxic extrasynaptic 
NMDAR-signalling. In addition, we found that the regulation of NMDARs 
may be in part due to the transcriptional repression of the ubiquitous 
GluN1 subunit of NMDARs. One would assume that the mechanisms 
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underlying this transcriptional suppression are indirect due to the 
coactivating nature of PGC-1α on its target transcription factors. Although 
our results are inconclusive as to how the loss of PGC-1α could 
directly/indirectly bring about an increase in NMDAR expression, we do 
know that a resulting excess of NMDARs are preferentially located at 
extrasynaptic sites. Whether NMDARs always selectively occupy 
extrasynaptic when overly abundant or whether this loss in extrasynaptic 
retention is downstream of PGC-1α signalling is unstudied. However, 
recently published data from our lab shows that overexpression 
GluN1/GluN2A of GluN1/GluN2B cDNAs does not change the proportion 
of receptors at synaptic and extrasynaptic sites (Martel et al., 2012). 
Below, I will discuss known regulatory pathways involved in the 
expression, stability and function of NMDARs. 
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3.3.2 Potential routes to altered NMDAR-activity 
 
There are two possible explanations for the increase in the total whole-cell 
current density in cells after PGC-1α knockdown (i) an increase in the 
function of pre-existing receptors, (ii) an increase in the NMDAR 
expression across the postsynaptic membrane. Evidence for increased 
surface expression and forward trafficking of GluN2B-containing 
receptors by the PGC-1α- repressor mtHtt in HD models (Milnerwood et 
al., 2010) combined with the repression of the GluN1-promoter 
downstream of exogenous PGC-1α (this study), supports the latter. These 
two pieces of evidence suggest the involvement of post-translation 
modifications and transcriptional regulation respectively. Given its known 
role as a transcriptional coactivator, how might PGC-1α-repress the 
expression of NMDARs? 
 
 
3.3.3 Transcriptional regulation of NMDAR subunit expression 
 
Transcription of genes encoding the NMDAR subunits is the first stage in 
the physiological regulation of NMDAR expression and appears to etain 
the susceptibility to environmental cues throughout development and 
maturation (Bai and Hoffman. 2009). With that said the majority f factors 
known to bind to the regulatory cis elements within the GluN1, GluN2 or 
GluN3 promoters act to enhance transcriptional output. These include the 
following transcription factors; Specific Protein family (SP-1), Early 
growth response family (Egr), T box (Tbr), Fos, Jun,  cAMP response 
element-binding (CREB), and nuclear respiratory factor-1 (NRF-1) 
(Reviewed by  Bai and Hoffman 2009, Dhar & Wong-Riley 2009).  
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Of interest, NRF-1 activity is positively regulated by the PGC-1α activity 
(Wu et al. 1999).  This potential PGC-1α -NRF-1-GluN1 pathway would 
in theory oppose our findings the PGC-1α represses GluN1 transcription. 
However, by nature transcriptional coactivators upregulate only a selection 
of the genes transcribed by their target transcription factor and there is no 
evidence that PGC-1α activity is involved in NRF-1-dependent 
transcription of GluN1. 
Although reduced NMDAR-expression is a phenotype of neurological 
disorders including schizophrenia (Olney & Farber, 1995), little is know 
about specific repressors counteracting the transcription of the NMDAR 
subunits. However, all three of GluN1, GluN2A, GluN2B promoters 
contain the repressor element RE-1/NRSF. The trans factor RE1 silencing 
transcription factor (REST) or neuron-restrictive silencer factor (NRSF) 
(REST/NRSF) binding to the RE1 element repressing GluN1 and GluN2B 
expression (Bai et al., 2003). We have yet to investigate whether 
REST/NRSF activity may be regulated by PGC-1α. Alternatively 
transcriptional repression could occur via epigenetic remodelling of the 
GluN promoters. Promoters often contain clusters off CpG dinucleotides 
termed CpG islands and methylation of these CpG islands negatively 
regulates transcription. CpG island have been found in the promoter or 
proximal regions of GluN1, GluN2A, GluN2B (Bai and Kusiak, 1993; 
Suchanek et al., 1995; Liu et al., 2003; Kim et al., 2006). This represents 
another potential target for the repression of NMDAR- exprssion. In 
addition, although there is no evidence that the GluN subunits are subject 
to chromatin remodelling themselves, such modifications are known to 
regulate the GluN-activating transcription factor CREB (reviewed Bai and 
Hoffman, 2009; Levenson & Sweatt 2005). 
Of note, a number of independent groups have shown that mRNA-
transcription, specifically of GluN1 is not rate-limiting in the expression of 
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functional NMDARs (Huh and Wenthold, 1999; Chazot and Stephenson, 
2002; Prybylowski et al., 2002). Pryblowski et al., (200 ) found that 
increasing GluN1-mRNA alone in granule or cortical cells is insufficient to 
increase NMDAR-currents and rather the co-expression of GluN2 is the 
rate-limiting step and is able to recruit more GluN1 to the surface. This is 
consistent with the theory that there is an excess pool of unassembled 
GluN1 subunits retained within the ER that are rapidly degraded if 
unrecruited (Huh and Wenthold, 1999; Chazot and Stephenson, 2002). Of 
course a significant upregulation of receptor expression may require de 
novo transcription; however increased transcription alone may be 
insufficient to push more active receptors to the plasma membrane. In 
agreement with this, we have found that overexpressing a GluN1 plasmid 
in neurons causes no further increase in whole-cell current amplitude 
(experiment performed by Marc-Andre Martel; unpublished data). 
Vazhappilly & Sucher  (2004) reported translational regulation f 
transcribed-mRNA as a second regulatory step; however, consistent with 
pool of unassembled subunit, much more focus has been paid to the 
regulation of assembly, trafficking and receptor stability of NMDARs. 
 
3.3.4 Receptor stability at synaptic and extrasynaptic sites 
 
Throughout maturation NMDARs are trafficked in and out of he plasma 
membrane between synaptic and extrasynaptic sites (Groc et al., 2006;
Bard and Groc, 2011). Protein-protein interactions play an important role 
in regulating the stability of NMDARs. Even before leaving the 
endoplasmic reticulum, nascent NMDARs bind to MAGUKs such as PSD-
95, PSD-93, SAP-102 which facilitate cytoskeletal interactions necessary 
for receptor trafficking to both synaptic and extrasynaptic si es (Groc et al., 
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2006; Petralia et al., 2010). Once at the plasma membrane, NMDARs can 
directly interact with the cytoskeletal mesh, by binding to the actin binding 
protein, α-actinin (Wyszynski et al., 1997; Dunah et al., 2000) andthe 
cytoskeletal protein, spectrin (Wechsler and Teichberg, 1998). However, 
NMDAR-MAGUK interactions continue to regulate NMDAR stability by 
promoting the protein-protein interactions required for pst-translational 
modifications such as phosphorylation, ubiquitination, palmitoylation or 
calpain cleavage. Some specific modifications that retain receptors a  
synaptic sites over extrasynaptic sites have been identified. 
For example, specific phosphorylation of tyrosine (tyrosine1472) by Src 
and serine (Serine1480) by casein kinase II on the GluN2B-subunit are 
known to promote and disrupt synaptic retention of the receptor 
respectively. In contrast Src- phosphorylation of GluN2B tyrosine Y1336 
promotes extrasynaptic retention. NMDARs have two C-terminal cysteine 
clusters that once palmitoylated enhance synaptic trafficking and stability 
(Prybylowski et al., 2002; Hayashi et al., 2009). Similarly synaptic 
targeting of PSD-95 is thought to require its palmitoylation by the 
palmitoyl-acyl-transfrase (PAT), huntingtin interacting protein 14 (HIP14) 
(Huang et al., 2004; Huang and El-Husseini, 2005). Monoubquitination of 
GluN1 by F-box protein Fbx2 activity also regulates localisation (Hicke, 
2001), whereas, polyubiquitination recruits the ubiquitin/proteasome 
system and targets receptors for degradation (Ehlers, 2003). The C-
terminal of the NMDAR can be cleaved by calpain, and although this 
appears not to effect the biophysical function of the receptor (Guttmann et 
al. 2001; Puddifoot et al. 2009) it can disrupt interactions between the 
NMDAR and proteins of the post synaptic density. With such a complex 
mesh of NMDAR-regulating proteins there are many candidates for the 
indirect suppression of NMDAR activity by PGC-1α regulation of proteins 
involved in transcription right through to membrane stability. Given that 
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the mechanisms for targeting NMDARs to synaptic versus extrasynaptic 
sites are not well understood, this requires further investigation before we 




3.3.5 Mitochondrial function and NMDARs 
 
One explanation for the increase in NMDAR currents downstream of 
PGC-1α is that deregulation of NMDAR activity is a possible by-product 
of disruptions in mitochondrial function. In such knocking down PGC-1α 
disrupts the transcription of mitochondrial genes including members of the 
electron transport chain such as complex II. Consistent with this theory, 
the complex II inhibitor 3-NP, which mimics both behavioural and 
pathological phenotypes of HD, can induce LTP by increasing ynaptic 
NMDAR activity in the corticostriatal pathway (Calabresi et al.,2001; 
Gubellini et al., 2004). Furthermore, in addition to the essential role of 
mitochondrial-ATP production for ionic homeostasis in neurons, ATP has 
the ability to repress both GluN1/GluN2B-currents and NMDA-induced 
neurotoxicity in cultured hippocampal neurons (Ortinau et al., 2003). It is 
possible that the ability of PGC-1α to repress NMDAR-receptors is via 
regulatory mechanisms downstream of its known enhancement of 
mitochondrial biogenesis and function. 
 
Additional clues may be sought from neurodegenerative disease  known to 
display increased excitotoxicity and NMDAR deregulation as well as 
PGC-1α repression. The role of PGC-1α in neurodegeneration has been 
most widely studied in HD (Cui et al., 2006; Weydt et al., 2006; Okamoto 
et al., 2009). An imbalance of synaptic and extrasynaptic NMDAR activity 
also contributes to the toxicity of HD. In the next chapter w  investigate 
whether mutant huntingtin-induced changes in NMDAR expression and 









Chapter 4:  
PGC-1α repression underlies the effect of mtHtt on 
extrasynaptic NMDAR currents 
 





4.1 Chapter summary  
 
In this chapter we investigate the relationship between the HD protein 
mutant huntingtin (mtHtt) and PGC-1α in excitotoxic cell death and the 
regulation of NMDAR currents. We find that overexpressing the N-
terminal fragment of the mutant huntingtin protein containing a 148 
polyglutamine repeat (mtHtt (148Q)) in both cortical and striatal neurons 
increases excitotoxicity. We also show that mtHtt (148Q) increases 
NMDAR currents in both striatal and cortical neuronal culture. In addition, 
mtHtt (148Q) causes a specific increase in the extrasynaptic NMDAR 
currents in cortical cultures. These results are consistent with studies in 
YAC128 HD mouse model (Milnerwood et al., 2010; Fan et al., 2007) and 
confirm our in vitro model of the actions of mutant huntingtin in neurons. 
Given the known repression of PGC-1α by mutant huntingtin and the 
increase in extrasynaptic NMDARs and excitotoxicity after knockdown of 
PGC-1α we show in chapter three, we hypothesized that mutant 
huntingtin-repression of PGC-1α may mediate its effects on NMDAR 
currents and excitotoxicity. In this chapter we report tha in the absence of 
PGC-1α MtHtt has no further effect on NMDAR currents or excitotoxicity. 
We also show that restoring high levels of PGC-1α reverses the effect of 
mutant huntingtin on NMDAR currents and excitotoxicity. Together this 
data suggests that PGC-1α may be downstream of mtHtt in the regulation 
of NMDAR currents and that there may exist a common mechanism by 
which these two proteins mediate their effects on NMDAR currents. Data 






4.2.1 MtHtt increases excitotoxicity in primary cortical neurons 
 
Previous studies have shown enhanced excitotoxicity in mouse models of 
HD (Zeron et al., 2002; Zhang et al., 2008). We therefore inv stigated 
whether expressing the N-terminal mtHtt exon 1 (mtHtt (148Q)) 
containing the polyglutamine repeat in cultured neurons enhanced 
excitotoxicity compared to N-terminal wtHtt (wtHtt (18Q)) control. Our 
studies focussed initially on cortical neurons, and subsequently striatal 
neurons, both of which are effected in HD. Cortical neurons were 
transfected with GFP plus either control (globin), wtHtt (Q18) or mtHtt 
(148Q). Neurons transfected at DIV7 were imaged 48h later and 
stimulated with a low dose of NMDA (10 µM) for 1h. Stimulation was 
stopped by the addition of MK-801(10 µM) and 24h after stimulation 
neurons are re-imaged to track cell fate. Cell death was quantified as the 
loss of GFP-positive cells as a percentage of GFP-positive cells before 
insult. Cell death in untreated neurons was quantified by the same means 
and subtracted from the total death in NMDA-treated cells. Consistent with 
aforementioned studies, we observed an increase in vulnerability to sub-
toxic doses of NMDA (10 µM) in neurons expressing mtHtt (148Q) 
compared to wtHtt (18Q) or control (Globin)-expressing cells (fig 4.1). 
This indicates that our in vitro model of mutant huntingtin expression in 
neuronal cells mimics the neurotoxic phenotype of HD mouse models. 
Using this in vitro expression system in neuronal cultures, we can analyse 





















Figure 4.1 Mutant Huntingtin mtHtt (148Q) increases vulnerability to 
excitotoxicity in vitro
control (globin), wtHtt (Q18) or mtHtt (148Q) before and 24h after NMDA 
stimulation. Neurons transfected at DIV7 were imaged 48h later nd 
stimulated with a low dose of NMDA (10 µM) for 1h. (B) Cell death was 
quantified as the loss of GFP
positive cells before insult. MtHtt (148Q) dramatically increased 
vulnerability of cortical neurons to a low dose of NMDA (
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4.2.2 MtHtt increases whole-cell NMDAR currents in cortical 
neurons 
 
Previous studies have shown the YAC HD mouse models have incr ased 
NMDAR expression in the cortical and striatal neurons (Zeron t al., 2002; 
Zeron et al., 2004; Li et al., 2004; Fan et al., 2007) with a specific 
enhancement of extrasynaptic NMDARs (Milnerwood et al., 2010). These 
changes in NMDAR expression are thought to account for increased 
excitotoxicity in the YAC HD mouse models, and blocking the 
extrasynaptic NMDARs with the selective extrasynaptic NMDAR 
antagonist memantine rescues neuronal health (Milnerwood et al., 2010; 
Okamoto et al., 2009). We next investigated whether the increased 
vulnerability we observed after in vitro transfection of mtHtt(148Q) 
corresponds to changes in NMDAR currents in these cells.  
Cultured cortical rat neurons were transfected with GFP pluscontrol 
plasmid (Globin), wtHtt (18Q) or mtHtt (148Q) at DIV 8 and whole-cell 
patch-clamp analysis of NMDA-evoked currents was performed at DIV10.  
Neurons were transferred to Mg2+-free external recording solution and 
GFP-expressing cells were voltage-clamped at -60 mV using whole-cell 
patch-clamp technique. NMDA (100 µM) was bath-applied to the cells 
evoking an inward current. NMDAR- current density was calculated s the 
steady-state current amplitude normalised to the cell capacitance. 
Expression of mtHtt (148Q) caused an increase in NMDAR current density 
compared to control or wtHtt (18Q) (fig 4.2; p<0.05). This result agrees 
with data from the YAC HD mouse model and previous in vitro studies 
that show mtHtt-driven increase in excitotoxicity results in part from 
increased NMDAR currents (Milnerwood et al., 2010; Fan et al., 2007).  
Figure 4.2 MtHtt (148Q) expression 
NMDAR currents Agonist
neurons transfected with GFP plus (A) control plasmid (Globin) (B) wtHtt 
(18Q) (C) mtHtt (148Q).  Neurons were transferred to Mg
recording solution and voltage
clamp technique. NMDA (100 µM)  was bath
an inward current (D) NMDAR
steady-state current amplitude normalised to the cell capacitance. 
Expression of mtHtt (148Q) caused an increase in NMDAR curren
compared to control or wtHtt (18Q) cells *one way ANOVA followed by 
post hoc Dunnett’s test p<0.01, p<0.001 (
(Traces scale bar 5 s by 300 pA)
A B 
D 
in vitro increases whole
-evoked whole-cell currents from cortical 
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Our next aim was to test whether this increase is whole cell current and 
concurrent cell death was due to a preferential increase in extrasynaptic 
NMDAR activity as found in Milnerwood et al., (2010). To do this we 
used the ‘quantal block’ protocol described in chapter 2. To validate the 
use of this protocol, we first investigated whether mtHtt-expression altered 
mEPSCs amplitude or frequency, as well as confirming the saturation of 




4.2.3 No change in mEPSCs in cells expressing mtHtt (148Q) 
 
To study the effects of mtHtt expression on mEPSCs, neuro s were 
transfected (DIV7) with GFP plus wtHtt (18Q) or mtHtt (148Q). 48h post 
transfection, neurons were placed in recording solution supplemented with 
PTX (50 µM), TTX (300 nM) and Mg2+ (1.3mM). MEPSCs were recorded 
in voltage clamp (-70 mV) for 5-10 min using whole-cell patch-clamp. 
Analysis of mEPSC recordings showed that the amplitude and inter-event-
interval distributions were similar for both wtHtt (18Q) and mtHtt (148Q)-
expressing cells. Furthermore, no change was observed in mean a plitude 
or frequency between groups (Fig 4.3, mtHtt vs. wtHtt; p=0.26, 0.31 
respectively, T-test (n=6)). This confirmed that the synaptic mEPSC 
frequency and amplitude were unaffected by mtHtt (148Q)-expression in 




4.2.4 ‘Quantal block’ of synaptic NMDARs 
As in the previous chapter, we applied the ‘quantal block’ protocol using 
TTX/MK-801/ zero Mg2+  to selectively block synaptic NMDARs. This 
protocol requires that all of the synaptic NMDARs are activated during the 
quantal block period, such that they can be blocked by the irreversible 
open-channel antagonist MK-801. To confirm that the expression of 
mtHtt(148Q) does not effect the rate of blockade of synaptic NMDARs we 
performed a time-course experiment in which the coverslips containing the 
neuronal cultures were bathed in TTX/MK-801/ zero Mg2+ for increasing 
amounts of time to establish the time point of saturation of MK-801 
antagonism. 48h after transfection with globin (control), mtHtt(18Q) or 
mtHtt(148Q) plus an eGFP marker, neurons were placed in Mg2+--free 
recording solution supplemented with PTX (50 µM), TTX (300 nM) and 
MK-801 (10 µM). Neurons were incubated for 0-30 minutes at room 
temperature, and then washed with aCSF to remove residual MK-801. 
Coverslips were transferred to patch-clamp recording chamber containing 
aCSF supplemented with PTX, TTX and Zero Mg2+. GFP-expressing 
neurons were voltage-clamped at -60mV using whole cell patch clamp and 
NMDAR-currents were evoked. We confirmed that 10 minutes stimulation 
was sufficient to reach a saturated blockade of the synaptic proportion of 
the whole cell current and the time course of synaptic NMDAR blockade 
by MK-801 did not differ between wtHtt(18Q)-expressing and 
mtHtt(148Q)-expressing cells (Fig 4.4). In this experimnt we can see that 
both mtHtt(148Q) and wtHtt(18Q) reach saturating MK-801 block by 10 
minutes incubation; in addition, we observe reduction in the percentage of 
the mean whole cell current that is blocked by MK-801 in mtHtt(148Q) 
neurons. In mtHtt(148) cells only 54% of mean pre-treatmen  current is 
blocked by MK-801, compared to 64% in wtHtt-neurons. MtHtt-mediated 
changes specific to extrasynaptic NMDARs are analysed below. 
 
 
Figure 4.3 mtHtt(148Q) expression does not alter mEPSC frequency of 
amplitude in cortical neuronal culture 
cortical neurons transfected (DIV7) with GFP plus wtHtt (18Q) or mtHtt 
(148Q). 48h post transfection, neurons were placed in recording s
supplemented with PTX (50 µM), TTX (300 nM) and Mg
MEPSCs were recorded in voltage clamp (
whole-cell patch-clamp. (B) The amplitude distribution was similar for 
both wtHtt (18Q) and mtHtt (148Q)
change was observed in the inter
groups (300 events per cell from N=6 cells). No change was observed in 
either the (D) mean mEPSC amplitude or (E) mean frequency between 
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4.2.5 MtHtt enhances extrasynaptic NMDAR currents 
 
Milnerwood et al., (2010) presented evidence for enhanced extrasynaptic 
NMDAR activity in the YAC128 model of HD. In addition whereas 
increased extrasynaptic NMDAR signalling increases excitotoxic cell 
death, synaptic NMDAR activity is neuroprotective (reviewed Hardingham 
and Bading, 2010). We therefore applied the quantal block protocol 
described in chapter 3 to assess whether the extrasynaptic current density 
is altered after in vitro expression of mtHtt(148Q)  compared to 
wtHtt(18Q) control. Neurons were stimulated for 10 minutes with aCSF 
containing MK-801/TTX/zero Mg2+ to block spontaneously active synaptic 
NMDARs. Agonist activation of the remaining extrasynaptic NMDARs, 
which were not active during the quantal block protocol, was measured by 
subsequent bath application of NMDA (100 µM). MtHtt (148Q)expression 
led to an increase in extrasynaptic NMDAR currents compared to wtHtt 
(Fig. 4.5). Furthermore, the effect of mtHtt (148Q) onextrasynaptic 
currents was far greater than its effect on total currents (mean increase: 
139.0±22% extrasynaptic, 41.02±7.2% total current 
(synaptic+extrasynaptic) N=5, 4 p<0.01). At this stage of development in 
vitro, the extrasynaptic pool represents ~30% of the total population of 
receptors as described in chapter 3; this indicates a preferential ffect of 
mtHtt(148Q) on expression levels of extrasynaptic NMDARs over 
synaptic NMDARs (Fig. 4.6). As discussed in Milnerwood et al., (2010), 
this increase in extrasynaptic NDMAR activity may account for the













Figure 4.5 Extrasynaptic NMDAR current density is increased in 
cortical neurons expressing mtHtt(148Q) 
were placed in Mg2+--
µM), TTX (300 nM) and MK
temperature. After a 10 minute incubation, neurons were wa
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Figure 4.6 The effect of mtHtt
NMDAR- currents compared to the total whole
currents (A) mtHtt(148Q)
extrasynaptic NMDAR
cell current (mean increase 125.1% ± 2
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4.2.6 Does mtHtt alter NMDAR activity via the repression of PGC-
1α? 
 
In chapter 3 we described the bidirectional control of extrasynaptic 
NMDAR currents downstream of PGC-1α. Mutant huntingtin protein has 
previously been shown to suppress PGC-1α expression by directly 
interacting with the PGC-1α promoter (Weydt et al., 206). Therefore, we 
proposed that the effects of mtHtt on extrasynaptic NMDAR currents 
could be due to its known effects on suppressing PGC-1α expression. If 
this was the case we would expect the effects of PGC-1α knockdown and 
mtHtt (148Q) expression to be non-additive and occlude each other. 
Secondly, since overexpression of PGC-1α is known to counter both the 
toxicity of mutant huntingtin and suppress extrasynaptic NMDAR activity 
(this study) we hypothesised that exogenous PGC-1α expression should 
rescue the effect of mtHtt (148Q) on extrasynaptic NMDAR currents and 
toxicity. 
We first confirmed the repression of PGC-1α by mtHtt (148Q) - expression 
in cultured cortical neurons compared to wtHtt (18Q) control. 
MtHtt(148Q)  reduced PGC-1α-promoter activity assayed by the 
coexpression of mtHtt(148Q) or wtHtt(18Q) with a 5.4kb PGC-1α-














Figure 4.7 mtHtt expression significantly reduces PGC-1α promoter 
activity Cultured cortical neurons coexpressing a PGC-1α-promoter-
luciferase reporter plus either wtHtt(18Q) of mtHtt(148) were assayed for 
luciferase activity 48h post transfection. 24h after transfection neurons 
were stimulated with Bic/4AP to induce higher levels promoter activity 
(Soriano et al., 2011). The expression of mtHtt (148Q) significantly 
reduced promoter activity, n= 3 cultures, ttest p<0.05. 




4.2.7 MtHtt (148Q) and PGC-1α knockdown cause a non-additive 
increase in excitotoxicity 
 
Since we have evidence that mtHtt represses PGC-1α transcription in this 
model we hypothesised that this repression of PGC-1α may contribute to 
the mtHtt (148Q) increase in excitotoxicity. To test this, we analysed 
whether mtHtt (148Q) expression increased excitotoxicity in neurons that 
no longer express PGC-1α. PGC-1α siRNA was coexpressed with mtHtt 
(148Q) or wtHtt (18Q) plus an eGFP marker. Images of the same neurons 
were taken pre and 24h post a 1h NMDA (10 µM) stimulation. 
PGC-1α knockdown and mtHtt (148Q) both increased excitotoxicity 
compared to control (Fig 4.8). However, in neurons transfected with PGC-
1α siRNA, mtHtt (148Q)-expression had no additional effect on NMDA-
induced excitotoxicity (Fig 4.8, Two way, interaction factor p=0.0379). 
This suggests that the PGC-1α pathway is involved in the mtHtt 
excitotoxic pathway and that inhibiting PGC-1α expression is sufficient to 
mimic excitotoxicity of mtHtt. This agrees with data from the PGC-1α KO 
mice in which striatal lesions closely replicate those seen in HD mice (Cui 
et al., 2006). 
 
4.2.8 MtHtt (148Q) and PGC-1α knockdown cause a non-additive 
increase in NMDAR current density  
 
We next tested the combined effects of mtHtt (148Q) and PGC-1α 
knockdown on whole cells NMDAR currents. Neurons were transfected 
with wtHtt (18Q) or mtHtt (148Q) in the presence of either control non-
targeting siRNA or PGC-1α-targeting siRNA. Whole-cell current density 
was increased by mtHtt (148Q)-expression in control siRNA-expressing 
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neurons (t-test **p<0.01). Concurrently, siRNA knockdown of PGC-1α 
caused an increase in NMDAR-current density in wtHtt (18Q)-expressing 
cells (t-test *P<0.05). However, no significant difference in NMDAR 
current density was observed in cells co-expressing wtHtt (18Q) versus 
mtHtt (148Q) in PGC-1α siRNA-expressing cells (Fig 4.9) this result 
suggests for the first time, that the repression of PGC-1α by mutant 
huntingtin may account in part for the observed alteration in NMDAR 
activity reported in HD. 
 
4.2.9 MtHtt-increase in extrasynaptic NMDAR-currents is 
occluded by knockdown of PGC-1α 
 
Finally, we investigated whether the expression of mtHtt in cells 
expressing PGC-1α siRNA had further increase in extrasynaptic NMDAR 
activity. Expression of mtHtt (148Q) significantly increasd extrasynaptic 
NMDAR current density in control siRNA neurons but not in neurons 
expressing PGC-1α siRNA. Likewise, these observations support the 
hypothesis that mtHtt increases extrasynaptic NMDAR activity, at least in 





















Figure 4.8 MtHtt(148Q) expression and siRNA knockdown of PGC
have a non-additive effect on excitotoxicity 
1h NMDA (10 µM) stimulation. Cortical neurons were transfected with 
wtHtt (18Q) or mtHtt (148Q) in the p
targeting siRNA or PGC
MtHtt (148Q) expression caused an increase in NMDA
in control cells. No significant increase in cell death by mtHtt (148Q) 
compared to wtHtt (18Q)
expressing PGC-1α siRNA. (
analysed per group for each stimulation) *
Two-way ANOVA results show a significant interaction factor (p=0.0379) 
between the effects of PGC
expression on the loss of GFP
A 
B 
(A) Images pre and 24h post 
f
resence of either control non 
-1α targeting siRNA (PGC-1α siRNA (i)). (B) 
-induced cell death 
t
-expressing cells was observed in cells co
n=3, for each culture, 50-100 cells were 
t-test p<0.05 **p<0.01. (C) 























Figure 4.9 Co-expression of MtHtt (148Q) and PGC
in a non-additive increase in agonist
Neurons transfected with (A, C) wtHtt (18Q) or (B, D) mtHtt (148Q) in the 
presence of either (A, B) control non
targeting siRNA (PGC
increased by mtHtt (148Q)
neurons (t-test **p<0.01). Concurrently, siRNA knockdown of PGC
caused an increase in NMDAR
cells (t-test *P<0.05). No significant difference in NMDAR current density 
was observed in cells co
PGC-1α siRNA-expressing cells. (F) Two
significant interaction between the effect of PGC
and mtHtt (148Q)-expression on whole
the context of reduced PGC
whole-cell NMDAR currents. (T
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Figure 4.10 Increase of extrasynaptic NMDAR current density by 
mtHtt(148Q)-expression and siRNA knockdown of PGC
additive (A) Expression of mtHtt(148Q) significantly increased 
extrasynaptic NMDAR current density in control neurons but no i  
neurons expressing PGC
cultures, t test *p<0.05)
interaction between PGC
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4.2.10 PGC-1α rescues mtHtt (148Q)-mediated increase in 
excitotoxicity 
 
Given that mtHtt and PGC-1α knockdown occlude each other’s effect on 
excitotoxicity and NMDAR deregulation, we next tested the hypothesis 
that expression of exogenous PGC-1α can rescue the changes in 
extrasynaptic NMDAR activity and toxicity by mtHtt. Previous studies 
have shown that PGC-1α overexpression can protect against mtHtt toxicity 
in STHdhQ111 HD cell line, in vivo in the R6/2 cells the death as well as 
against cell death induced by TTX blockade of synaptic activity in primary 
striatal cells expressing mtHtt (Okamoto et al., 2009). Cortical neurons 
were transfected with GFP plus either control (globin) or PGC-1α 
alongside either wtHtt (Q18) or mtHtt (148Q). Coexpression of PGC-1α 
completely reversed the effect of mtHtt on excitotoxicity (Fig 4.10, mean 
cell death: 30.51 % ± 3.79 in mtHtt(148Q) + globin cells,   0.5404 % ± 
2.64 in mtHtt(148Q) + PGC-1α cells,  p<0.001). PGC-1α expression can 
counteract the toxicity of mtHtt. 
 
4.2.11 PGC-1α rescues mtHtt (148Q)-induced increase in NMDAR 
current density 
 
The ability of PGC-1α to rescue mtHtt-increases in excitotoxicity 
combined with the repression of NMDAR currents by PGC-1α expression, 
shown in chapter 1, suggests that exogenous PGC-1α may reverse the 
increase in NMDAR currents by mtHtt. To test this hypothesis, we again 
transfected cortical neurons with GFP plus either control (glbin) or PGC-
1α alongside either wtHtt (Q18) or mtHtt (148Q). MtHtt expression caused 
an increase in NMDAR currents in control cells; the increase in NMDAR 
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currents was significantly  reduced in cells expressing exogenous PGC-1α 
expression (Fig 4.11).  
 
4.2.12 PGC-1α overexpression rescues mtHtt (148Q) increase in 
extrasynaptic currents 
 
We tested the effect of mtHtt on extrasynaptic NMDAR currents in cells 
co-expressing exogenous PGC-1α. The increase in extrasynaptic NMDAR 
current density in mtHtt-expressing cells was rescued by the coexpression 
of PGC-1α (Fig 4.12). Indeed, analysis by two-way ANOVA shows that in 
the context of exogenous PGC-1α expression, the effect of mtHtt on 
excitotoxicity and extrasynaptic NMDAR currents is significantly 
decreased (Fig 4.11, Fig 4.12). 
 
Summary: Together this data shows that the repression of PGC-1α by 
mtHtt contributes to enhanced extrasynaptic NMDAR currents and
excitotoxicity in HD. Given that mtHtt has no further effect on NMDAR 
currents or excitotoxicity in the absence of PGC-1α , this suggests that the 
effect of mutant huntingtin and loss of PGC-1α share common 
mechanisms in mediating these effects. Consistent with this t eory, 
restoring PGC-1α expression reverses the changes in NMDAR currents 















excitotoxicity Cortical neurons were transfected with GFP plus either 
control (globin) or PGC
(A) Images before and 24h after NMDA stimulation. Neurons transfected 
at DIV7 were imaged 48h later and stimulated
(10 µM) for 1h. (B) Cell death was quantified as the lossof GFP
cells 24h post stimulation. In control cells, mtHtt (148Q) increased 
excitotoxic cell death (*
dramatically rescued mtHtt(148Q)
cell death: 30.51 % ± 3.79, 0.5404 % ± 2.64 in control + mtHtt(148Q) and 
PGC-1α + mtHtt(148Q) respectively, ***
cultures for each culture, a total of 200
for each stimulation).  (C) Two way ANOVA results show a significant 
interaction between PGC
expression on loss of GFP
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cortical neurons transfected with (A, C) wtHtt (18Q) or (B, D) mtHtt 
(148Q) in the presence of either (A, B) control (globin) plasmid or (C,D) 
PGC-1α. (E) PGC-1α
NMDAR-current density in both wtHtt(18Q) and mtHtt(148Q)
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4.2.13 Striatal neurons 
 
Many studies have reported that the medium spiny neurons of the striatum 
are particularly vulnerable to mtHtt toxicity (Ferrante et al. 1991; 
Graveland et al., 1985; Klapstein et al., 2001). In HD patients a specific 
loss of PGC-1α is observed in the caudate nucleus of the striatum (Cui et 
al., 2006). We therefore wanted to test the relative effects of mtHtt and 
PGC-1α on the vulnerability to excitotoxicity and NMDAR currents in 
striatal cultures. 
 One major caveat to the study of striatal NMDAR population is that 
glutamatergic inputs onto striatal neurons originate from utside the 
striatum. We therefore hypothesised that changing our cell culture protocol 
to enrich for striatal neurons restricts the glutamatergic input these cells 
receive in culture, and therefore we cannot guarantee the (stable) pres nce 
of spontaneous release of glutamate in such cultures and we can no lo ger 
use the ‘quantal block’ method to isolate extrasynaptic NMDAR currents.  
However, we were able to test whether mtHtt expression and PGC-1α 
knockdown have an additive effect on total NMDAR currents and 
excitotoxicity in cultured striatal cells, enriched with DARPP-32 positive 
neurons. Secondly, we examined whether PGC-1α could rescue mtHtt-






4.2.14 A non-additive increase in excitotoxicity by mtHtt 
expression and PGC-1α knockdown in striatal cultures 
 
Striatal neurons were transfected with wtHtt(18Q) or mtHtt(148Q) in the 
presence of either control non targeting siRNA or PGC-1α targeting 
siRNA (PGC-1α siRNA(i)). Images were taken before and 24h after 
NMDA stimulation and cell death was quantified as the percentag  loss of 
GFP-positive cells. Both mtHtt(148Q)  and PGC-1α knockdown caused an 
increase in NMDA-induced cell death in control cells. No signif cant 
increase in cell death by mtHtt(148Q) compared to wtHtt(18Q)-expressing 
cells was observed in cells co-expressing PGC-1α siRNA. Thus, PGC-1α 
knockdown and mtHtt(148Q) expression increased NMDAR in a non-
additive manner (Fig 4.12B). 
 
4.2.15 PGC-1α rescues mtHtt-increase in excitotoxicity in striatal 
cells 
We next assessed whether PGC-1α reverses mtHtt-induced increase in 
excitotoxic vulnerability in striatal cells as it does so in cortical cells. 
Striatal neurons were transfected with GFP plus either control (globin) or 
PGC-1α alongside either wtHtt (18Q) or mtHtt (148Q). Neuronal death 
was stimulated with a toxic dose of NMDA (20 µM) for 1h. In control 
cells, mtHtt (148Q) increased excitotoxic cell death (*t-test p<0.5). 
Whereas co-transfection of PGC-1α dramatically rescued mtHtt (148Q)-















Figure 4.14 NMDA-induced death in mtHtt-expressing cells in striatal 
cultures in the context of PGC-1α knockdown or overexpression 
(A) DARPP-32 -enriched striatal cultures. In our hands striatal cultures 
were approx. 50% DARPP-32+.(B) Striatal neurons were transfected with 
wtHtt(18Q) or mtHtt(148Q) in the presence of either contr l non targeting 
siRNA or PGC-1α targeting siRNA (PGC-1α siRNA(i)). Both 
mtHtt(148Q)  and PGC-1α knockdown caused an increase in NMDA 
(10µM)-induced cell death in control cells. No significant increase in cell 
death by mtHtt(148Q) compared to wtHtt(18Q)-expressing cells was 
observed in cells co-expressing PGC-1α siRNA. (C) Striatal neurons were 
transfected with GFP plus either control (globin) or PGC-1α alongside 
either wtHtt(Q18) or mtHtt(148Q). Neuronal death was stimulated with a 
toxic dose of NMDA (20 µM) for 1h. In control cells, mtHtt(148Q) 
increased excitotoxic cell death (*t-test p<0.5). Whereas co-transfection of 
PGC-1α dramatically rescued mtHtt(148Q)-induced NMDA vulnerability 







4.2.16 In striatal cultures, mtHtt and PGC-1α knockdown increase 
NMDAR currents non-additively  
 
To test whether mtHtt and PGC-1α alter NMDAR currents in striatal 
neurons and whether they do so in an additive way, we carried out the 
following experiment. Striatal neurons were transfected with tHtt(18Q) 
or  mtHtt(148Q) in the presence of either control siRNA or PGC-1α 
siRNA. Reflecting results from studies in cortical neurons, whole-cell 
currents were increased by both mtHtt(148Q)-expression and by PGC-1α 
knockdown in striatal cultures. However, as we saw in the cortical 
neurons, in the context of PGC-1α knockdown, mtHtt(148Q) caused no 
further increase in NMDAR currents compared to wtHtt(18Q)-expr ssing 
cells (Fig 4.13A). This result suggests that in the absence of PGC-1α mtHtt 
can no longer exert its effects on NMDAR current density. From this we 
can extract that mtHtt and PGC-1α knockdown share a common 
mechanism in the regulation of NMDAR currents in striatal neurons and 
potentially, mtHtt requires the presence of PGC-1α to be able to drive 
NMDAR currents away from baseline levels. An alternative explanatio  is 
that intrinsic regulation of NMDAR expression prevents extrasynaptic 
NMDARs increasing above a certain threshold. Given that the excitotoxic 
cell death is also non-additive in mtHtt(148) and siRNA-exprssing cells, 
we can assume that the failure to see an additive effect of mtHtt(148Q) and 













Figure 4.15 In striatal cultures, mtHtt and PGC-1α knockdown 
increase NMDAR currents non-additively, while PGC-1α 
overexpression rescues mtHtt-induced increase in currents (A) Striatal 
neurons transfected with wtHtt(18Q) or  mtHtt(148Q) in the presence of 
either control siRNA or  PGC-1α siRNA. Whole-cell current density was 
increased by mtHtt(148Q)-expression in control siRNA-exprssing 
neurons. Concurrently, siRNA knockdown of PGC-1α caused an increase 
in NMDAR-current density in wtHtt(18Q)-expressing cells. However, no 
significant difference in NMDAR current density was observed in cells co-
expressing wtHtt(18Q) versus mtHtt(148Q) in PGC-1α siRNA-expressing 
cells. (B) Striatal neurons transfected with wtHtt(18Q) or mtHtt(148Q) in 
the presence of either control (globin) plasmid or PGC-1α. PGC-1α 
overexpression caused a significant decrease in NMDAR current density. 
Moreover, in cells expressing exogenous PGC-1α, mtHtt no longer 





4.2.17 PGC-1α overexpression rescues mtHtt-induced increase in 
currents 
In preceding experiments, we describe the ability of PGC-1α to protect 
against mtHtt-induced increase the total whole-cell and extrasynaptic 
NMDAR currents in cultured cortical neurons. We now show that PGC-1α 
can protect against excitotoxic cell death in striatal neurons and investigate 
whether this is concurrent with the repression of mtHtt-induced increase in 
NMDAR currents. To investigate whether PGC-1α could rescue 
augmented NMDAR currents in mtHtt-expressing striatal neurons, the 
cells were transfected with wtHtt(18Q) or mtHtt(148Q) in the presence of 
either control (globin) plasmid or PGC-1α. PGC-1α overexpression caused 
a significant decrease in NMDAR current density in cells expressing 
wtHtt(18Q). Furthermore, exogenous expression of PGC-1α prevented 
mtHtt-mediated increases in NMDAR currents (Fig. 4.13B).  
This result is consistent with our results in cortical ells and agrees with 
the anti-excitotoxic capacity of PGC-1α in striatal neurons presented above 
(Fig 4.14). In addition this present a novel explanation for the 
neuroprotection of virally expressed PGC-1α in the striatum of HD mice 
reported by Cui et al., (2006) 
 
 
Summary: These data support the notion that mtHtt-repression of PGC-1α 
contributes to the deregulation of NMDAR currents and excitotoxicity in 
striatal neurons as well as cortical neurons, the major sites of 







This study confirmed our hypothesis, that pathological upregulation of 
extrasynaptic NMDAR activity by mutant huntingtin is occluded by PGC-
1α knockdown and conversely rescued by PGC-1α overexpression in both 
cortical and striatal neurons. This finding suggests that the mutant 
huntingtin repression of PGC-1α is mechanistically linked to the 
pathological extrasynaptic activity in HD.  
4.3.1 Consequences for neurological disease 
HD: A reciprocal relationship between mtHtt-toxicity and the balance of 
synaptic and extrasynaptic NMDAR activity was identified by two 
independent studies in 2009-10. Okamato et al., (2009) found that synaptic 
NMDAR activity suppressed mtHtt-toxicity by inducing the expression of 
the chaperonin subunit TCP-1 which leads to formation of non-toxic 
inclusions of the mutant huntingtin protein. In contrast, extrasynaptic 
NMDARs activate the GTP-binding protein Rhes, which causes 
sumoylation and disaggregation of mutant huntingtin (Okamoto et al., 
2009; Subramaniam et al., 2011b). In addition, Milnerwood et al., (2010) 
described an increase in extrasynaptic NMDAR-activity, CREB-
dephosphorylation and increased toxicity in the YAC128 HD mouse. 
MtHtt is known to disrupt the CREB-target PGC-1α by both directly 
interacting with and suppressing the PGC-1α promoter and by the 
repression of CREB-activity downstream of exaggerated extrasynaptic 
NMDAR activity. Together these results present a complex three-tiered 
feedforward signaling cascade. The presence of mutant huntingtin  HD 
represses the CREB-driven PGC-1α expression. Loss of PGC-1α increases 
extrasynaptic NMDAR activity. Extrasynaptic NMDARs disrupt both 
inclusion formation and the CREB-signaling cascade causing further 
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repression of PGC-1α. The current study builds on our previous 
understanding that the mtHtt-repression of PGC-1α contributes to HD 
phenotype by its known regulation of mitochondrial function and 
biogenesis. The mechanisms behind the imbalance of extrasynaptic and 
synaptic NMDAR signaling downstream of PGC-1α remain unknown. 
Milnerwood et al., (2010) describe an increase in protein expression of 
both GluN1 and GluN2B in ‘non-PSD’ membrane fractions from striatal 
and cortical cells, consistent with the ifenprodil-sensitivity of augmented 
extrasynaptic NMDAR activity this is attributed to increased forward 
trafficking of GluN2B-containing receptors (Fan et al., 2007; Milnerwood 
et al., 2010).  
The mechanisms behind increased NMDAR expression in HD remain 
relatively unexplored. However, many studies point to defects in protein-
protein interactions and post-translational modifications f NMDARs in 
HD that may lead to defects in synaptic targeting. Endoplasmic retention 
and forward trafficking is mediated by PKA phosphorylation of GluN1 
S896 and S897 (Tingley et al., 1997; Scott et al., 2003). There are reports 
of increased GluN1 S897 phosphorylation in the HD striatum, however 
this is still under dispute (Jarabek et al., 2004; Ariano et al., 2005). 
Retention of NMDARs at the plasma membrane is regulated by 
interactions with PSD-95, enhanced binding of GluN2B to PSD-95 may 
alter extrasynaptic stability of NMDARs (Fan et al., 2009; Milnerwood et 
al., 2010). In addition, elevated calpain levels are reported in the YAC HD 
mouse model (Cowan et al., 2008). As discussed in chapter 2. calpain 
cleavage of the GluN2B C-terminus disrupts interactions with proteins of 
the post synaptic density, and has been found to increase functional 
membrane bound receptors (Prybylowski et al., 2005). Our results indicate 
that mtHtt-repression of PGC-1α is part of the signaling cascade that leads 
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to increased extrasynaptic NMDAR activity, but the common mechanisms 
downstream await investigation. 
Alzheimer’s disease: Alzheimer’s disease (AD) is an age-related 
progressive disorder characterised by the formation of two classical 
lesions: senile plaques composed of amyloid-β peptides and neurofibrillary 
tangles (Selkoe, 2001). A recent study by Qin et al. (2009) reports the 
decline of PGC-1α mRNA and protein concurrent with increased dementia 
rating, Aβ plaque formation and Aβ peptide in AD human tissue. In 
addition, exogenous PGC-1α expression was able to reverse 
hyperglycemia induced amyloidogeneis.  
In striking resemblance to HD a reciprocal relationship has been 
discovered between the balance of synaptic and extrasynaptic NMDAR 
activity and the toxicity of Aβ peptides. Excess Aβ peptide in Alzhiemer’s 
disease brain is thought to selectively reduce glutamatergic synaptic 
transmission by reducing synaptic retention of NMDARs (Snyder et al., 
2005). Aβ is though to prevent the degradation of the tyrosine phosphatase 
STEP with leads to inactivation of the tyrosine kinase Fyn, as well as 
enhanced GluN2B Y1472 dephosphorylation, resulting in reduced 
exocytosis and increased endocytosis of synaptic NMDARs (Kurup et al., 
2010). In return, chronic extrasynaptic NMDAR activity increases the 
production of Aβ peptides, exacerbating toxicity (Bordji et al., 2010). 
Combining this with our findings, PGC-1α is able to reduce the production 
of Aβ peptide by reducing amyloidogeneis (Qin et al., 2009) and indirectly 





4.3.2 Current therapeutic targets: Extrasynaptic NMDAR activity 
Given the necessity of synaptic NMDAR signaling for cell survival and 
function, pharmacological interventions for the prevention of excitotoxic 
cell death associated with neurodegenerative disease have been 
complicated. In accord, the use of NMDAR antagonists for the treatment 
of excitotoxicity associated with ischemic brain injury in stroke proved to 
be poorly tolerated and ineffective (Ikonomidou & Turski 2002; Muir 
2006). Current understanding of the dichotomy of NMDAR signaling to 
pro-death and pro-survival cascades depending on their location means 
that selective targeting of the extrasynaptic NMDAR cascade is dsired. 
The biophysical properties of the NMDAR antagonist memantine e able it 
to be both effective at reducing excitotoxic damage and well tol rated in 
vitro and in vivo (Chen & Lipton 2006; Chen et al. 1998; Léveillé et al. 
2008). Firstly, memantine is a non-competitive, open channel blocker of 
NMDARs and in such is highly effective at blocking the prolonged 
activation of extrasynaptic NMDARs (Chen & Lipton 2006). In contrast, 
the voltage-dependence and fast-off rate of memantine means it does not 
accumulates in the synaptic cleft and is ineffective at blocking sy aptic 
NMDARs at low doses (Chen & Lipton 2006; Xia et al. 2010). Results 
from two independent groups support the potential neuroprotection 
afforded by memantine antagonism of extrasynaptic NMDARs in HD. 
(Okamoto et al., 2009, Milnerwood et al., 2010). Low dose memantine was 
shown to restore phospho-CREB activity in the YAC128 striatum 
consistent with antagonism of the dominant extrasynaptic CREB-shut off 
pathway (Milnerwood et al., 2010). In addition injection f low dose 
memantine at either 2 months (Milnerwood et al., 2010) or 12 months 





5.3 Future potential: Targeting PGC-1α  
The observation that PGC-1α expression can repress neurotoxic 
extrasynaptic NMDAR currents and reverse the vulnerability of HD
models, proposes an alternative target to intervene against excitoto i ity 
aside from pharmacological antagonism of the receptors themselves. Due 
the diverse functions of PGC-1α targets in an array of tissues, strategies for 
enhancing its function would ideally be tissue specific, if not target 
specific. Furthermore, transcriptional coactivators by definitio  do not 
possess DNA or ligand binding domains; as a result, pharmacological 
activation of PGC-1α is unfeasible. Regulation of PGC-1α activity is 
restricted to increasing its expression, stability or interaction with its 
targets. 
Transglutaminase 2 is a selective corepressor of nuclear genes and is 
upregulated in HD (Karpuj et al., 2002). A recent study has shown that 
PGC-1α is a target of TG2 activity and inhibition of TG2 is sufficient to 
derepress both PGC-1α and cytochrome C in HD models (McConoughey 
et al., 2010). This was achieved not only by RNAi knockdown and genetic 
knockout of TG2, but also by the application of a novel peptid , the 
transglutaminase inhibitor ZDON. ZDON restored PGC-1α expression and 
protects YAC128 primary striatal neurons from NMDA-excitotoxicity 
(McConoughey et al., 2010). Interesting, the ameliorating effects of ZDON 
were not associated with alterations in mitochondrial biogenesis, consistent 
with the additional neuroprotective properties of PGC-1α expression 










PGC-1α knockout mice have alterations in AMPA but not 





PGC-1α is highly expressed in multiple brain regions in mice including 
cerebral cortex, striatum and substantia nigra (Tritos et al., 2003). Previous 
studies in mice have shown PGC-1α expression to protect against neuronal 
stress in a number of neurodegenerative diseases including HD, 
Alzhiemer’s disease, Parkinson’s disease, Amyotrophic lateral sclero is 
and Ischemia (Chen et al., 2010; Cui et al., 2006; Luo et al., 2009; Qin et 
al., 2009; Shin et al., 2011; Zhao et al., 2011). In addition to our findings 
of the role of PGC-1α in excitotoxicity (Soriano et al., 2011; Puddifoot et 
al., 2012) this clearly demonstrates a functional role for PGC-1α signalling 
in the brain. In accord two independent groups have reportd neurological 
impairment in two PGC-1α knockout (KO) mouse lines discussed below.  
Lin et al., (2004) created PGC-1α null mice by LoxP deletion of exon 3-5; 
although these mice were viable through embryogenesis only 50%
survived to adulthood. Lin et al., (2004) showed that in addition to brain 
lesions in the striatum and cortical layers V/VI, the nucleus accumbens, 
substantia nigra, hippocampus and mammalliary body, 3 month old PGC-
1α knockout mice displayed behavioural abnormalities including 
exaggerated startle response, dystonic postering and frequent limb 
clasping. Finally, primary striatal neurons isolated from the PGC-1α 
knockout mice showed aberrant neurite outgrowth (Lin et al., 2004). 
Another PGC-1α KO mouse was created by Leone et al., (2005) using 
neomycin based gene targeting of exon 4-5 of PGC-1α resulting in a 
recombination/insertion of a repeat in exon 3, ultimately causing premature 
termination at amino acid 255 which results in an unstable PGC-1α 
transcript (Leone et al., 2005). These KO mice displayed increased anxiety 
accompanied by microvacuolation in the pyramidal neurons of the basal 
ganglia, cerebral cortex, hippocampus and brainstem (Leone et al., 2005). 
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PGC-1α null mice were also more sensitive to the neurodegenerative 
effects of the oxidative stressors MPTP and kainic acid affecting the 
substantia nigra and hippocampus, respectively (Leone et al.,2005). 
Given the changes in NMDA-type glutamate receptor expression and 
potent neuroprotection downstream of mutant huntingtin repressed-PGC-
1α, described in chapters 3 and 4 (now published; Puddifoot et al., 2012), 
we proposed that alterations in glutamate signalling may contribute to the 
neurological phenotypes observed in the PGC-1α knockout mouse.  
In order to test our hypothesis we used cortical neurons fr m the PGC-1α 
knockout mice created by AstraZeneca Transgenic and Comparative 
Genomics, Sweden (D’Errico et al., 2011). We obtained PGC-1α KO and 
WT pups from Alberto Camacho Morales (Cambridge); knockout pups 
contain LoxP delta deletion between exons 3-5 of PGC-1α gene. PGC-1α 
KO and WT mice were produced by crossing heterozygote mice. 
Subsequently, neuronal cultures were made from E.16.5 PGC-1α(-/-) and 
PGC-1α (+/+) pups.  
The chronic loss of PGC-1α in the knockout mouse enables us to 
investigate whether losing PGC-1α throughout development may affect 
glutamatergic signalling both at post synaptic and presynaptic sites. 
Transient knockdown of PGC-1α described in chapters 3 and 4 is limited 
to studying acute changes in the post synaptic cell due to the specific 
knockdown in a small (<5%) number of cells making it highly unlikely 
that presynaptic cells incorporate the siRNA. Finally, whereas low/variable 
efficiency of transfection hinders mechanistic insight into functional 
changes after acute knockdown of PGC-1α, RNA analysis of the PGC-1α 
knockout is possible in this model. 
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 5.2 Results 
 
5.2.1 PGC-1α(-/-) display no change in whole-cell NMDAR currents  
 
Cortical neurons cultured from embryonic day 16.5 PGC-1α(-/-) and PGC-
1α (+/+) mice were used to study the expression of two major glutamate 
receptors; AMPAR and NMDAR. Knock out and wildtype pups were bred 
by crossing two PGC-1α heterozygotes; each pup was then cultured 
independently enabling us to compare neurons from PGC-1α (+/+) and PGC-
1α(-/-) littermates. Both AMPA and NMDA-receptors are essential for 
excitatory neurotransmission in the central nervous system and the 
regulation of their expression both independently and with respect to each 
other has been the focus of many neurophysiological studies ( reviewed by 
Rousseaux et al., 2008). 
Our specific interest in the expression profile of NMDARs is due to their 
critical role in neuronal health (Hardingham and Bading, 2010). Activation 
of synaptic NMDARs bestows long-lasting neuroprotection, whereas 
activation of NMDARs located outside of the synapse triggers pro-death 
signalling cascades (Hardingham et al., 2002). In chapter three, we have 
shown that neurons lacking PGC-1α, due to targeted siRNA knockdown of 
PGC-1α in neuronal cultures, are more susceptible to NMDA-induced cell 
death and have greater amplitude of whole-cell NMDAR currents, 
resulting from the preferential enhancement of extrasynaptic NMDAR 
currents.  
We undertook our studies in the PGC-1α knockout mice on observation of 
increased whole cell current amplitude and cell death after siRNA 
knockdown of PGC-1α in vitro, but prior to our understanding of the 
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distinct role played by extrasynaptic NMDARs in this cascade. We
therefore hypothesised that the PGC-1α knockout mouse would display 
increased neuronal vulnerability and increased NMDAR currents. To 
investigate cell vulnerability, our colleague, Karen Bell, carried out cell 
death assays on neuronal cultures from the PGC-1α(-/-) and PGC-1α(+/+) 
mice. Low dose NMDA (10 µM) was used; a dose sufficient to induce 
death after PGC-1α knockdown with siRNA in vitro (Chapter 3). Cells 
were stimulated with NMDA (10 µM) for 1h, after which the stimulation 
was stopped by applying the NMDAR antagonist MK-801 (10 µM). 24h 
post stimulation, the cells were fixed with 4% PFA and DAPI was used to 
stain the cell nulcei. Images of the cells were taken to enable quantification 
of cell death based on the morphology of the nucleus. NMDA stimulation 
had comparable effect on PGC-1α(+/+) and PGC-1α(-/-) neurons (Data not 
shown), indicating no change in the vulnerability of these cells to this 
insult.   
 
We next tested whether the change in whole-cell NMDAR currents after 
siRNA knockdown of PGC-1α was mimicked in the PGC-1α knockout 
neurons. To do this, we used whole-cell patch clamp to hold cultured 
cortical neurons from PGC-1α(-/-) and PGC-1α(+/+) mice at -60mV in Mg2+-
free external recording solution. We measured the current response t  bath 
application of NMDA (100 µM) in cultured cortical neurones. No changes 
in whole-cell NMDAR current density was observed in PGC-1α(-/-) 
compared to PGC-1α(+/+) mice (Fig 5.1C). In order to calculate the current 
density, we measure the cell capacitance of the neurons. The capacitance is 
proportional to the membrane surface area of the cell, and thus represents 
the size of the neuron. We found no difference in the capacitance of 
neurons from PGC-1α(-/-) and PGC-1α(+/+) mice (Fig 5.1D). 
  
 
Figure 5.1 No change in NMDAR
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5.2.2 PGC-1α(-/-) mice have reduced AMPAR current density 
 
Despite observing no change in NMDAR whole-cell currents/NMDA-
induced death, given the striking neurological phenotype previously 
reported in PGC-1α knockout lines, we were interested in investigating 
whether changes in another subtype of glutamate receptors, the AMPA 
receptors, may occur. AMPA receptors are responsible for fast excitatory 
neurotransmission in the CNS (Hollmann and Heinemann, 1994) and the 
dynamic regulation of AMPA receptor insertion and internalisation from 
the synaptic membranes plays an integral role in synaptic plasticity 
(reviewed by Malenka, 2003).  
AMPA receptors are named after the artificial glutamate analog AMPA 
which selectively activates this subclass of receptors. AMPARs are 
tetramers composed of four types of subunits, designated as GluA1, 
GluA2, GluA3, and GluA4. Unlike NMDARs, most AMPARs have very 
low permeability to Ca2+ ions due to the incorporation of an edited GluA2 
subunit which has a positive arginine residue which repels Ca2+ ions. This 
is thought to prevent AMPAR activity from contributing to excitotoxicity 
(Kim et al., 2001). However, AMPA receptor activity is necessary to 
depolarise the cell and relieve the Mg2+-block from NMDAR pores, and 
therefore plays a role in their activation.  
 
To assess whether neurons from PGC-1α(-/-) mice have changes in AMPAR 
expression, we used whole-cell patch clamp to record AMPA-induced 
currents in cultured cortical neurons from PGC-1α(-/-) and PGC-1α(+/+)  
mice. Neurons were voltage clamped at -60mV in external recording 
solution. We measured the current response to bath application of AMPA 
(50 µM). AMPAR steady state current response was normalised to cell 
150 
 
capacitance to calculate the AMPAR current density in these cells. We 
observed a significant reduction in AMPAR current density in PGC-1α(-/-) 




Figure 5.2 Cortical neurons from PGC
agonist-evoked AMPAR current density compared to wild type 
controls Agonist evoked w
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5.2.3 PGC-1α(-/-) mice have reduced AMPAR GluA1-4 mRNA 
expression 
 
The current response to bath application of the AMPA-receptor agonist 
AMPA (50 μM) depends on a number of variables including (i) the 
number of receptors expressed on the cell (ii) the conductance of each 
receptor channel (iii) the efficacy of agonist binding and channel 
activation. It is well accepted that both subunit composition and post-
translation modifications contribute to the diversity of AMPAR responses 
and can play a key role in synaptic plasticity (reviewed by Lu and Roche, 
2011). However, since in the absence of external signalling, steady state 
protein levels are highly dependent on mRNA expression (Lu et al., 2007), 
in order to determine whether any changes in expression of each AMPAR 
subunit contribute to decreased AMPAR responses, we analysed RNA 
extracted from neuronal cultures from PGC-1α(-/-)  and PGC-1α(+/+)  mice 
using qPCR. Interestingly, PGC-1α(-/-)  neurons have lower mRNA 
expression of all four AMPA receptor subunits; GluA1, GluA2, GluA3, 




Fig 5.3 PGC-1α(-/-)  neurons have reduced mRNA expression of 
AMPAR subunits GluA1-4 RNA was collected DIV9 from neuronal 
cultures from PGC-1α(-/-)  and PGC-1α(+/+)  mice. Quantification of mRNA 
expression was done by qPCR. (A) PGC-1α(-/-)  neurons have lower 
expression of GluA1 (B) GluA2 (C) GluA3 (D) GluA4 mRNAs (n = 7 











5.2.4 Cortical neurons from PGC-1α(-/-) mice have reduced mEPSC 
frequency and amplitude 
Given the evidence for lowered AMPAR expression in the PGC-1α(-/-) 
neurons we hypothesised that knockout cells may have smaller AMPAR 
quantity at synapses. If this was the case, we would expect to see a drop in 
the amplitude of mEPSCs in the knockout neurons. To test our hypothesis 
we recorded miniature excitatory post synaptic currents (mEPSCs) from 
PGC-1α(-/-)and PGC-1α(+/+) neurons and analysed the frequency and 
amplitude of AMPAR-mediated mEPSCs. Neurons were placed in 
recording solution supplemented with PTX (50 µM), TTX (300 nM) and 
Mg2+ (1.3mM; this blocks NMDAR activity). mEPSCs were recorded in 
voltage clamp (-70 mV) for 5-10mins using whole-cell patch clamp. We 
observed a reduction in both the mean amplitude (Fig.5.3C) and mean 
frequency (Fig.5.3D) of mEPSC events in the PGC-1α(-/-) cells. Further 
analysis showed that the amplitude distribution of PGC-1α(-/-) neurons was 
skewed to the left, indicating an absence of high amplitude events 
(Fig.5.4E).  Likewise the distribution of inter-event-inerval (i.e.i) is 
altered in the PGC-1α(-/-) neurons (Fig5.3F). The i.e.i is the time between 
mEPSC events, a trend towards higher i.e.i indicates the absence of high 





















































































Figure 5.4 Cultured cortical neurons from PGC-1α(-/-) mice have reduced 
mEPSC frequency and amplitude (A) Example mEPSC traces from (A) 
PGC-1α(+/+) and (B) PGC-1α(-/-) mouse cortical neurons. Neurons were placed 
in recording solution supplemented with PTX (50 µM), TTX (300 nM) and 
Mg2+ (1.3mM). mEPSCs were recorded in voltage clamp (-70 mV) for 5-10 
mins using whole-cell patch clamp. We observed a reduction in both the mean 
amplitude (C) and mean frequency (D) of mEPSC events in the PGC-1α(-/-) 
cells. (E) Furthermore, the amplitude distribution of PGC-1α(-/-) neurons was 
skewed to the left, indicating an absence of high amplitude events.  (F) The 
distribution of inter-event-interval (i.e.i) is altered in the PGC-1α knockout 
mice. Mean amplitude and frequency *t test p<0.05; cumulative distributions 
KS test p<0.05 (from n= 6, 7, cells, each from 6 independent cultures, 







The 30% reduction in mEPSC amplitude corresponds to the (38%) 
reduction in whole cell current response to AMPAR application as well as 
the 25-40% reduction in AMPAR GluA1-4 subunit mRNA expression. 
Together this provides a strong argument for reduced AMPAR signalling 
in the PGC-1α knockout neurons. 
 
Of interest is the change in mEPSC frequency in these cells. mEPSC 
frequency is determined by both the number of synapses on the post 
synaptic cell, and the frequency of release of glutamate from pre-synaptic 
cells. We have yet to investigate whether this is a presynaptic or 
postsynaptic mechanism. In order to do this, future experiments could 
include the overexpression of PGC-1α along with a fluorescent marker into 
knockout neurons, to test whether this recues the mEPSC profile and 
AMPAR expression in the post synaptic cell. Due to the mouse line no 
longer being available in the UK, these experiments were not carried out in 
this study. However the reduction in AMPAR mRNA and whole-cell 
currents suggest that control of AMPAR expression is disrupted in the 
PGC-1α(-/-) neurons. Our final analysis, outlined below, suggests that this 




5.2.5 Decreased complexin I: a candidate for altered AMPAR 
exocytosis 
Finally, with the aim of gaining mechanistic insight into changes in 
AMPAR profile in PGC-1α(-/-) we performed microarray analysis on PGC-
1α(-/-) and PGC-1α(+/+) neurons. Two way ANOVA analysis of microarray 
data from PGC-1α(-/-)  mice (n=3  PGC-1α(-/-)   and 3 PGC-1α(+/+)) from 3 
independent litters indicates a significant effect of PGC-1α knockout on 
the regulator of exocytosis: complexin I (-1.8 fold change in complexin 1 
expression in PGC-1α(-/-)  compared to PGC-1α(+/+)  p<0.01; Fig 5.5). We 
confirmed this reduction in complexin I in neuronal cultures from PGC-
1α(-/-) compared to their littermate controls using qPCR (Fig 5.6).  We also 
confirmed the reduction of the PGC-1α target cytochrome C (ref) as a 
positive control (Fig 5.6) (n = 7 PGC-1α(-/-)  and 7 PGC-1α(+/+)  mice from 
7 independent litters). A recent study indicates a role for complexin I in 
AMPAR exocytosis (Ahmad et al., 2012), suggesting a possible 
mechanism of altered AMPAR expression in the PGC-1α(-/-) neurons, this 
is discussed below. 
  
Fig 5.5 Microarray analysis of cultured cortical neurons from 
1α(-/-) and PGC-1α(+/+)
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Fig 5.6 PGC-1α(-/-)  neurons have reduced complexin I mRNA 
expression RNA was collected DIV 7-9 from neuronal cultures from 
PGC-1α(-/-)  and PGC-1α(+/+)  mice. Quantification of mRNA expression 
was performed by syber green qPCR. (A) PGC-1α(-/-)  neurons have lower 
expression of complexin I. (B) The PGC-1α target gene cytochrome C was 
also reduced in the PGC-1α(-/-)  neurons, acting as a positive control. n = 7 







5.3.1 Disregulation of AMPARs in PGC-1α(-/-) neurons 
This study clearly shows an alteration in AMPAR response to both bath 
application of the AMPAR agonist AMPA, and spontaneous excitatory 
activity. In addition we identify two potential mechanisms for the 
reduction in AMPAR responses.  
Firstly, reduced steady state expression of AMPAR subunit (GluR1-4) 
mRNA could limit the rate of translation of the subunit proteins, leading to 
a reduction in the steady state function of the receptor complex. In order to 
directly test this, future studies may involve overexpressing GluR1-4 under 
the control of highly active promoters which, if the hypothesis is true, 
should counteract any affect of mRNA deficiencies and rescue the 
reduction in AMPAR currents. The mechanisms by which loss of PGC-1α 
may alter expression of GluR1-4 remains unclear, but could be potential 
way of linking energy homeostasis to highly energy demanding synaptic 
activity. 
Secondly, the reduction in complexin I in PGC-1α(-/-) neurons may limit 
AMPAR exosytosis in these cells. At the presynaptic site, complexions 
play an essential role in calcium-dependent vesicle fusion as well as being 
necessary to restrain the exocytosis SNARE proteins to prevent 
inappropriate vesicle release (Yang et al., 2010). In such, presynaptic 
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knockdown of complexin I causes an increase in mEPSC frequency 
(Maximov et al., 2009) in striking contrast to the reduction n mEPSC 
frequency in the PGC-1α(-/-) neurons (Fig 5.4). However, a recent study by 
Ahmad et al. (2012) has found that on the postsynaptic side, viral 
knockdown of complexin I and complexin II in hippocampal neurons 
disrupts AMPA receptor exocytosis during LTP. This result is consistent 
with our observed reduction of AMPAR whole cell currents, mini 
amplitude, and mini frequency, and proposes a change in the development 
of AMPAR synapses due to disruption in AMPAR delivery to the synapse; 
although we cannot be sure that this mechanism would affect th  steady 
state AMPAR expression measured here, it could potentially have a potent 
affect if altered during development, such as in our knockout system. In 
order to assess whether this hypothesis is true, it would be necessary to do 
a number of rescue experiments. For example, analysing AMPAR 
expression in PGC-1α(-/-) cells after transfection of complexins would 
enable us to study the contribution of these proteins, at postsynaptic site, to 
the observed phenotype, whereas the transfection of PGC-1α  itself into 
PGC-1α(-/-) neurons should rescue the loss of complexin, GluR1-4 mRNA 
and may allow recovery of AMPAR profile.  Together these findings 
strongly suggest alterations in AMPAR expression is the mechanism 




5.3.2 Discrepancies between acute and chronic PGC-1α 
knockdown on NMDARs. 
In chapters three and four we demonstrate a functional role for PGC-1α 
signalling in the determining the amplitude of agonist-evoked NMDAR 
currents. Loss of PGC-1α was found to increase extrasynaptic NMDAR 
currents with concurrent increase in vulnerability to NMDA-induced cell 
death in rat cortical and striatal cultures (Chapter 3; Puddifoot et al., 2012). 
We therefore proposed that NMDAR signalling may be altered in the 
 PGC-1α(-/-) mice. In this chapter we report no change in the whole-cell 
NMDAR current density in cortical neuronal cultures from PGC-1α(-/-)) 
mice compared to PGC-1α(+/+). Furthermore we found no change in 
vulnerability to NMDA in these cultures (Karen Bell). There ar  a number 
of possible explanations for this discrepancy. 
Firstly, it is possible that the differential effects of PGC-1α(-/-) loss in the 
acute versus the chronic scenario is determined by developmental aspects. 
Throughout maturation NMDAR expression is dynamically regulated at 
the level of transcription, translation and post translation l modifications. 
Transcription factors known to enhance transcriptional output of NMDAR 
subunits GluN1-3 include Specific Protein family (SP-1), Early growth 
response family (Egr), T box (Tbr), Fos, Jun,  cAMP response element-
binding (CREB) (reviewed by  Bai and Hoffman 2009). Vazhappilly & 
Sucher  (2004) suggest that translational regulation of GluN s bunit 
proteins can alter the rate of NMDAR expression. In addition, the 
regulation of receptor trafficking and stability at the plasm embrane can 
be altered by post-translation protein modifications (Hayashi & Huganir, 
2009; Huang & El-Husseini, 2005). This suggests that many regulatory 
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elements coordinate to control the expression of functional NMDARs on 
the plasma membrane and a number of sequential steps exist that could 
potentially compensate for any disruption in this system to maintain 
synaptic homeostasis. The ability of the knockout neurons t  compensate 
for the chronic loss of PGC-1α seems to be the most plausible explanation 
for the discrepancies observed in the chronic knockout versus ac te 
knockdown. Indeed, compensation for the loss of synaptic proteins by 
enhancing proteins with homologous functions has previously been 
observed in studies of mice with specific knockout of MAGUK proteins 
(Elios et al., 2006). Whereas siRNA knockdown of endogenous PSD-95 or 
PSD-93 disrupts AMPA receptor expression at excitatory synapses, in 
adult PSD-95/ PSD-93 double knockout animals, SAP-102 is upregulated 
and compensates for the loss of synaptic AMPA-Rs (Elios et al., 2006). It 
is possible that compensation takes place at any stage in the unmapped 
pathway between PGC-1α signalling and the amplitude of NMDAR 
currents. 
 
However, we cannot rule out alternative explanations for the diff rential 
effects of PGC-1α knockout and knockdown in these experiments. For 
example at the time in which these experiments were carried out, we did 
not have our current understanding of the specific changes in extrasynaptic 
NMDARs that occur after siRNA knockdown in rat neuronal cultures; we 
therefore omitted to test the proportion of NMDARs at synaptic and 
extrasynaptic sites in the PGC-1α(-/-).  In the acute studies, we found 
siRNA knockdown of PGC-1α to have a significantly higher effect on 
extrasynaptic currents compared to the whole cell currents (Chapter 3; Fig 
3.9), therefore it is possible that changes that occur at extrasynaptic 
NMDARs, which can make up between 25-50% of NMDARS at this age 
point (Rosemund et al., 1994), are masked in this study. The PGC-1α 
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mouse line used in this study was frozen before this result came to light; 
therefore we have yet to test this hypothesis. However, changes in the ratio 
of extrasynaptic and synaptic NMDARs that would normally alter 
neuronal vulnerability (Hardingham and Bading, 2010) are inconsistent 
with the absence of increased vulnerability in the PGC-1α(-/-) neurons 
undermining this explanation.  
An alternative possibility is that PGC-1α(-/-) does cause disturbances in 
NMDAR activity levels but those cells with prolonged elevated NMDAR 
activity are not surviving during the culture process. Due to the housing 
location of the PGC-1α(-/-)  mice, the PGC-1α(-/-)  and PGC-1α(+/+) mouse 
brains were subject to an extended culture protocol which could have lead 
to increased cellular stress. This scenario was previously seen in arly 
studies in post mortem tissue from HD patients in which radiolabeled 
ligand binding assays show a disproportionate loss of glutamate receptors 
in striatal tissue from HD patients (Young et al., 1988). In this case the 
expression of glutamate receptors are thought to be reduced, as the neurons 
with higher levels of NMDAR activity are the most vulnerable and have 
already died, however, we have no evidence to suggest cell death occurred 
in our cultures. 
Finally, I must cknowledge that species differences could contribute to 
discrepancy in data since the acute studies reported in chapter 3 we 
performed in rat neurons rather than mice. However, this seems unlikely 
given that much this work performed in rat neurons agrees with data from 
HD mouse models including the upregulation of extrasynaptic NMDAR 
currents and excitotoxicity downstream of mutant huntingtin (Milnerwood 












In this thesis I studied the role of PGC-1α in excitotoxic cell death. I 
identified the unexpected neuroprotective mechanism of PGC-1α by the 
downregulation of extrasynaptic NMDARs. Furthermore, I show that the 
repression of PGC-1α by mutant huntingtin protein in Huntingtin’s disease 
may contribute to excessive extrasynaptic NMDAR activity and 
excitotoxicity in this disease. By showing that mtHtt does not exacerbate 
toxicity or extrasynaptic currents in cells in which PGC-1α is knocked 
down, my data suggest that the action of mtHtt on PGC-1α may be 
significant in the deregulation of NMDARs by this protein (summarised in 
Fig 6.1).  
This data adds mechanistic insight into previous understanding of the 
synergistic roles of mtHtt, NMDAR activity and PGC-1α in HD. During 
the course of this study two groups reported a reciprocal rel tionship 
between mtHtt toxicity and extrasynaptic/synaptic NMDAR signalli g in 
HD. Synaptic activity protects against mtHtt toxicity by increasing mtHtt 
inclusion formation and upregulating pro-survival transcriptional activity, 
including the expression of PGC-1α (Okamoto et al., 2009; Soriano et al., 
2009). In contrast, extrasynaptic activity represses inclusion formation, and 
CREB-dependent PGC-1α expression (Okamoto et al, 2009; Hardingham 
et al., 2002). PGC-1α transcription is further repressed by mtHtt 
antagonising the PGC-1α promoter (Cui et al 2006). Exacerbating this 
cascade is the upregulation of extrasynaptic NMDARs by mutant 
huntingtin (Milnerwood et al., 2010). This thesis addresses the increase in 
extrasynaptic NMDAR signalling in HD, showing that the repression of 
PGC-1α contributes to the increase in excitotoxicity by tipping the balance 
of NMDAR expression toward the neurotoxic extrasynaptic pools. Since 
extrasynaptic activity represses CREB-dependent PGC-1α expression this 







Fig 6.1 This study provides mechanistic insight in to the role of PGC-
1α in NMDAR excitotoxicity in HD  MtHtt has also been shown to 
preferentially increase extrasynaptic NMDAR currents. Tipping the 
balance of NMDAR activity in favour of excitotoxic extrasynaptic 
NMDAR pools increases excitotoxicity in HD. This thesis provides 
evidence that mtHtt regulates extrasynaptic NMDARs and excitotox city 
via the repression of PGC-1α which I show to be a potent repressor of 









I also show the ability of PGC-1α to rescue both the excitotoxicity and 
enhanced extrasynaptic NMDAR currents caused by mtHtt expression. 
This suggests that targeting PGC-1α may provide therapeutic benefits in 
HD. A recent study by McConoughey et al (2010) identify a novel 
compound ZDON, a transglutaminase 2 inhibitor capable of upregulating 
endogenous PGC-1α. ZDON was able to protect neurons against mtHtt-
mediated increase in excitotoxicity. Future studies may address whether 
this compound can reverse the effects of mtHtt on extrasynaptic NMDAR 
currents. In addition to being a potential therapeutic, such experiments 
would confirm the ability of endogenous PGC-1α expression to counteract 
this imbalance in the extrasynaptic pool of NMDARs. 
Prior to this thesis, PGC-1α was widely studied for its capacity to increase 
mitochondrial biogenesis and antioxidant defences (Handschin et al., 2009) 
and although it was known that PGC-1α expression is neuroprotective, my 
finding that this transcriptional coactivator can repress NMDAR activity 
was surprising. One theory derived from this study is that mitochondrial 
health and energy metabolism might be intrinsically linked to the 
regulation of NMDAR expression and localisation. This would imply that 
the effects of altering PGC-1α on NMDAR currents may be downstream of 
its ability to boost mitochondrial health and dampen the toxic effects of 
reactive oxidative species. In order to directly test the role of mit chondrial 
health on glutamatergic receptor expression, it would be necessary to study 
the effects of mitochondrial stressors on NMDAR currents. Alternatively it 
would be interesting to test whether altered NMDAR currents in response 
to loss of PGC-1α persist in conditions where the mitochondrial health is 
maintained. Opposing this theory is the ability of the PGC-1α-inducer 
ZDON to protect against NMDA- excitotoxicity in the absence of 
increased mitochondrial function (McConoughey et al., 2010). Much is left 
to be understood about the regulation of extrasynaptic and sy aptic 
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NMDAR expression in both physiological and pathological conditions and 
whether this is directly related to the mitochondrial dysfunctio  apparent in 
many neurological disorders (Table 1.1) may prove interesting.  
Finally, I present findings from my study on chronic loss of PGC-1α  in the 
PGC-1α knockout mouse. Although the chronic knockout of PGC-1α did 
not mimic the effects observed in acute knockdown of PGC-1α in vitro, I 
found that loss of PGC-1α during embryogenesis altered both the whole 
cell expression and synaptic activity of AMPA receptors, microarray 
analysis indentified the regulator of exocytosis complexin I as a potential 
regulator of this process in addition to an observed reduction in AMPA 
subunit mRNA. As seen from the microarray data presented here, a 
number of changes occur in response to transgenic knockout of a gene and 
full analysis of glutamate receptor signalling throughout development and 
adulthood may need to be considered to elucidate the effects of hr nic 
knockout of PGC-1α. This thesis provides some mechanistic insight into 
the role of PGC-1α in the regulation of glutamate receptor currents 
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